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Abstract 
 
 
Expression, Purification and Characterisation of Tryptophan Hydroxylases 
 
Tryptophan hydroxylase (TPH) catalyses the first and rate-limiting step in the 
biosynthesis of the neurotransmitter and hormone serotonin (5-hydroxytryptamine). 
Although serotonin has many physiological functions, it is mainly known as a 
neurotransmitter. Abnormalities in the serotonergic neurons are implicated in a wide 
range of neuropsychiatric disorders such as depression, obsessive-compulsive disorder 
and schizophrenia.  
TPH is a mononuclear non-heme iron enzyme which catalyses the reaction between 
tryptophan, O2 and tetrahydrobiopterin to produce 5-hydroxytryptophan and 4a-
hydroxy-tetrahydrobiopterin. TPH is a homotetrameric three domain enzyme; its three 
domains are an N-terminal regulatory domain, a catalytic domain and a small C-
terminal tetramerisation domain. Two isoforms of TPH exist: while isoform 1 (TPH1) is 
primarily found in the mast cells, pineal gland and enterochromaffin cells, isoform 2 
(TPH2) appears mostly in the serotonergic neurons of the brain and gut.  
This study concerns the chicken TPH1 and the human TPH2 and 17 different variants 
of these two enzymes have been expressed in Escherichia coli. Three of these variants 
could be purified to homogeneity using only two simple chromatographic steps. These 
variants were the catalytic domain of chicken TPH1, the catalytic domain of human 
TPH2 and the catalytic and tetramerisation domain of human TPH2. The expression 
and purification of the three variants yielded 11-60 mg purified TPH/L culture; the 
specific activities of these three variants ranged from 0.6 to 5.9 μmol/min/mg. 
The TPH variants that could not be purified all contain the regulatory domain. This 
indicates that the regulatory domains of TPH1 and TPH2 when expressed in Escherichia 
coli are responsible for aggregation. This aggregation obstructs the purification.  
For all three variants that could be purified the Km and Vmax values were determined 
for all three substrates. Large differences were observed between some of the Km 
values of isoform 1 and 2: the Km,tetrahydrobiopterin of the catalytic domain of chicken TPH1 
is 324±10 μM, while for its counterpart the catalytic domain of human TPH2 it is 
26.5±1.3 μM; the respective Km,O2 values of the catalytic domains of chicken TPH1 and 
human TPH2 are 39±2 μM and 273±9 μM. While substrate inhibition by tryptophan is 
observed with a Ki,tryptophan of 164±24 μM for the catalytic domain of chicken TPH1, no 
such inhibition is observed for the variants of human TPH2.  
Having investigated the kinetic mechanism of the catalytic domain of human TPH2, I 
have found that the mechanism is sequential, that is, all three substrates must be bound 
in the enzyme before the enzymatic reaction proceeds. The results also ascertained the 
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order of substrate addition: tryptophan binds as the first substrate, followed by a 
random addition of tetrahydrobiopterin and O2.   
The extensive screenings of crystallisation conditions performed for all three variants 
revealed crystallisation conditions for the catalytic domain of chicken TPH1. A data set 
was collected to 3 Å and the structure was solved by molecular replacement. The 
subsequent trials to optimise the crystallisation have currently not resulted in a better 
data set. The structure was refined to an Rfree of 32.8% and the overall structure is 
compared to the overall structure of the catalytic domain of human TPH1 co-
crystallised with dihydrobiopterin. This structure is the only other structure of TPH. 
Rather large conformational changes are seen upon binding of substrate analogue 
dihydrobiopterin. Furthermore, the structure of the C-terminal end of the catalytic 
domain is visible, which is not seen in the structure of the catalytic domain of human 
TPH1. 
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Dansk resumé 
 
 
Ekspression, oprensning og karakterisering af tryptophanhydroxylaser 
 
Tryptophanhydroxylase (TPH) katalyserer det første og hastighedsbestemmende trin i 
biosyntesen af serotonin (5-hydroxytryptamin). Serotonin har mange fysiologiske 
funktioner, men er hovedsagelig kendt for sin funktion som signalstof i hjernen. 
Unormalheder i de serotoninholdige neuroner menes at spille en rolle i flere 
psykiatriske lidelser såsom depression, obsessiv-kompulsiv lidelse (OCD) og 
skizofreni. 
TPH er et jern-holdigt enzym, som katalyserer reaktionen mellem tryptophan, O2 og 
tetrahydrobiopterin under dannelsen af produkterne 5-hydroxytryptophan og 4a-
hydroxytetrahydrobiopterin. TPH er en homotetramer, hvor hver monomer består af 
tre domæner. De tre domæner er et N-terminalt regulatorisk domæne, et katalytisk 
domæne og et mindre C-terminalt tetrameriseringsdomæne. 
Der findes to isoformer af TPH, hvor isoform 1 (TPH1) hovedsagligt findes i 
mastcellerne, pinealkirtelen og i de enterochromaffine celler og isoform 2 (TPH2) 
findes i de serotoninholdige neuroner i hjernen og tarmen.  
I dette projekt er kylling TPH1 og human TPH2 blevet studeret. Sytten forskellige 
varianter af disse to enzymer er blevet udtrykt i Escherichia coli. Tre af disse varianter 
kan oprenses ved brug af to simple kromatografiske trin. De tre varianter er det 
katalytiske domæne af kylling TPH1, det katalytiske domæne af human TPH2 samt det 
katalytiske domæne sammen med det efterfølgende tetrameriseringsdomæne af 
human TPH2.  Ekspressionen af de tre varianter gav et udbytte på 11-60 mg oprenset 
TPH/L kultur. De opnåede specifikke aktiviteter for disse tre varianter er 0,6-5,9 
μmol/min/mg. 
De varianter af TPH, som ikke kunne oprenses, indeholder alle det regulatoriske 
domæne. Dette indikerer, at de regulatoriske domæner af TPH1 og TPH2 er ansvarlige 
for aggregeringen af TPH ved ekspression i Escherichia coli.  
For de tre varianter der kunne oprenses blev Km- og Vmax-værdierne bestemt for alle tre 
substrater. Der er store forskelle mellem Km-værdier for isoform 1 og 2. For det 
katalytiske domæne af kylling TPH1 er Km,tetrahydrobiopterin 324±10 μM, mens den er 
26,5±1,3 μM for det katalytiske domæne af human TPH2. Km,O2 for det katalytiske 
domæne af kylling TPH1 er 39±2 μM, mens den er 273±9 μM for det katalytiske 
domæne af human TPH2. Derudover blev der observeret substrat-inihibering af 
tryptophan for det katalytiske domæne af kylling TPH1 med en Ki,tryptophan på 164±24 
μM. Substrat-inhibering blev ikke observeret for de to humane TPH2 varianter. 
Enzymkinetikmekanismen for det katalytiske domæne af human TPH2 blev ligeledes 
undersøgt. Det blev vist, at den er sekventiel, dvs. at alle tre substrater skal være 
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bundet, før den enzymatiske reaktion kan forløbe. Resultaterne viser derudover, at 
tryptophan bindes som det første substrat fulgt af en tilfældig bindingsrækkefølge af 
tetrahydrobiopterin og O2.  
Der er udført omfattende screeningsforsøg for at finde krystallisationsbetingelser for 
alle tre varianter. Krystallisationsbetingelser er fundet for det katalytiske domæne af 
kylling TPH1. Et datasæt til 3 Å er opsamlet, og strukturen er løst. Forsøg på at 
optimere krystallisationen har foreløbig ikke resulteret i et forbedret datasæt. Den 
overordnede struktur af det katalytiske domæne af kylling TPH1 er sammenlignet med 
den overordnede struktur af den eneste anden struktur af TPH, nemlig det katalytiske 
domæne af human TPH1. Der ses forskelle i substratbindingsregionen samt i et 
fleksibelt loop. Desuden ses strukturen af den C-terminale ende af det katalytiske 
domæne, som ikke er synlig i strukturen af det katalytiske domæne af human TPH1. 
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CHAPTER ONE 
1 Introduction 
 
 
This dissertation deals with the important iron containing enzyme tryptophan 
hydroxylase (TPH) which catalyses the first and rate limiting step in the biosynthesis of 
serotonin [1]. The TPH catalysed reaction is furthermore the first step in biosynthesis of 
the indoleamines shown in figure 1.1 with the hormone melatonin as the final 
compound [2,3]. Since 1948, when Rapport et al. first isolated and identified the 
vasoconstrictor from serum as 5-hydroxytryptamine (serotonin), the biosynthesis of 
serotonin has been in constant focus by many researchers [4,5,6]. It was found that 
serotonin had many important physiological functions but most importantly it was 
found to be a neurotransmitter. The interest in tryptophan hydroxylase further 
increased as serotonin was hypothesised to be implicated in a wide range of 
neuropsychiatric disorders such as depression and obsessive-compulsive disorder [7]. 
Even though TPH has been studied for many years several issues still remain to be 
resolved. The three-dimensional structure of the whole protein is for example 
unknown and the mechanism of enzyme regulation has not been determined.  
NH3+
O
N
O
NH3+
O
N
O
OH
NH3+N
OH
N
OH
N
O
N
O
N
O
Tryptophan 5-hydroxytryptophan Serotonin N-acetylserotonin Melatonin
Tryptophan 
hydroxylase
Aromatic amino acid
decarboxylase
Arylalkylamine
N-acetyltransferase
Acetylserotonin
O-metyltransferase  
Figure 1.1 The biosynthesis of the indoleamines 5-hydroxytryptophan, serotonin, N-
acetylserotonin and melatonin. Tryptophan hydroxylase is the rate limiting enzyme in the 
biosynthesis of serotonin [2,3]. 
The initial work on TPH in the Bioinorganic Research Group at DTU was done with 
chicken (Gallus gallus) TPH (gTPH1) [8]. TPH contains three domains being an N-
terminal regulatory domain (r), a catalytic domain (c) and a small C-terminal 
tetramerisation domain (t). Truncated versions of gTPH1 were made and expressed in 
Escherichia coli [8,9]. During my master thesis I worked on two truncated versions, one 
containing the catalytic domain (cgTPH1) and one containing the regulatory and 
catalytic domain (rcgTPH1) [10]. Different versions of gTPH1 were further studied by 
students in the Bioinorganic Research Group [11,12,13]. 
Just before I started my Ph.D. study, the identification of a second gene for TPH in 
human was reported [14].  This human TPH isoform 2 (hTPH2) was the brain specific 
isoform while the isoform 1 was expressed in peripheral parts of the body. Reports on 
purification of TPH from natural sources had earlier claimed the presence of two 
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isoforms of TPH but because of the instability and low concentrations of TPH in 
natural sources the existence of two isoforms were never proven.  
Since hTPH2 had not been expressed recombinantly and characterised thoroughly we 
decided to focus on this isoform. My initial goal of this project was to express 
recombinant hTPH2 in Escherichia coli (E. coli), purify it and characterise it. The main 
methods chosen for characterisation were enzyme kinetic studies and X-ray crystallo-
graphy. 
Enzyme kinetics study how the reaction rate is affected by different factors. These 
factors are typically the substrate concentrations. From enzyme kinetic studies one 
determines the Km and Vmax parameters for the enzyme. One may also determine the 
kinetic mechanism of the enzyme. 
X-ray crystallography is used to determine the three-dimensional structures of 
proteins. The structure of a protein holds much information of its function. For 
example, the architecture of the active site is very useful when studying the kinetic and 
enzymatic mechanisms. The structure may also elucidate mechanism of allosteric 
regulation or mechanism of cooperativity in multimeric enzymes. Furthermore, the 
structure can be used in designing molecules that will interact with the enzyme and 
regulate its activity. 
In my Ph.D. study I therefore set forth to characterise hTPH2 by enzyme kinetics and to 
crystallise it for X-ray crystallographic characterisation. As the project developed it 
became evident that hTPH2 was difficult to express in E. coli in a form that could be 
purified. Subsequently, truncated versions of hTPH2 were made of which two could be 
purified. In addition to these variants the cgTPH1 could also be purified. These three 
TPH variants were subjected to enzymatic characterisation and crystallisation 
experiments. Conditions for crystallising cgTPH1 were found by C. R. Petersen [15] 
and I continued the crystallisation when she finished her M. Sc. project. 
1.1 Outline of the dissertation 
In chapter 2 an introduction to the properties of TPH will be given. The important 
functions of serotonin will be introduced as well as disorders related to serotonin.  
Chapter 3 starts with a small introduction of proteonomics tools used to analyse the 
TPH sequences. Then ubiquitin and the solubility-enhancement tag are introduced as 
these are used as fusion proteins in the expression of some TPH variants. This is 
followed by a presentation of the 17 different E. coli expression constructs of gTPH1 
and hTPH2 tested in this project.  The procedure for expression and protein solubility 
tests are presented and followed by the results. 
In chapter 4 the expression of three TPH variants are described. The first variant is 
catalytic domain of gTPH1 (cgTPH1). The second variant is the catalytic domain of 
hTPH2 (chTPH2), and the third variant holds the catalytic and tetramerisation domain 
of hTPH2 (cthTPH2). The purification procedures for these proteins are presented 
followed by the results of expression and purification.  
Chapter 5 gives an introduction to selected topics of enzyme kinetics. TPH catalyses 
the reaction between three substrates. Such a reaction may follow different kinetic 
mechanisms and these will be presented as will the corresponding rate equations. A 
method for studying the kinetic mechanisms will be presented. 
Chapter 6 describes the assay used to measure the formation of 5-hydroxytryptophan, 
followed by the procedure used for measuring the initial rates. For the three variants 
cgTPH1, chTPH2 and cthTPH2 the initial rates were measured in experiments where 
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the substrate concentrations were varied one at a time. From these initial rates the Km 
and Vmax parameters are determined and discussed. 
In chapter 7 the kinetic mechanism of the catalytic domain of hTPH2 is investigated by 
the method presented in chapter 5. The data are analysed graphically and by global 
curve fitting. The results are presented and discussed. 
Chapter 8 serves a short introduction to the crystallisation of proteins. Chapter 9 deals 
with the trials to crystallise the three TPH variants purified in chapter 4. Results of data 
collection on cgTPH1 crystals are described as well as the overall structure of cgTPH1. 
Chapter 10 is the final chapter giving a short status. 
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CHAPTER TWO 
2 Tryptophan hydroxylase 
 
 
 
This chapter serves as an introduction to TPH and summarises the most important 
properties of TPH. A short introduction to the co-substrate tetrahydrobiopterin and 
related pterins are given, as it will be useful in the further reading. Serotonin will also 
be introduced as well as disorders related to the serotonin functions. The possible roles 
of TPH in these disorders are presented. The enzymes phenylalanine hydroxylase and 
tyrosine hydroxylase are closely related to TPH. These enzymes are characterised to a 
greater extent than TPH. Knowledge obtained from these enzymes will therefore be 
presented here in order to fill some of the gaps in the knowledge of TPH.  
2.1 The aromatic amino acid hydroxylases 
Tryptophan hydroxylase (TPH) (tryptophan 5-monooxygenase, EC 1.14.16.4) catalyses 
the reaction between tryptophan, 5,6,7,8-tetrahydrobiopterin (BH4) and O2 to give 5-
hydroxytryptophan and 4a-hydroxy-tetrahydrobiopterin (4a-hydroxy-BH4) as shown 
in scheme 2.1 [16,17,18].  
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Scheme 2.1 
Together with phenylalanine hydroxylase (EC 1.14.16.1) and tyrosine hydroxylase (EC 
1.14.16.2), TPH form the small enzyme family of aromatic amino acid hydroxylases 
(AAAH) [18]. These enzymes all contain iron and use BH4 as a co-substrate in the 
hydroxylation of their respective aromatic amino acids [1,19,20]. Additionally all 
mammalian AAAH form homotetramers and each monomer consists of three domains. 
These domains are the N-terminal regulatory domain (100-150 residues), the catalytic 
domain (approximately 315 residues) and the C-terminal tetramerisation domain 
(approximately 30-40 residues) [21,22,23,24].  
2.1.1 Phenylalanine hydroxylase and tyrosine hydroxylase 
Phenylalanine hydroxylase (PAH) is found in the liver where it catalyses the 
hydroxylation of phenylalanine to tyrosine. This is the first step in the oxidative 
degradation of phenylalanine [25]. Mutations in PAH, which lead to a decrease in 
enzyme activity result in the disease phenylketonuria, where phenylalanine is conver-
2 Tryptophan hydroxylase
 
 
6 
ted to phenylpyruvate. Phenylpyruvate is toxic and leads to mental retardation, but 
this can generally be avoided through a low phenylalanine diet [26]. PAH is also found 
in some bacteria, but only PAH from the bacteria Chromobacterium violaceum and 
Colwellia psychrerythraea have been characterised [27,28,29]. The bacterial PAHs are 
monomeric and do not contain a regulatory domain [28,29]. Therefore, all the AAAH 
are believed to have evolved from common ancestor containing only the catalytic 
domain [21]. 
Tyrosine hydroxylase (TH) is found in the brain and in the adrenal gland where it 
catalyses the conversion of tyrosine to 3,4-dihydroxyphenylalanine (dopa) [30]. This is 
the first and rate limiting step in the biosynthesis of the catecholamines dopamine, 
norepinephrine and epinephrine as illustrated in figure 2.1 [31]. Deficiency in TH has 
been observed in dopa responsive dystonia and juvenile parkinsonism. A reduced 3,4-
dihydroxyphenylalanine production is also observed in Parkinson’s disease [31].  
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Figure 2.1 The biosynthetic pathway of the catecholamines dihydroxyphenylalanine (dopa), 
dopamine, norepinephrine and epinephrine [32].  
2.2 The two isoforms of tryptophan hydroxylase  
TPH exists in two isoforms called TPH isoform 1 (TPH1) and TPH isoform 2 (TPH2) 
[14]. The existence of two isoforms was observed when TPH was purified and 
characterised from different tissues [33,34,35,36,37]. The gene encoding for rabbit TPH1 
was identified in 1987 by Grenett et al.[21] and a few years later the human gene for 
TPH1 was identified on chromosome 11 [38,39]. The gene for isoform 2 was identified 
in 2003 by Walther et al. and the human gene is located on chromosome 12 [14].  
The two isoforms are expressed in different tissues. TPH2 is mainly expressed in 
serotonergic neurons of the brain and gut [14,40,41,42,43]. TPH1 is expressed in other 
parts of the body such as the pineal gland [1,40], skin cells [44], mast cells [16], 
intestinal mucosa and enterochromaffin cells [45] and in cancer cells [46,47]. The most 
pronounced difference between the two isoforms is that the N-terminal is extended by 
46 residues in TPH2 (see sequence alignment in figure 2.2) [48].  
No isoforms are reported of PAH and non-primate TH, while four isoforms of human 
TH exist. Only one human TH gene exists and the isoforms are the result of alternative 
mRNA splicing. The differences between the four isoforms are found in the regulatory 
domain [49].  
2.3 Sequence alignment of the aromatic amino acid hydroxylases 
The sequence alignment of gTPH1 [50], hTPH1 [38], hTPH2 [14], human PAH [51] and 
human TH isoform 4 [52] is shown in figure 2.2. The sequence identities are listed in 
table 2.1. 
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Figure 2.2. Alignment of sequences of gTPH1, hTPH1, hTPH2, human PAH and human TH 
isoform 4. The sequences are obtained from the ExPASy server [53] with the primary accession 
numbers P70080 (gTPH1), P17752 (hTPH1), Q8IWU9 (hTPH2), P00439 (human PAH) and 
P07101 (human TH4). The alignment was done using ClustalW 1.83 [54]. Green background 
indicates conserved residues in all sequences. Yellow background indicates conserved residues 
in at least all TPHs. “:” means that conserved substitutions have been observed within the 
groups (AVFPMILW), (DE), (RHK), (STYHCNGQ). “.” means that semi conserved substitutions 
are observed. The domain boundaries as used in this project are marked by a black vertical line.  
     hTPH2     ------------------------------------------------MQPAMMMFSSKY 12 
     human PAH ------------------------------------------------------------ 
     human TH4 MPTPDATTPQAKGFRRAVSELDAKQAEAIMVRGQGAPGPSLTGSPWPGTAAPAASYTPTP 60 
 
                        |         |         |         |         |         | 
     gTPH1     -----------------------------MIEDNKENK-----DHAPE-RGRTAIIFSLK 25 
     hTPH1     -----------------------------MIEDNKENK-----DHSLE-RGRATLIFSLK 25 
     hTPH2     WARRGFSLDSAVPEEHQLLGSSTLNKPNSGKNDDKGNKGSSKREAATE-SGKTAVVFSLK 71 
     human PAH -------MSTAVLENPGLG----------RKLSDFGQETSYIEDNCNQ-NGAISLIFSLK 42 
     human TH4 RSPRFIGRRQSLIEDARKEREAAVAAAAAAVPSEPGDPLEAVAFEEKEGKAVLNLLFSPR 120 
                                          .:  :          :  .   ::   : 
                        |         |         |         |         |         | 
     gTPH1     N-EVGGLVKALKLFQEKHVNLVHIESRKSKRRNS---EFEIFVDCDSNREQLNEIFQLLK 81 
     hTPH1     N-EVGGLIKALKIFQEKHVNLLHIESRKSKRRNS---EFEIFVDCDTNREQLNDIFHLLK 81 
     hTPH2     N-EVGGLVKALRLFQEKRVNMVHIESRKSRRRSS---EVEIFVDCECGKTEFNELIQLLK 127 
     human PAH E-EVGALAKVLRLFEENDVNLTHIESRPSRLKKD---EYEFFTHLD--KRSLPALTNIIK 96 
     human TH4 ATKPSALSRAVKVFETFEAKIHHLETRPAQRPRAGGPHLEYFVRLEVRRGDLAALLSGVR 180 
                 : ..  :.::: :   .::  : :  ::       .    .  :  : .:  :   :: 
                        |         Catalytic domain--> |         |         | 
     gTPH1     SHVSIVSMNPTEHFNVQEDGDMENIPWYPKKISDLDKCANRVLMYGSDLDADHPGFKDNV 141 
     hTPH1     SHTNVLSVTPPDNFTMKEEG-MESVPWFPKKISDLDHCANRVLMYGSELDADHPGFKDNV 140 
     hTPH2     FQTTIVTLNPPENIWTEEEE-LEDVPWFPRKISELDKCSHRVLMYGSELDADHPGFKDNV 186 
     human PAH ILRHDIGATVHELSRDKKKD---TVPWFPRTIQELDRFANQILSYGAELDADHPGFKDPV 153 
     human TH4 QVSEDVRSPAGP-----------KVPWFPRKVSELDKCHHLVTKFDPDLDLDHPGFSDQV 229 
                    :                  :  : :.:.:  :  : :  :..:        .    
                        |         |         |         |         |         | 
     gTPH1     YRKRRKYFADLAMNYKHGDPIPEIEFTEEEIKTWGTVYRELNKLYPTHACREYLKNLPLL 201 
     hTPH1     YRKRRKYFADLAMNYKHGDPIPKVEFTEEEIKTWGTVFRELNKLYPTHACREYLKNLPLL 200 
     hTPH2     YRQRRKYFVDVAMGYKYGQPIPRVEYTEEETKTWGVVFRELSKLYPTHACREYLKNFPLL 246 
     human PAH YRARRKQFADIAYNYRHGQPIPRVEYMEEEKKTWGTVFKTLKSLYKTHACYEYNHIFPLL 213 
     human TH4 YRQRRKLIAEIAFQYRHGDPIPRVEYTAEEIATWKEVYTTLKGLYATHACGEHLEAFALL 289 
                      :.::    :: :   .: :           :   .          : . :.   
                        |         |         |         |         |         |       
     gTPH1     TKYCGYREDNIPQLEDVSRFLKERTGFTIRPVAGYLSPRDFLAGLAFRVFHCTQYVRHSS 261 
     hTPH1     SKYCGYREDNIPQLEDVSNFLKERTGFSIRPVAGYLSPRDFLSGLAFRVFHCTQYVRHSS 260 
     hTPH2     TKYCGYREDNVPQLEDVSMFLKERSGFTVRPVAGYLSPRDFLAGLAYRVFHCTQYIRHGS 306 
     human PAH EKYCGFHEDNIPQLEDVSQFLQTCTGFRLRPVAGLLSSRDFLGGLAFRVFHCTQYIRHGS 273 
     human TH4 ERFSGYREDNIPQLEDVSRFLKERTGFQLRPVAGLLSARDFLASLAFRVFQCTQYIRHAS 349 
                ::. ::   :          :  :   :        .    ..  :   :    :  . 
                        | Fe   Fe |         |         |         |      Fe |  
     gTPH1     DPLYTPEPDTCHELLGHVPLLAEPSFAQFSQEIGLASLGASDEAVQKLATCYFFTVEFGL 321 
     hTPH1     DPFYTPEPDTCHELLGHVPLLAEPSFAQFSQEIGLASLGASEEAVQKLATCYFFTVEFGL 320 
     hTPH2     DPLYTPEPDTCHELLGHVPLLADPKFAQFSQEIGLASLGASDEDVQKLATCYFFTIEFGL 366 
     human PAH KPMYTPEPDICHELLGHVPLFSDRSFAQFSQEIGLASLGAPDEYIEKLATIYWFTVEFGL 333 
     human TH4 SPMHSPEPDCCHELLGHVPMLADRTFAQFSQDIGLASLGASDEEIEKLSTLSWFTVEFGL 409 
               . :::              :::: .      :        .:  ::  :   :  : 
                        |         |         |         |         |         |  
     gTPH1     CKQEGQLRVYGAGLLSSISELKHSLSGSAKVKPFDPKVTCKQECLITTFQEVYFVSESFE 381 
     hTPH1     CKQDGQLRVFGAGLLSSISELKHALSGHAKVKPFDPKITCKQECLITTFQDVYFVSESFE 380 
     hTPH2     CKQEGQLRAYGAGLLSSIGELKHALSDKACVKAFDPKTTCLQECLITTFQEAYFVSESFE 426 
     human PAH CKQGDSIKAYGAGLLSSFGELQYCLSEKPKLLPLELEKTAIQNYTVTEFQPLYYVAESFN 393 
     human TH4 CKQNGEVKAYGAGLLSSYGELLHCLSEEPEIRAFDPEAAAVQPYQDQTYQSVYFVSESFS 469 
                   ..::.:        .   :.    . : .:: : :.        :    : :   . 
                        |         |         |    Tetramerisation|domain   | 
     gTPH1     EAKEKMREFAKTIKRPFGVKYNPYTQSVQILKDTKSIASVVNELRHELDIVSDALSKMGKQLEV 445 
     hTPH1     DAKEKMREFTKTIKRPFGVKYNPYTRSIQILKDTKSITSAMNELQHDLDVVSDALAKVSRKPSI 444 
     hTPH2     EAKEKMRDFAKSITRPFSVYFNPYTQSIEILKDTRSIENVVQDLRSDLNTVCDALNKMNQYLGI 490 
     human PAH DAKEKVRNFAATIPRPFSVRYDPYTQRIEVLDNTQQLKILADSINSEIGILCSALQKIK----- 452 
     human TH4 DAKDKLRSYASRIQRPFSVKFDPYTLAIDVLDSPQAVRRSLEGVQDELDTLAHALSAIG----- 528 
               :  : : .::       .  ::     ::: ...: :    : :. ::. :.     :   
2 Tryptophan hydroxylase
 
 
8 
Table 2.1 Sequence identities between the gTPH1, hTPH1, hTPH2, human PAH and human TH 
isoform 4. The numbers in parenthesis are the sequence identities for the catalytic domains of 
the respective enzymes. The sequence identity calculation was done using ClustalW 1.83 [54].  
 Sequence identity in % 
Protein hTPH1 hTPH2 human PAH human TH isoform 4 
gTPH1 86 (91) 74 (82) 54 (63) 46 (60) 
hTPH1  70 (81) 53 (64) 47 (59) 
hTPH2   54 (64) 44 (62) 
human PAH    48 (62) 
2.4 Pterins 
Pterins got their name from the greek word pteron meaning wing, because the first 
pterins were originally isolated as pigments from butterfly wings [55]. The structures 
of pterin and the derivatives (6R,1’R,2’S)-6-(1’,2’-dihydroxypropyl)-5,6,7,8-tetrahydro-
pterin (tetrahydrobiopterin, BH4), 7,8-dihydro-L-biopterin (BH2), quinonoid-7,8-
dihydro-L-biopterin (qBH2), 6-methyl-5,6,7,8-tetrahydropterin (6MePH4) and 6,7-
dimethyl-5,6,7,8-tetrahydropterin (DMPH4) relevant to AAAH are shown in figure 2.3 
[55,56].  
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Figure 2.3 Structures of pterin, 6(R)-5,6,7,8-tetrahydro-L-biopterin (BH4), 7,8-dihydro-L-
biopterin (BH2), quinonoid-7,8-dihydro-L-biopterin (qBH2), 6-methyl-5,6,7,8-tetrahydropterin 
(6MePH4), and 6,7-dimethyl-5,6,7,8-tetrahydropterin (DMPH4) [55,56].  
BH4 is the naturally occurring co-substrate for the AAAH [1,57], glyceryl-ether 
monooxygenase (EC 1.14.16.5) [58] and nitric oxide synthase (EC 1.14.13.39) [59]. At 
neutral pH BH4 is prone to oxidation by O2 [60,61]. The initial step in this oxidation is a 
slow electron transfer from BH4 to O2, producing the free −2O . radical as shown in 
equation 2.1 [62].  
 ⋅+⋅→+ + -2424 O  BHOBH  (2.1) 
This reaction initiates a chain reaction involving several intermediates yielding BH2 as 
the final oxidation product. Equation 2.2 summarises the overall auto oxidation 
reaction of BH4 in the presence of catalase. For details on the chain reaction see Kirsch 
et al. [62]. 
 O2H2BHO2BH 2224 +→+  (2.2)   
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At acidic pH BH4 is protonated at N5 (pKa 5.6) and at N1 (pKa 1.3). The protonation of 
N5 increases the stability of BH4 toward the autooxidation [55]. 
In the reaction catalysed by TPH BH4 is converted to 4a-hydroxy-BH4 also called BH4-
carbinolamine. In vivo 4a-hydroxy-BH4 is then regenerated by the enzymes pterin-4a-
carbinolamin dehydratase and dihydrobiopteridine reductase at the expense of NADH 
[63] This is schematically shown in figure 2.4. In vitro 4a-hydroxy-BH4 spontaneously 
decomposes to qBH2 [61]. 
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Figure 2.4 The TPH catalysed reaction and regeneration of BH4. TPH uses BH4 as an electron 
donor in reduction of O2 and hydroxylation of tryptophan. The 4a-hydroxy-BH4 is converted by 
the enzyme pterin-4a-carbinolamine dehydratase to qBH2. qBH2 is then reduced to BH4 by 
dihydrobiopteridine reductase at the expense of NADH [63]. 
2.5 The three-dimensional structure of tryptophan hydroxylase 
As described in section 2.1 TPH consists of a regulatory, a catalytic and a 
tetramerisation domain [21,22,23]. The X-ray crystal structure of the catalytic domain of 
hTPH1 (chTPH1) is the only structure that has been determined for any TPH. It was 
determined by Wang et al. to a 1.7 Å resolution and refined to an Rfree of 23.1 % [64]. 
The overall structure is illustrated in figure 2.5A. It is similar to the catalytic domains 
of PAH and TH with a root mean square deviation of 1.0 Å for PAH (PDB entry 1PAH) 
and 0.9 Å for TH (PDB entry 1TOH) [64]. The structure of TPH was solved with ferric 
iron, while the active form is ferrous iron [64,65]. The iron is octahedrally coordinated 
by His272, His277, Glu317 on one face and three water molecules on the other (see 
figure 2.5B) [64]. The coordination of the iron by 2 histidines and a glutamate is also 
seen in PAH and TH [66,67,68,69]. This coordination of iron by two histidines and 
glutamate/ aspartate motif is also called the facial triad and is seen in many iron 
enzymes involved mainly in O2 activation [70,71].  
In chTPH1 the iron is found in a cavity being 9 Å deep and 10 Å wide which is 
accessible for substrates. The BH2 bound in the active site is sandwiched between 
2 Tryptophan hydroxylase
 
 
10 
Tyr235 and Phe241 (see figure 2.5B). Furthermore, BH2 is hydrogen bonded to the 
backbone of Gly234 and Leu236 (not shown in figure 2.5) and through bridging water 
molecules to Glu273 and Glu317 [64].  
B  
Figure 2.5 (A) The overall structure of the catalytic domain of hTPH1 (Protein data bank (PDB) 
entry 1MLW). (B) The catalytic site with the iron in green coordinated by His 272, His 277, 
Glu317 and three water molecules (red). The BH2 is bound by π-stacking interactions with 
Tyr235 and Phe241 [64]. The figures were made using Pymol [72]. 
The structures of the regulatory and tetramerisation domains of TPH are not known, 
but are believed to be similar to that of PAH and TH [73]. All new structural 
information of TPH will be useful in a better understanding of this enzyme. Infor-
mation about the structures of the N-terminals of TPH1 and TPH2 would especially be 
interesting, since this is where the largest sequence differences are seen. Some 
structural properties of PAH and TH are presented in the next section. 
2.5.1 Structures of tyrosine hydroxylase and phenylalanine 
hydroxylase 
TH and especially PAH have been more extensively characterised structurally than 
TPH. The crystal structures that have been determined for TH and PAH are 
summarised in table 2.2. The structure of a full length enzyme has not yet been deter-
mined. Truncated versions of TH and PAH containing the catalytic and tetramerisation 
domain have been crystallised as tetramers [68,69] and the structure of PAH (PDB 
entry 2PAH) is shown in figure 2.6. The tetramerisation domains interact through 
hydrophobic interactions in a coiled-coil motif [68]. 
The structure of the regulatory and catalytic domains of rat PAH has been determined 
(see figure 2.7) [74]. The first 18 residues are not visible in the structure. Residues 19-33 
extends across the catalytic domain partially blocking the entrance to the active site 
(see figure 2.7). Movement of this N-terminal part of the regulatory domain is believed 
to be involved in the regulation of PAH [74]. 
All three AAAH have been crystallised with BH2 and Fe(III). It has not been possible to 
obtain crystals with bound aromatic amino acids, but PAH-Fe(II) has  been crystallised 
with BH4 and thienylalanine (PDB entry 1MMK)[75]. Comparison of this structure with 
the structure without thinenylalanine (PDB entry 1J8U) reveals large structural changes 
2.5 The three-dimensional structure of tryptophan hydroxylase
 
11 
upon thienylalanine binding. The loop containing Tyr138 moves from a surface 
position to a buried position as shown in figure 2.8 [75]. This loop flexibility has also 
been reported for TH [76,77], but has not been studied for TPH. 
Table 2.2 Three-dimensional structures of TH and PAH determined by X-ray crystallography. 
Cv is Chromobacterium violaceum and Cp is Colwellia psychrerythraea. 
PDB  
entry 
Organism Domains Resolution  Comments Ref. 
Tyrosine hydroxylase 
1TOH Rat ct 156-177, 200-498 2.3 Å Fe(III) [68] 
2TOH Rat ct 160-182, 186-498 2.3 Å Fe(III), BH2 [78] 
Phenylalanine hydroxylase 
1PAH Human c 117-424 2.0 Å Fe(III) [69,79] 
2PAH Human ct 118-136, 143-452 3.1 Å  Fe(III) [80] 
3PAH Human c 117-424 2.0 Å Fe(III), adrenaline [81] 
4PAH Human c 117-424 2.0 Å Fe(III), noradrenaline [81] 
5PAH Human c 117-424 2.1 Å Fe(III), dopamine [81] 
6PAH Human  c 117-424 2.15 Å Fe(III), dopa [81] 
2PHM Rat rc 19-136, 143-427 2.6Å Fe(III), dephosphorylated [74] 
1PHZ Rat rc 19-136, 143-427 2.2 Å Fe(III), phosphorylated [74] 
1DMW Human c 118-424 2.0 Å Fe(III), BH2 [82] 
1KW0 Human c 118-424 2.5 Å Fe(II), BH4, thienylalanine [83] 
1MMK Human c 117-425 2.0 Å Fe(II), BH4, thienylalanine [75] 
1MMT Human c 117-424 2.0 Å Fe(II), BH4, norleucine [75] 
1J8T Human c 118-424 1.7 Å Fe(II)  [84] 
1J8U Human c 118-424 1.5 Å Fe(II), BH4 [84] 
1TDW Human c 117-424 2.1 Å Fe(III), A313T [85] 
1TG2 Human c 117-424 2.2 Å Fe(III), BH2, A313T [85] 
1LRM Human c 118-424 2.1 Å Fe(III), BH2  
1LTU Cv 2-285 1.74 Å  [86] 
1LTV Cv 9-283 2.0 Å Fe(III) [86] 
1LTZ Cv 7-253, 257-284 1.4 Å Fe(III), BH2 [86] 
2V27 Cp 4-267 1.5 Å Fe(III) [29] 
2V28 Cp 7-267 1.95 Å  [29] 
2.6 Substrate specificities of TPH, TH and PAH 
TPH can hydroxylate tryptophan, phenylalanine and tyrosine with efficiencies in this 
order [87]. PAH can hydroxylate phenylalanine and tryptophan, but not tyrosine 
[88,89]. TH can hydroxylate tyrosine, phenylalanine and tryptophan with efficiencies in 
this order [90]. 
The substrate specificity is mainly governed by the catalytic domains of the respective 
enzymes. The Phe313 (in hTPH1) located in active site cavity is conserved in all TPHs 
and is important for the substrate specificity [91,92]. In PAH the equivalent residue is 
Trp326 and in TH Trp372. By mutating Phe313 in hTPH1 to a tryptophan, hTPH1 no 
longer showed a preference of tryptophan over phenylalanine. Mutating the equivalent  
Trp372 in TH and Trp326 in PAH to a phenylalanine, resulted in a decrease in the 
affinity of their respective natural substrates [91,92]. For TH the Asp425 has been 
reported as very important for tyrosine hydroxylation. A mutation of the Asp425 to 
valine, which is found in PAH, drastically decreased the affinity for tyrosine and 
improved the ability of hydroxylating phenylalanine [93]. 
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Figure 2.6 The crystal structure of the catalytic and tetramerisation domains of tetrameric PAH 
(PDB entry 2PAH) [80]. The coiled-coil motif is seen in the centre of the structure. The figure 
was made using Pymol [72]. 
 
Figure 2.7 The crystal structure of the regulatory and catalytic domain of rat PAH residues 19-
427(PDB entry 1PHZ) [74]. The catalytic domain is shown in green with iron as a red-brown 
sphere. The regulatory domain is shown in blue with the side chains shown for residue Gly19-
Asp27. Gly19-Asp27 partially blocks the entrance to the active site. The figure was made using 
Pymol [72].  
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Figure 2.8 Structural alignment of the catalytic domain of PAH-Fe(II)-BH4 (green backbone, 
PDB entry 1J8U) with PAH-Fe(II)-BH4-thienylalanine (blue backbone, PDB entry 1MMK). The 
largest differences are seen for Tyr138 which moves from a surface position (shown in green) to 
a buried position (shown in yellow) close to the active site. Tyr138, BH4 (1MMK) and 
thienylalanine are shown as sticks. The iron of 1MMK is shown as a red sphere. The structural 
alignment was done with Coot [94] and the figure was made using Pymol [72]. 
2.7 Order of substrate binding 
No enzyme kinetic investigations of TPH have been carried out to determine the order 
of substrate binding. This is probably due to the limited availability and the instability 
of TPH. The kinetic mechanisms of rat TH and Chromobacterium violaceum PAH 
(CvPAH) have been investigated [95,96,97]. All three reports agree upon a sequential 
mechanism, i. e. all three substrates must be bound before a chemical reaction can 
occur. However, the three disagree on the binding order of the substrates. 
For rat TH the binding order is 6MePH4 first, followed by O2 and then tyrosine [95]. 
For CvPAH Pember et al. report that O2 binds first, followed by random binding of 
DMPH4 and phenylalanine [96]. It should be noted that Pember et al. at the time 
believed that CvPAH was a Cu-dependent enzyme and the assay conditions were 
therefore not supplemented with iron, which might have affected the outcome of the 
investigation [27,28,98,99]. Volner et al. have reported an ordered binding for CvPAH 
of DMPH4, phenylalanine and O2 in this order [97].  
Substrate inhibition by the respective amino acids has been observed for the three 
AAAH [87,95,97,100,101], which is usually a sign of the amino acid not being the first 
substrate to bind ( see section 5.3). As mentioned in section 2.5.1 all three AAAH have 
been crystallised with BH2 or BH4, but not with any of the respective amino acids. This 
indicates that binding of BH4 occurs before the amino acid.  
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2.8 Mechanism of the enzymatic reaction 
Because of the high homology between the catalytic domains of TPH, TH and PAH it is 
generally believed that they share a common catalytic mechanism [102,103]. It has been 
shown that the source of the oxygen incorporated into phenylalanine by PAH is 
molecular oxygen [104], while the other oxygen atom is incorporated into the 
6MePH4/BH4 [105]. All three AAAH can be inhibited by catechols which chelate the 
iron [106,107,108]. The active form of the iron is the ferrous state, and ferric iron can be 
reduced to ferrous iron by BH4 [109,110,111]. 
The catalytic mechanism can be separated in two partial reactions, where the first is the 
formation of the hydroxylating intermediate and the second is the oxygen transfer to 
tryptophan [102]. No intermediates have been trapped for direct detection for any of 
the AAAH [102].  
2.8.1 Mechanism of oxygen activation 
Different hydroxylating intermediates have been proposed. One of these is a peroxo-
BH4 species seen in figure 2.9 (compound I) [112]. The formation and the following 
reaction of this species does not include the function of iron, and as the hydroxylation 
of the amino acid does not occur without the presence of iron, the peroxo-BH4 species 
is not a likely candidate.   
An Fe(II) μ-peroxy-BH4 species (compound II) has been proposed as the hydroxylating 
species [105]. If this is the hydroxylating species the cleavage of the O-O bond should 
be concerted with the oxygen addition to the amino acid [102]. Subsequently the 
amount of hydroxylated amino acid should equal the amount of produced 4a-hydroxy-
BH4. This is not always the case. When tyrosine is the substrate in TPH or PAH the 
enzymes primarily function as a BH4 oxidase without hydroxylating tyrosine 
[113,114,115]. This suggests that the Fe μ-peroxy-BH4 is not the hydroxylating species 
[102].  
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Figure 2.9 Proposed hydroxylating species of the aromatic amino acid hydroxylases. I is the 
peroxo-BH4 species, II the Fe μ-peroxy-BH4 species and III the ferryl oxo species [102]. 
A ferryl oxo species (compound III) was proposed based on the observation that PAH 
was able to hydroxylate an aliphatic carbon in norleucine to ε-hydroxynorleucine [116]. 
Theoretical investigations show that the ferryl oxo species is a likely candidate for the 
hydroxylating intermediate in the AAAH [117,118]. The ferryl oxo species has been 
detected as an intermediate in the catalytic mechanisms of taurine/α-ketoglutarate 
dioxygenase [119,120,121,122] and of prolyl-4-hydroxylase [123]. In both of these 
enzymes the iron is coordinated in the 2 histidine-carboxylate facial triad. The ferryl 
oxo species is expected to be an intermediate in several mononuclear iron enzymes 
with facial triad coordination [124]. Currently no report has been published on the 
detection of the ferryl oxo species in any AAAH. 
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In the AAAH the ferryl oxo species is believed to be formed from the Fe μ-peroxy-BH4 
by cleavage of the O-O bond. Whether O2 binds to Fe(II) or to BH4 in the initial step is 
uncertain. Theoretical investigations suggest that O2 initially binds to iron and then the 
Fe-O-O2- species attacks the C4a of BH4 [117,118]. An Fe-O-O species has recently been 
structurally characterised in the oxidative ring cleavage of 4-nitrocatechol by homo-
protocatechuate 2,3-dioxygenase also containing iron coordinated by the 2 histidine-
carboxylate facial triad [125]. 
2.8.2 Mechanism of hydroxylation  
The first step in the hydroxylation of the aromatic amino acid is believed to be an 
electrophilic attack of the Fe(IV)=O on the aromatic C atom (see scheme 2.2) making an 
arenium cation intermediate [102]. This mechanism is different from that of the α-
ketoglutarate dependent oxygenases, where the initial step in the hydroxylation is H 
atom abstraction from the substrate and subsequent OH transfer [124]. The cationic 
intermediate is consistent with the observation that when [5-3H]-tryptophan is 
hydroxylated by TPH, tritium is shifted to position 4 [126]. This is called the NIH- shift 
and is also observed in the hydroxylations by PAH and TH [127,128,129]. The believed 
electrophilic attack of the Fe(IV)=O is furthermore supported by theoretical investi-
gations [130,131]. 
The generally accepted mechanism of the enzymatic reaction is summarised in scheme 
2.2 [102]. 
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Scheme 2.2 
The hydroxylation step of tryptophan is the rate limiting step in the enzymatic 
turnover by TPH [87, 103,113,132], while the oxygen activation step is believed to be 
the rate limiting step of TH and PAH (when BH4 is used) [95,133,134]. This difference is 
believed to occur because the hydroxylation of tryptophan is slower than hydroxy-
lation of phenylalanine and tyrosine [113].  
2.9 Expression of recombinant tryptophan hydroxylases 
TPH has been expressed in E.coli, Pichia pastoris, insect cells and mammalian cell 
cultures. A list summarising selected reports is shown in table 2.3.  
Not surprisingly E. coli dominates in expression of recombinant TPH, since it is well 
studied as an expression host and offers rapid and inexpensive production of 
recombinant proteins [135,136]. Unfortunately, some proteins expressed in E. coli do 
not fold properly and subsequently form insoluble aggregates called inclusion bodies 
[137].  
When TPH is expressed in E. coli, insolubility and instability have been reported to be a 
general problem [21,138,139,140,141,142]. In a few cases these problems seem to have 
been overcome [143,144], but detailed explanations on how this was done is lacking. 
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Table 2.3 A summary of selected reports on expression of recombinant TPH variants. 
Abbreviations for fusion proteins are: 6 histidine tag (6His), maltose binding protein (MBP), 
thioredoxin (Trx), glutathione transferase (GST) and N-utilization substance A (NusA). COS7 
cells are the African green monkey SV40-transfected kidney fibroblast cell line.  
Organism 
and isoform 
Domains Fusion protein Expression host Expression  
temp. / time 
Ref. 
Human TPH1 Full length 6His-TPH  
MBP-TPH 
6His-Trx-TPH 
E. coli BL21 Star 
(DE3) 
37˚C/4 h or 
27˚C/18 h 
[138] 
Human TPH1 Full length None Pichia pastoris 
KM21 
30˚C/24 h [138] 
Human TPH1 Full length None E.coli BL21(DE3) Room temp./ 
overnight 
[143] 
Human TPH1 Full length 
ct, 92-444 
c, 92-425 
MBP-TPH E. coli DH5 Not reported [139]  
Human TPH1 ct, 91-444 6His-Trx-TPH E.coli TOP10 37˚C/>3 h [92] 
Human TPH1 c, 103-401 TPH-6His E.coli BL21(DE3) 25˚C/15 h [64] 
Human and 
Rabbit TPH1 
Full length  E.coli BL21(DE3), 
pLysS 
37˚C/2 h [140] 
Rabbit TPH1 Full length 6His-TPH Spodoptera 
frugiperda 21 
27˚C/72 h [145] 
Rabbit TPH1 c, 102-416 None E.coli BL21 (DE) 20˚C/7.5 h [87] 
Rat TPH1 Full length 
ct, 99-444 
GST-TPH E. coli BL21 30˚C/2 h [146] 
Rat TPH1 Full length None Human fibroblast 
cell line  GM4429 
37˚C/48 h [147] 
Mouse TPH1 Full length None E. coli MC 1061 Not rep. /15 h [148] 
Schistosoma 
mansoni 
Full length 6His-TPH E.coli BL21(DE3), 
pLysS 
30˚C/2.5 h [149] 
Human TPH2 Full length 6His-TPH 
Trx-6His-TPH 
6His-GST-TPH 
6His-MBP-TPH 
NusA-6His-
TPH 
E.coli BL21(DE3), 
pLysS 
27˚C/6 h [141] 
Human TPH2 Full length 
ct, 151-490 
c, 151-466 
6His-TPH E. coli BL21-
CodonPlus(DE3)- 
RIL 
15˚C/45 h [21] 
Human TPH2 Full length  
45-490 
1-473 
None 
 
COS7 cells 37˚C/48 h [150] 
Mouse TPH2 Full length GST-TPH E. coli Probably 
30˚C/2 h 
[144] 
 
Truncated versions of TPH have been expressed in E. coli more successfully, yielding 
protein suitable for characterisation. These truncated versions contain either the 
catalytic domain alone or the catalytic-tetramerisation domains [64,87,92].  
If expression of a protein in E. coli fails, expression in eukaryotic cell cultures is 
sometimes tried [151,152]. TPH has been expressed in yeast [138], insect cells [145] and 
mammalian cell cultures [147,150]. The results in these reports do not indicate that 
eukaryotic expression of TPH is superior to expression in E. coli.  
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In summary none of the expression reports listed in table 2.3 is superior to the others, 
so no method can be singled out as the one to use. 
2.10 Purification of tryptophan hydroxylases 
Several different strategies have been applied in the purification of recombinant TPH 
and TPH from natural sources. Generally these can be divided into three groups, one 
using hydroxyapatite chromatography in combination with other methods, another 
using affinity chromatography with immobilised DMPH4 and a third method using the 
properties of fusion proteins or tags for affinity chromatography. 
A combination of (NH4)2SO4 fractionation and hydroxyapatite chromatography have 
been used by several groups [87,153,154], most successfully by Moran et al. purifying 
the catalytic domain of rabbit TPH [87]. This procedure consists of an initial anion 
exchange on a Q Sepharose column, followed by (NH4)2SO4 precipitation. The redis-
solved pellet was then applied to a hydroxyapatite column and the fractions containing 
TPH was concentrated through another (NH4)2SO4 fractionation. From 1 L of cell 
culture this procedure gave 10 mg TPH with a specific activity of 0.6 μmol/min/mg 
[87]. 
The use of DMPH4 as an adsorbent was initially reported in the purification of PAH 
[155] and was later applied to TPH [34,36,37,143,156,157,158]. The report by Nakata 
and Fujisawa is most noteworthy of these, since TPH was highly purified in one step 
only, with a 48% yield and a specific activity of 5.28 μmol/min/mg [36]. The elution of 
TPH from a DMPH4 column was in most cases done with a NaHCO3/NaOH buffer pH 
10.8, while Nakata and Fujisawa used a Tris/acetate buffer pH 7.6 containing 50% 
ethylene glycol [36]. Additionally Cash has reported that TPH can be eluted by 5 mM 
tryptophan in a 50 mM glycine buffer pH 8.0 [157]. 
Most of the more recent reports on purification of TPH have used immobilised metal 
affinity chromatography (IMAC) [21,64,92,138,141] or affinity chromatography using 
either glutathione agarose as an adsorbent for glutathione S-transferase (GST) [144,146] 
or an amylose resin as the adsorbent for the maltose binding protein (MBP) 
[138,139,141]. Attempts to cleave the fusion protein have proven difficult in several 
cases leading to unstable TPH and incomplete cleaving [21,138,139,141]. The C-
terminally His-tagged chTPH1 was purified using IMAC (twice) and anion exchange 
chromatography and subsequently crystallised with the His-tag. The His-tag and the 
C-terminal end of chTPH1 were not visible in the X-ray crystal structure [64]. 
2.11 Regulation of tryptophan hydroxylases 
The regulation of TPH1 and TPH2 is not well understood [18]. TH and PAH are 
activated by phophorylation of serines in the regulatory domain [18]. PAH is 
furthermore allosterically activated by binding of phenylalanine in the regulatory 
domain which induces a conformational change [159,160]. This activating conforma-
tional change in PAH can also be induced by phospholips such as lysolechitin and by 
sulfhydryl modifications [161,162,163]. The extent of the conformational change has not 
been determined, but is likely to involve movement of the N-terminal end which 
blocks the entrance to the active site (see figure 2.7) [74,164]. TH is, in addition to 
regulation by phosphorylation, feedback inhibited by the catecholamines dopamine, 
norepinephrine and epinephrine [165]. 
The differences in the regulatory domains of TPH1 and TPH2 may allow for 
differentiated regulations, but this still has to be proven [48]. Phosphorylation is 
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believed to be important in the regulation of both isoforms [48]. TPH1 has been 
reported to be phosphorylated at Ser58 by protein kinase A [141,166]. TPH2 is also 
phosphorylated by protein kinase A [141,167] and by calmodulin-dependent 
phosphorylation [168,169]. Phosphorylated TPH and TH have been reported to interact 
with 14-3-3 protein [170,171]. The 14-3-3 protein is believed to bind to the regulatory 
domain of TPH and TH increasing the enzyme activity and prevent dephosphorylation 
[145,172]. In humans 7 isoforms exist of the 14-3-3 protein. All isoforms are acidic 
dimeric proteins which have been found to interact with more than 100 different 
proteins with various functions [173,174]. It has been hypothesised that the 14-3-3 
protein binding has a function in stabilising the phosphorylated TPH [145]. This is 
further supported by reports showing that phosphorylated TPH is degraded faster in 
the cells than nonphosphorylated TPH [175]. The degradation of TPH in rat basophilic 
leukaemia cells (RBL2H3) and in mouse mastocytoma cells has been reported to be 
rapid with half-life times of 11-15 min in RBL2H3 cells and 40-60 min in the 
mastocytoma cells [176,177]. The rapid turnover of TPH also indicates that regulation 
at the transcriptional level is important for the immediate TPH activity [175,178].  
2.12 Serotonin 
Serotonin is a hormone and a neurotransmitter [179,180]. Serotonin functions as a 
neurotransmitter in the serotonergic neurons of the brain and gut [7]. In the rest of the 
body serotonin is involved in a wide range of physiological functions such as: 
mediating liver regeneration [180], immune system [181], peristaltic function of the gut 
[182], cardiac function [183], cardio vascular regulation, body temperature regulation 
and appetite [7]. In the pineal gland serotonin serves as a precursor for melatonin 
which is a hormone involved in circadian rhythm control [3]. Arylalkylamine N-
acetyltransferase catalyses the rate-limiting step in the biosynthesis of melatonin 
[3,184].  
2.12.1 Disorders related to serotonin 
Serotonin has been implicated in a wide range of disorders [179]. In the pheripheral 
part of the body serotonin is believed to play a role in ulcerative colitis and in irritable 
bowel syndrome [43]. Dysfunction of the central serotonergic system is found in 
psychiatric disorders like obsessive-compulsive disorder (OCD), depression, anxiety 
disorders, attention deficit hyperactivity disorder (ADHD), anorexia nervosa and 
schizophrenia [7,185]. Behaviours such as substance abuse, gambling, aggression and 
suicide attempts may also have been associated with altered serotonin function [7]. 
Furthermore, dysfunction of the central serotonergic system is also believed to be 
implicated in sudden infant death syndrome [186]. 
Neuropsychiatric disorders like those mentioned above are very complex diseases. 
These may be caused by gene polymorphisms influencing a multitude of biochemical 
pathways. Environmental influences further add to this complexity.  
In the case of depression it has been hypothesised that major depression is caused by a 
deficiency of available serotonin in the brain [187]. Selective serotonin re-uptake 
inhibitors (SSRI) are commonly used in the treatment of depression, OCD and anxiety 
disorders [179]. This medicine increases the serotonin concentration in the synapse by 
inhibiting the serotonin transporter [188].  
Since TPH is the rate limiting step in the biosynthesis of serotonin many studies have 
been performed on the possible correlations between genetic variation in the TPH 
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genes and the occurrence of some of the above mentioned disorders [189]. Correlation 
between the TPH1 and suicide attempts have been reported, but the two 
polymorphisms are found on introns and their effect is not understood [190]. Even 
though TPH1 is not expressed in the developed brain evidence suggests that TPH1 has 
a function in the late developmental stage of the brain [191]. Serotonin synthesis is 
important during the development of the brain and TPH1 may therefore still have a 
role in psychiatric disorders [192]. Correlations have been reported between the TPH2 
gene and OCD [193], ADHD [185,194] and depression [195,196]. Zhang et al. reported a 
single nucleotide polymorphism correlated with depression, which results in a 
mutation in TPH2 of Arg441 to a histidine [196]. Zhang et al. have also reported a 
single nucleotide polymorphism, not necessarily correlated to depression, which 
causes a mutation of Pro449 to an arginine [42]. These two mutations are believed to 
decrease stability or activity of the mouse TPH2 and hTPH2 [144,196,197]. 
2.13 The perspectives of tryptophan hydroxylase research 
TPH is centrally positioned in the regulation of serotonin synthesis. Serotonin is 
involved in a wide range of important physiological and neurobiological functions. A 
full understanding of the biochemistry of TPH1 and TPH2 is a necessary foundation in 
understanding the complex functions of serotonin. Knowledge about the three-
dimensional structure of the full-length enzymes and their regulatory mechanisms 
may also lead to the identification of compounds that modulate the activity of TPH. 
The differences in the regulatory domains of TPH1 and TPH2 may also allow isoform 
specific modulation of activity. 
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CHAPTER THREE 
3 Sequence analysis and expression 
of different TPH constructs 
 
 
 
This chapter starts with an introduction to selected protein sequence analysis tools 
which are later applied to the sequences of gTPH1 and hTPH2. During this project I 
have tested 17 different constructs of TPH in order to obtain soluble TPH that can be 
purified. These constructs and the fusion proteins used will be presented. This is 
followed by experimental, result and discussion sections for these constructs.  
3.1 Theoretical methods for predicting protein properties 
Many proteonomics tools are available for predicting the properties of proteins based 
upon their amino acid sequences. Some of these predict for example glycosylation 
sites, phosphorylation sites or helical content of the protein. Predictions can be useful 
but one should not blindly trust these predictions, since proteins are complicated 
molecules making it difficult to predict anything for sure. Therefore, predictions 
should always be treated with some scepticism. I will present some prediction tools, 
which I have used to analyse the TPH sequences. 
3.1.1 Protein instability index 
The protein instability index was developed by Guruprasad et al. [198] and is imple-
mented in the ProtParam tool of the ExPASy proteonomics server [53]. The instability 
index predicts the in vivo stability of a protein from its primary sequence. In a statistical 
analysis of 12 unstable and 32 stable proteins Guruprasad et al. found that certain 
dipeptide sequences were more frequent in the unstable proteins than in the stable 
proteins. For each possible dipeptide they calculated a dipeptide instability weight 
value. When a protein sequence is analysed all the dipeptide instability weight values 
are calculated and from these values an instability index for the protein is calculated. A 
protein is predicted to be stable when the instability index is below 40. 
3.1.2 Solubility of protein expressed in Escherichia coli 
A model for predicting the solubility of proteins expressed in E. coli was developed by 
Wilkinson and Harrison [199]. This model was later modified, since it was realised that 
only two of the original five parameters were critical in predicting soluble versus 
insoluble protein expression in E. coli [200]. A canonical variable (cv) is calculated from 
the two critical parameters as shown in equation 3.1. 
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(3.1) 
N, G, P, S, R, K, D and E represent the number of the respective amino acids in the 
protein and n is the total number of residues in the protein. When cv < 1.71 the protein 
is predicted to be soluble. This means that a protein is more likely to be expressed in a 
soluble form if it is highly charged, preferably negatively charged. The fewer of the 
turn forming residues asparagine, glycine, proline the more likely is soluble 
expression. For the probability calculation based on the cv see Davis et al. [200]. The 
probability can be calculated on www.biotech.ou.edu [201]. 
3.1.3 Prediction of intrinsic disorder in proteins  
Some proteins or regions of some proteins exist naturally in a disordered state [202]. 
This is also called intrinsic disorder. If a protein contains disordered regions it might 
lead to problems with recombinant expression, protein purification and crystallisation 
[203]. It is sometimes necessary to truncate a multi-domain protein in order to obtain a 
domain suitable for crystallographic characterisation. Being able to predict disordered 
regions can be useful when deciding on where in the amino acid sequence to make 
such truncations [203]. 
Several computer programs have been developed to predict intrinsic disorder of a 
protein from its primary sequence. I will briefly introduce the 8 programs used later 
and which criteria they use for detection.  
Disopred uses a support vector machine which is trained on proteins with disordered 
regions found in the PDB [204]. FoldIndex uses an algorithm based on average residue 
hydrophobicity and net charge of the protein [205,206]. FoldUnfold calculates the 
expected average number of close residue contacts computed from the amino acid 
sequence [207]. Globplot calculates a tendency for disorder based on the propensity for 
a given amino acid to be in a random coil or in an ordered secondary structure [208]. 
IUPred makes an estimate on the potential of the amino acids to form stabilising inter-
residue interactions [209]. PONDR VL3 uses a neural network trained on a data set 
consisting mostly of proteins from the PDB [210]. Prelink calculates a probability of a 
given sequence fragment of being in a structured or unstructured region based on 
known amino acid distributions in structured and unstructured regions. Furthermore, 
this is combined with the distance of a given region to the nearest hydrophobic cluster 
[211]. RONN uses a neural network trained on the amino acid sequences which were 
not visible in the electron density maps obtained by X-ray crystallography [212]. Links 
to all these programs can be found on www.disprot.org [213].  
The amino acid sequences of gTPH1 and hTPH2 have been tested using these 8 
programs and the predicted disordered regions are shown in figure 3.1.  
gTPH1 is generally predicted to be a structured protein with possible dynamic turns, 
since no region is predicted disordered by all programs. The N-terminal end is 
identified by 6 programs as disordered and this may be similar to PAH where the first 
19 residues of the N-terminal are not visible in the crystal structure [74]. 
For hTPH2 a region in the regulatory domain is predicted disordered by all programs 
with a consensus from amino acid 42-55. Little is known about the regulatory domain 
of hTPH2 but it might very well be that it contains a region with no structure. This 
region could also extend over the active site opening or be important in amino acid 
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binding or enzyme regulator binding for example of the 14-3-3 proteins (see section 
2.11)[214]. 
 
Figure 3.1 The predicted disordered regions of gTPH1 (top) and hTPH2 (bottom) are shown by 
the coloured bars. The prediction programs used are listed to the right of the prediction. The 
domains of gTPH1 and hTPH2 are shown as the blue-green-red bar just above the amino acid 
numbers. Blue is the regulatory domain, green is the catalytic domain and red is the tetrameri-
sation domain. 
3.1.4 Similarities of the regulatory domains of TPH with other 
proteins 
BLAST search for protein sequences that are homologues to the regulatory domain of 
hTPH2 (rhTPH2) was performed [215]. Different TPH variants obviously appear 
followed by PAH variants. Following PAH, sequences of the bifunctional enzyme 
chorismate mutase - prephenate dehydratase, also called the P-protein, from different 
bacteria appears. The enzyme from the hyperthermophilic bacteria Aquifex aeolicus (A. 
aeolicus) shows the highest identity with 25 out of 60 amino acids being identical to 
rhTPH2. The P-protein consists of three domains: a chorismate mutase domain (N-
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terminal), a prephenate dehydratase domain (middle) and a regulatory domain (C-
terminal). The chorismate mutase catalyses the conversion of chorismate to 
prephenate, which is the first committed step in the biosynthesis of phenylalanine and 
tyrosine [216].  Prephenate is then decarboxylated  and dehydrated to phenylpyruvate 
by the prephenate dehydratase domain [217]. These reactions are allosterically 
controlled by feedback inhibition by phenylalanine, which binds to the C-terminal 
regulatory domain [218]. It is this C-terminal domain of the P-protein which is 
homologues to residues 59-146 in hTPH2 and also to the corresponding sequence of 
gTPH1. A sequence alignment of the regulatory domains of gTPH1 and hTPH2 with 
the C-terminal domain of the A. aeolicus P-protein is shown in figure 3.2. Through a 
mutational study on the P-protein from E. coli the phenylalanine binding sequence was 
identified to be GALV and ESRP [218]. The equivalent sequences (GGLV/GALY, 
ESRK) are coloured blue in figure 3.2.  
 
Figure 3.2 Sequence alignment of the regulatory domain of gTPH1, regulatory domain of 
hTPH2, and the P-protein from A. aeolicus. For the sequences shown the identities of the P-
protein with gTPH1 and hTPH2 are 23% and 24%, respectively. The primary accession numbers 
in the ExPASy database are shown in parenthesis.  Residues with green background are 
conserved in all three enzymes. Residues with yellow background are conserved between one 
of the TPHs and P-protein. “:” means that conserved substitutions have been observed within 
the groups (AVFPMILW), (DE), (RHK), (STYHCNGQ). “.” means that semi-conserved 
substitutions are observed. The proposed phenylalanine binding sequences are shown in blue.  
Thr59 in hTPH2 is shown in red. The alignment was done with ClustalW [54]. 
 
Domains that are homologues to the regulatory domain of TPH and C-terminal 
domain of the P-protein are observed in many different enzymes [219,220,221]. This 
domain type is named the ACT domain after aspartokinase, chorismate mutase and 
TyrA (prephenate dehydrogenase) [219].  It has been shown that the ACT domains of 
many enzymes are responsible for allosteric regulation of the enzymes upon binding of 
an amino acid, for example phenylalanine in the P-protein and serine in D-3-
phosphoglycerate dehydrogenase [220]. Therefore, speculations have been that the 
observed stimulating effect of phenylalanine on PAH is due to the binding in the 
regulatory domain [162]. For TPH very little is known about the function of the 
regulatory domain. However, tryptophan is likely to have the same function as 
phenylalaine in PAH [220].  
gTPH1 (P70080)      
hTPH2 (Q8IWU9)  
P-protein A. aeolicus (O67085)      
                                    59              GALV 
    ---------------MIEDNKENK-----DHAPERGRTAIIFSLKNEVGGLVKALKLFQE 40 
27  EHQLLGSSTLNKPNSGKNDDKGNKGSSKREAATESGKTAVVFSLKNEVGGLVKALRLFQE 86 
241 YTYHLNILARNIQDSGDNFTRFLVIAKRDLKPTGSDKTSILFGVKDEPGALYKALEVFYK 300 
                     :  :          ..  .: ::: .: :   .     .:  : 
        ESRP 
KHVNLVHIESRKSKRRNSEFEIFVDCDSNREQ--LNEIFQLLKSHVSIVSMNPTEHFNVQED 100 
KRVNMVHIESRKSRRRSSEVEIFVDCECGKTE--FNELIQLLKFQTTIVTLNPPENIWTEEE 146 
HGINLTKIESRPSKKKAWDYVFFVDLEGHKEEERVEKALKELKEKTQFLKVLGSYPKALLQE 362 
: : :.:      :::  :  :    :  : :  .:: ::    :. ::.:  .      :: 
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3.2 Fusion proteins 
Expression of recombinant protein fused to a tag or another protein is widely used to 
obtain soluble protein expressed in E. coli [222]. The most widely fusion proteins are 
the E. coli maltose binding protein (MBP), E. coli N-utilization substance A (NusA) 
[200], E. coli thioredoxin (Trx) and Schistosoma japonicum glutathione-S-transferase 
(GST)[222]. Other interesting fusion proteins or peptide tags are ubiquitin [223], small 
ubiquitin-related modifier (SUMO) [224] and solubility-enhancement tag (SET) [225]. 
Ubiquitin and SET will be further described since these have been used as fusion 
proteins/tags in this project. Expression of TPH fused to MBP, NusA, Trx, and GST 
respectively, have been tried by others with non-satisfactory results [138,141]. These 
fusion proteins have therefore not been tested in this project. 
3.2.1 Ubiquitin as a fusion protein 
Ubiquitin is a 76 amino acid protein found in eukaryotic cells where it functions in the 
degradation pathway of proteins [226]. Ubiquitin is highly resistant to proteolytic 
degradation and has a long half-life when expressed in E. coli [227]. Ubiquitin is used 
as a fusion protein for expression in E. coli where the ubiquitin fusion gives increased 
expression and solubility of the target protein [223,228]. An ubiquitin specific protease 
is often co-expressed with the fusion protein. This protease cleaves the fusion protein 
at the C-terminal end of ubiquitin [229,230]. The ubiquitin fusion protein/ubiquitin 
specific protease system has with success been used extensively in the Bioinorganic 
Chemistry Group at DTU [231].   
3.2.2 The solubility-enhancement tag 
Fusion proteins are used extensively in recombinant protein expression to increase 
expression and solubility of the target protein. The solubility-enhancement tag (SET) is 
small (43 amino acids) compared to fusion proteins like GST and MBP and has been 
reported to improve the solubility and stability of fusion products significantly [232]. 
SETs with different charges have been developed [225] and are available from 
Stratagene [233]. It is suggested that the negatively charged peptide extensions 
indirectly promote folding by increasing the electrostatic repulsion between nascent 
protein chains. This repulsion might provide more time for the protein to fold in a 
correct and stable conformation [225].  
3.3 Constructs of TPH expressed in Escherichia coli 
Several expression constructs for different variants of gTPH1 and hTPH2 have been 
made. A list with composition of constructs, molecular weight, pI and abbreviation is 
shown in figure 3.3. An introduction to the variants xchTPH2 and ychTPH2 and results 
of these variants will be presented separately in section 3.5.3.  
3.4 Experimental  
The cloning and preparation of expression strains were done by laboratory technicians 
or other students in the Bioinorganic Research Group. All constructs were expressed in 
E. coli BL21(DE3) cells. In some cases the expression and solubility tests were done by 
other students in the group. The gene for chicken (Gallus gallus) TPH1 were donated by 
Prof. J. S. Takahashi, Northwestern University, USA [50].  
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Chicken (Gallus gallus) tryptophan hydroxylase isoform 1
Amino acids 1-445, 51.1 kDa, pI 6.3
gTPH1
Catalytic domain of chicken (Gallus gallus) tryptophan hydroxylase isoform 1
Amino acids 101-414, 36.1 kDa, pI 6.5
cgTPH1
uhTPH2
Fusion protein of ubiquitin and human tryptophan hydroxylase isoform 2
Amino acids 1-490, 64.6 kDa, pI 6.1
Fusion protein of ubiquitin and chicken (Gallus gallus) 
tryptophan hydroxylase isoform 1, amino acids 1-445, 59.7 kDa, pI 6.4
ugTPH1
rcgTPH1
Regulatory and catalytic domain of chicken (Gallus gallus) 
tryptophan hydroxylase isoform 1, amino acids 1-414, 47.7 kDa, pI 6.4
Fusion protein of ubiquitin with regulatory and catalytic domains of chicken 
(Gallus gallus) tryptophan hydroxylase isoform 1, amino acids 1-414, 56.3 kDa, pI 6.4
urcgTPH1
Fusion protein of solubility-enhancement tag 3  and human 
tryptophan hydroxylase isoform 2, amino acids 1-490, 61.0 kDa, pI 5.2
SET3-hTPH2
Chicken TPH1
Human TPH2
Fusion protein of ubiquitin with regulatory and catalytic domains of human 
tryptophan hydroxylase isoform 2, amino acids 1-459, 61.1 kDa, pI 6.2
urchTPH2
SET3-rchTPH2
Fusion protein of solubility-enhancement tag 3 with regulatory and catalytic domains 
of human tryptophan hydroxylase isoform 2, amino acids 1-459, 57.5 kDa, pI 5.2
Full length human tryptophan hydroxylase isoform 2
Amino acids 1-490, 56.1 kDa, pI 6.0
hTPH2  
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Catalytic domain of human tryptophan hydroxylase isoform 2
Amino acids 146-459, 36.2 kDa, pI 5.6
chTPH2
cthTPH2
Catalytic and tetramerisation domains of human tryptophan hydroxylase 
isoform 2, amino acids 146-490, 39.6 kDa, pI 5.5
Regulatory and catalytic domains of human tryptophan hydroxylase isoform 2,
Amino acids 1-459, 52.6 kDa, pI 6.1
rchTPH2
Core of catalytic domain of human tryptophan hydroxylase isoform 2
Amino acids 146-451, 35.3 kDa, pI 5.7
Core of catalytic domain of human tryptophan hydroxylase isoform 2
Amino acids 146-439, 33.8 kDa, pI 5.6
xchTPH2
ychTPH2
Fusion protein of ubiquitin with regulatory domain of human 
tryptophan hydroxylase isoform 2, amino acids 1-145, 25.1 kDa, pI 8.5
Regulatory domain of human tryptophan hydroxylase isoform 2
Amino acids 1-145, 16.4 kDa, pI 8.9
urhTPH2
rhTPH2
 
Figure 3.3 Schematic representation of constructs of TPH which have been produced in this 
project. For each variant the number of amino acids is listed together with the molecular weight 
and theoretical pI. To the right for each construct is the abbreviation for each variant. The 
regulatory domain is shown in blue, the catalytic domain in green and the tetramerisation 
domain in red. Fusion proteins are shown in maroon for ubiquitin and orange for the solubility-
enhancement tag. The molecular weight and pI were calculated from the sequences using the 
ProtParam tool on ExPASy [53,234]. 
 
The gene for ubiquitin and the plasmid containing the ubiquitin-specific protease were 
donated by Prof. C. E. Cameron, Pennsylvania State University, USA [230]. An E. coli 
codon optimised version of the human TPH2 gene (gi:27497158) was obtained from 
Genscript, USA.   
The following experimental procedures comply with general protocols used in the 
Bioinorganic Research Group, but small variations have in some cases been tested. 
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Luria Bertani (LB) media and all chemicals used were analytical grade obtained from 
Sigma-Aldrich. All solutions were prepared using 18.2 MΩ cm water from a Milli-Q 
synthesis A10 Q-Gard system (Millipore). 
3.4.1 Expression of TPH variants 
From a frozen stock the E. coli BL21(DE3) strain containing the TPH expression 
plasmids was plated on a Luria Bertani (LB) agar plate containing 30 μg/mL kana-
mycin sulphate (30 Kan) and 20 μg/mL chloramphenicol  (20 Cam). 30 Kan was used 
to select for cells harbouring the TPH plasmids and 20 Cam was used to select for cells 
harbouring the ubiquitin-specific protease plasmid. The plate was incubated overnight 
at 37˚C. A single colony was used to inoculate 50 mL LB 30 Kan/20 Cam media and 
incubated at 37˚C in a 250 mL shake flask at 250 rpm. This pre-culture was incubated 
for approximately 4 hours until an optical density at 600 nm (OD600) of 0.6-1.0 was 
reached. The cells were then sedimented by centrifugation at 4˚C and 1800 × g for 10 
min. The cells were resuspended in 50 mL fresh LB 30 Kan/20 Cam media. 6.5 mL cell 
resuspension was used to inoculate 650 mL LB 30 Kan/20 Cam media in a 2 L triple 
baffled shake flask. The culture was incubated at 30˚C and 250 rpm for approximately 
5 hours. When an OD600 of 0.4 - 0.6 was attained the TPH expression was induced by 
adding isopropyl-β-D-thiogalactopyranoside (IPTG) to a final concentration of 0.1 mM. 
After incubation at 30˚C and 250 rpm for 4 hours the cells were harvested by 
centrifugation at 4˚C, 3000 × g for 15 min. The cells from 650 mL were resuspended in 
25 mL 4˚C 20 mM Tris/HCl pH 8.2 and transferred to 50 mL polypropylene tubes. The 
cells were again centrifuged at 4˚C, 3000 × g for 15 min. The supernatant was discarded 
and the cells stored at -80˚C until further use. 
For some variants expression was also tested at 10˚C or 20˚C. The same procedure as 
just described was used, except that the time of expression was extended.  
3.4.2 Solubility test for the TPH variants 
Cells from 650 mL culture containing the TPH variant were resuspended in 40 mL 20 
mM Tris/HCl pH 8.2. The cells were lysed on ice by sonication for 3 × 30 s using a 
Satorius Labsonic P at 80% amplitude. The cell extract was centrifuged (Eppendorf 
5810R) at 4˚C and 18000 × g for 20 min. The supernatant was collected. Samples for 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) analysis 
were taken from the raw extract from the cells, the supernatant and from resuspended 
pellet. Addition of glycerol, sucrose and/or tryptophan to the lysis buffer was tested 
for some of the TPH variants. For xchTPH2 and ychTPH2 cells were lysed in 20 mM Bis 
Tris Propane/HCl, 5% glycerol, pH 7.2. 
If the SDS-PAGE analysis showed TPH in the supernatant an initial purification test 
was done as described in the following. The supernatant was diluted with cold water 
to a conductivity below 1 mS/cm. The supernatant was then loaded onto a Q 
Sepharose Fast Flow 16/10 column equilibrated with 20 mM Tris/HCl pH 8.2 and the 
flow-through was collected. The column was washed with 1.5 column volume (CV) 20 
mM Tris/HCl pH 8.2. A linear gradient 0-100% 20 mM Tris/NaOH, 0.8 M (NH4)2SO4, 
pH 8.2 over 5 CV was applied to the column. Samples for SDS-PAGE analysis were 
taken from the flow through and the collected fractions.  
In a few cases 0.45 μm filtered (GHP Acrodisc GF syringe filters from Pall) flow-
through from the anion exchange was applied on a Superdex 200 26/60 prep grade 
column equilibrated in 20 mM Tris/NaOH, 200 mM (NH4)2SO4, pH 8.2.  
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Cation exchange was tested for some of the variants that did not bind to the anion 
exchange. In those cases the procedure was similar to that of the anion exchange 
described above, except that the cells were lysed in 20 mM MES/NaOH pH 6.0 and the 
supernatant was filtered through a 0.45 μm filter before applied to a Source 30 S 16/10 
column. The buffers used in the cation exchange were 20 mM MES/NaOH pH 6.0 and 
20 mM MES/NaOH 0.4 M (NH4)2SO4, pH 6.0. 
TPH enzyme activity was done by monitoring the formation of 5-hydroxytryptophan 
by fluorescence spectrophotometry essentially as described by Moran et al. [235]. A 
detailed description of the TPH activity assay is presented in section 6.1.  
3.4.3 SDS-PAGE analysis 
SDS-PAGE was done using either 7.5% or 12% Tris-HCl precast gels from Bio-Rad. 
Unstained SDS-PAGE low range standard was from Bio-Rad. The SDS-PAGE 
experiments were carried out as recommended by Bio-Rad and protein was stained 
using Coomassie Blue G-250. 
3.5 Results and discussion of expression and solubility tests of 
TPH variants 
All constructs were expressed in E. coli. The SDS-PAGEs will only be shown for 
selected variants. The solubility of the TPH variants will be described using three 
terms: soluble, partly soluble and insoluble protein. These terms are defined in the 
following. Soluble protein is detected in the supernatant, and can be purified. Partly 
soluble protein is found in the supernatant and in the flow-through from the anion 
exchange column. The insoluble protein is only found in the pellet.  
Table 3.1 The expressed variants of TPH with instability index, probability of solubility and the 
actual solubility detected from expression in E. coli at 30˚C. 
 Theoretical Experimental 
Protein Instability index* Probability of solubility Solubility 
cgTPH1 40.9 41.2 Soluble 
cthTPH2 44.3 60.1 Soluble 
chTPH2 41.3 61.0 Soluble 
ugTPH1 42.1 43.0 Partly soluble 
gTPH1 44.1 43.7 Partly soluble 
urcgTPH1 42.8 41.7 Partly soluble 
rcgTPH1 45.1 42.2 Partly soluble 
SET3-rchTPH2 51.5 61.6 Partly soluble 
uhTPH2 48.4 41.9 Insoluble 
SET3-hTPH2 52.8 61.0 Insoluble 
hTPH2 51.2 42.3 Insoluble 
urchTPH2 46.9 41.3 Insoluble 
rchTPH2 49.6 41.7 Insoluble 
xchTPH2 38.5 58.5 Insoluble 
ychTPH2 39.0 63.7 Insoluble 
urhTPH2 54.5 20.5 Insoluble 
rhTPH2 65.2 10.5 Insoluble 
* instability index < 40 is considered stable 
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The results of the solubility tests are summarised in table 3.1 with the calculated 
instability index and probability of solubility for each variant. The three variants 
cgTPH1, chTPH2 and cthTPH2 were found in a soluble form and the expression and 
purification of these variants are presented in chapter 4.  
All the constructs of gTPH1 containing the regulatory domain were to some extent 
found in the partly soluble form which could be filtered through a 0.45 μm filter. The 
partly soluble gTPH1 variants did not interact with either Q Sepharose FF or Source 30 
S media and were therefore found in the flow-through from the columns. Partly 
soluble gTPH1 variants eluted early in the gel filtration, equivalent to proteins with a 
mass of approximately 1000 kDa. Glycerol, sucrose, tryptophan and dithiothreitol were 
tested in the lysis buffer, but none of the tested additives yielded gTPH1 that could be 
purified. Lowering the expression temperature to 10˚C seemed to yield small amounts 
of gTPH1 variants that might bind to an anion exchange column, but the amount was 
so small that it was not a viable method. The partly soluble gTPH1 generally showed 
enzyme activity. 
The SET3-rchTPH2 was found in a partly soluble form and in the pellet. The partly 
soluble SET3-rchTPH2 showed enzyme activity. The remaining variants of hTPH2 were 
found only in the pellet as the insoluble form.  
The hTPH2 variant was expressed as a fusion protein to ubiquitin with the co-
expression of the ubiquitin specific protease. The cleavage of the fusion protein was 
incomplete and a 1:1 mixture of uhTPH2 and hTPH2 was observed. When the 
expression temperature was lowered to 10˚C the cleavage of ubiquitin-hTPH2 was 
increased to almost 100%. The lowered expression temperature also resulted in hTPH2 
being present in the partly soluble form and not only in the insoluble form. 
3.5.1 The partly soluble variants of gTPH1 
The partly soluble gTPH1 variants are believed to be small aggregates of variable sizes, 
small enough to be filtered through a 0.45 μm filter. These aggregates do not bind to 
ion exchange media. The reason for this may be that either the aggregates have no 
effective charge or the aggregates are larger than the exclusion limit of the ion 
exchange media and will therefore not have the possibility of binding.  
Since gTPH1 variants without the tetramerisation domain did not change the solubility 
properties compared to full length, it is very likely that the regulatory domain is 
responsible for the formation of some soluble aggregates. Since the partly soluble 
gTPH1 generally shows enzyme activity the catalytic domain must be correctly folded, 
while the regulatory domain may be in an improper conformation or disordered. Such 
a regulatory domain could be responsible for unspecific interactions with other 
regulatory domains causing aggregation.  Partly soluble aggregates have been reported 
for proteins fused to MBP [236,237,238] and proteins fused to the SET tag [225]. 
3.5.2 The insoluble variants of hTPH2 
Expression at 30˚C of hTPH2 variants containing the regulatory domain yielded only 
protein in the insoluble form, commonly called inclusion bodies [239]. The cleavage of 
ubiquitin-hTPH2 was increased to almost 100% when the expression temperature was 
lowered to 10˚C. This can be explained by a lower expression rate of uhTPH2 yielding a 
lower concentration of over-expressed protein in the cells. This might increase the time 
where uhTPH2 is soluble in the cells. It is likely that only soluble uhTPH2 is the 
substrate for the ubiquitin specific protease, since proteins in the inclusion body state 
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are generally known to be inert to protease degradation [240]. The lower rate of 
expression of uhTPH2 may also allow hTPH2 longer time to fold correctly which may 
explain the hTPH2 found in the partly soluble form when expressed at 10˚C. Inclusion 
bodies can be isolated from the cell pellet and solubilised in strong denaturants and in 
some cases subsequently refolded upon removal of the denaturant [240]. This was also 
tried with hTPH2 inclusion bodies, but primarily uhTPH2 was used since large 
amounts of homogeneous inclusion bodies could be isolated of this variant. 
Additionally, the ubiquitin might be beneficial in the folding process of the protein. 
Many different kinds of refolding experiments were carried out but none yielded a 
satisfactory product. The refolding experiments will not be further described. 
Since the chTPH2 and cthTPH2 can be expressed in a soluble form and can be purified, 
it is likely that the regulatory domain is responsible for the insolubility of hTPH2 when 
expressed in E. coli. The same observations have recently been published by Carkaci-
Salli et al. [22]. 
The partly soluble forms of gTPH1 can be interpreted as an intermediate between the 
insoluble inclusion bodies and a soluble monodisperse form. If this is the case, one will 
think of gTPH1 as being slightly more soluble than hTPH2. This is if the term solubility 
is thought of as the propensity of the protein to be produced in a correctly folded 
conformation in E. coli. McKinney et al. have reported that hTPH2 is more soluble than 
hTPH1, both of which were expressed as fusion proteins to MBP [141]. The criterion for 
solubility is not defined and no documentation for the differences in solubility is 
presented [141]. It might therefore be difficult to compare the observation of McKinney 
et al. with those observed in this project.  
The main difference between rgTPH1 and rhTPH2 is that rhTPH2 is elongated in the N-
terminal by 46 residues. It is seen in figure 3.2 that from Thr59 in rhTPH2 numbering 
the three sequences are highly homologous indicating a similar structured domain. 
Since intrinsic disorder is predicted for the amino acids 42-55 in hTPH2, a new variant 
of hTPH2 containing amino acids 59- 490 might form a structured protein that could be 
purified. The instability index and chance of solubility in E. coli for such a protein are 
51.7 and 55.9%, respectively, where the chance of solubility is much better than the 
predictions for the full length enzyme. Such a variant will probably not give 
information about the regulatory mechanism, but will give information on inter-
domain structure and possible amino acid binding in the regulatory domain of which 
very little is known.  
Expression of human intracellular multi-domain proteins in E. coli is known to be 
difficult and some estimates suggest that at the time being as little as 20% of human 
proteins can be expressed in E. coli in a soluble form [241,242,243]. Expression in 
eukaryotic cell cultures is more difficult and time consuming but eukaryotic cells 
contain the cellular machinery (i. e. folding chaperones and post translational modify-
cation enzymes)[244], which might be necessary to obtain soluble hTPH2. 
3.5.3 Truncating the C-terminal of the chTPH2 
The expression construct of the crystallised chTPH1 (PDB entry 1MLW) contains amino 
acids equivalent to 148-448 in hTPH2 and is followed by a 6His-tag [64]. The last amino 
acid with visible electron density for this crystal structure is equivalent to Ile439 in 
hTPH2 indicating that the residues 440-448 and the His-tag are disordered [64]. chTPH2 
was the initial variant made of the catalytic domain in this project. chTPH2 contain  
residues 146-459 and therefore contains 11 residues more in the C-terminal compared 
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to the crystallised chTPH1 variant. Later I suspected that the C-terminal end of chTPH2 
was floppy and could prevent crystal formation. Subsequently two new versions of the 
catalytic domain of hTPH2 were made, namely xchTPH2 (146-439) and ychTPH2 (146-
451).  The extents of the ychTPH2, xchTPH2 and chTPH2 are indicated in the structure 
of the catalytic domain of PAH [69] in figure 3.4 and are seen in the sequence 
alignment of the C-terminals of: visible residues of chTPH1, ychTPH2, xchTPH2 and 
chTPH2 and human PAH in figure 3.5. The structure of the catalytic domain of PAH 
contains the β-sheet (coloured magenta) which links the catalytic domain and the 
tetramerisation domain in the PAH [80] and TH [68] (see figure 2.6).  
 
Figure 3.4 The structure of the catalytic domain of human PAH (PDB entry 1PAH) [69]. The 
crystal structures of the catalytic domains of human TPH1 (PDB entry 1MLW) and PAH are 
very similar except that the C-terminal β-sheet shown in magenta, is not present in the 1MLW 
structure. The chTPH2 expressed in this project has the same length as the catalytic domain of 
PAH shown here. The figure was made using Pymol [72].  
 
Figure 3.5 Sequence alignment the C-terminals of the chTPH1 visible in the 1MLW structure 
[64], ychTPH2, xchTPH2, chTPH2 and human PAH. The secondary structure of PAH is shown 
as determined in the structure of tetrameric PAH (PDB entry 2PAH) [80] H is α-helices, S is β-
sheets and c is coil. The domain size as used in figure 3.3 is listed in bottom line.  
 
1MLW    387 REFTKTI 393 
ychTPH2 433 RDFAKSI 439 
xchTPH2 433 RDFAKSITRPFSVYFNPYT 451      
chTPH2  433 RDFAKSITRPFSVYFNPYTQSIEILKD 459 
hPAH    400 RNFAATIPRPFSVRYDPYTQRIEVLDNTQQLKILADSINSEIGILCSALQKIK 452 
S. struc.   HHHHHHHcccSSSSSSSSSSSSSSSSccHHHHHHHHHHHHHHHHHHHHHHHHH 
Domains     catalytic domain------------tetramerisation domain---    
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3.5.3.1 Results of truncating the C-terminal of chTPH2 
Both xchTPH2 and ychTPH2 were expressed in an insoluble form as shown by the SDS-
PAGEs in figure 3.6. No enzyme activity could be measured of any fractions of the 
ychTPH2. 
 
Figure 3.6 SDS-PAGE of ychTPH2 and xchTPH2. R is raw extracts of the cells, S is the soluble 
fraction, P is resuspended pellet. The molecular weight standard is shown in the lanes towards 
the middle. The cells were lysed in 20 mM Bis Tris Propane/HCl, 5% glycerol, pH 7.2. 
3.5.3.2 Discussion of the effect of the linking β-sheet of chTPH2 
The expression of xchTPH2 and ychTPH2 in an insoluble form indicates that the 
linking β-sheet is important in the formation, stabilisation or solubilisation of the 
catalytic domain. Since no enzyme activity could be detected for ychTPH2 it has 
probably lost its structure. The importance of the linking β-sheet to the catalytic 
domain will be studied further in the Bioinorganic Group through truncation and 
mutational studies.  
3.6 Conclusion 
The three variants, cgTPH1, chTPH2 and cthTPH2, were expressed in a soluble form 
that can be purified. Expression and purification of these variants are described in the 
following chapter. Variants of gTPH1 and hTPH2 containing the regulatory domain 
have proven difficult to express in a soluble form in E. coli. A partly soluble form of the 
gTPH1 variants was detected in the supernatant of centrifuged cell extract. This partly 
soluble form could not be purified. The hTPH2 variants containing the regulatory 
domain were only found in the cell pellet when expressed at 30˚C. When the 
expression temperature was lowered to 10˚C small amounts of the hTPH2 variants 
were found in the partly soluble form. A new expression construct of hTPH2 
containing residues 59-490 is suggested.  
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CHAPTER FOUR 
4 Expression and purification of 
tryptophan hydroxylase variants 
 
 
 
In Chapter 3 the constructed expression variants of gTPH1 and hTPH2 were presented. 
Three variants can be expressed in a soluble form that can be purified. The three 
variants are cgTPH1, chTPH2, and cthTPH2. In this chapter I will describe how these 
three variants were expressed and purified.  
4.1 Experimental 
UltraPureTM glycerol was obtained from Invitrogen. (6R)-5,6,7,8-tetrahydro-L-biopterin 
dihydrochloride (BH4) was from Schircks Laboratories, Jona, Switzerland. LB media 
and all other chemicals used were analytical grade obtained from Sigma-Aldrich. All 
solutions were prepared using 18.2 MΩ cm water from a Milli-Q synthesis A10 Q-Gard 
system (Millipore).  
4.1.1 Expression of tryptophan hydroxylase variants 
4.1.1.1 Expression of cgTPH1 
The cgTPH1 was expressed as a fusion protein with ubiquitin. The ubiquitin-specific 
protease, which cleaves the polypeptide chain at the C-terminus of ubiquitin, was co-
expressed together with ubiquitin-cgTPH1.   
From a frozen stock, the E. coli BL21(DE3) strain containing the cgTPH1 expression 
plasmid and ubiquitin-specific protease expression plasmid was plated on a LB 30 
Kan/20 Cam agar plate. The plate was incubated overnight at 37˚C. A single colony 
was used to inoculate 50 mL LB 30 Kan/20 Cam media and incubated at 37˚C in a 250 
mL shake flask at 250 rpm.  This pre-culture was incubated for approximately 4 hours 
until an optical density at 600 nm (OD600) of 0.6-1.0 was reached. The cells were then 
sedimented by centrifugation at 4˚C and 1800 × g for 10 min. The cells were 
resuspended in 50 mL fresh LB 30 Kan/20 Cam media. 6.5 mL cell resuspension was 
used to inoculate 650 mL LB 30 Kan/20 Cam media in a 2 L triple baffled shake flask. 
The culture was incubated at 30˚C and 250 rpm for 3½ hour. The incubator 
temperature was then set to 20˚C and incubation continued for approximately 1½ hour. 
When an OD600 of 0.4 - 0.6 was attained the cgTPH1 expression was induced by adding 
IPTG to a final concentration of 0.1 mM. After incubation at 20˚C and 250 rpm for 14 
hours the cells were harvested by centrifugation at 4˚C, 3000 × g for 15 min. Cells from 
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650 mL culture were resuspended in ice cold 25 mL 20 mM Tris/HCl pH 8.5 and 
transferred to 50 mL polypropylene tubes. The cells were again centrifuged at 4˚C, 3000 
× g for 15 min. The supernatant was discarded and the cells stored at -80˚C until 
further use. 
4.1.1.2 Expression of chTPH2 
The chTPH2 was expressed as a non-fusion protein (see section 3.3). The cell culture 
step and expression were performed as described for cgTPH1 in section 4.1.1.1, except 
that Cam was not added to the media and cells were washed with 20 mM Bis Tris 
Propane/HCl, 5% (w/v) glycerol, pH 7.2 in the last step.  
4.1.1.3 Expression of cthTPH2 
The cthTPH2 was expressed as a non-fusion protein (see section 3.3). The cell cultures 
were grown and cthTPH2 expressed as described for cgTPH1 in section 4.1.1.1, except 
that Cam was not added to the media and cells were washed with 20 mM Tris/HCl pH 
8.2 in the last step. 
4.1.2 Purification of tryptophan hydroxylase variants 
The purification protocols for the three TPH variants, described in the following 
sections, were developed from a common starting protocol. In summary the common 
protocol consisted of an initial anion exchange done at pH 8.2 using Tris buffers and a 
gel filtration done in Tris, 200 mM (NH4)2SO4, pH 8.2. From this protocol the 
purification parameters were optimised. Only the final procedures will be presented.  
The use of argon flushed buffers and addition of sodium dithionite were done to keep 
the TPH iron in the ferrous state during the anion exchange purification step.  
During the purifications the solutions containing TPH were kept on ice or at 4˚C except 
during the chromatographic steps which were carried out at room temperature. High 
Performance Liquid Chromatography was done using columns and an Äkta Purifier 
from GE Healthcare. Protein concentrations were determined using a HP 8453 diode 
array spectrophotometer. 
4.1.2.1 Purification of cgTPH1 
Cells from 3 × 650 mL culture, containing cgTPH1 (section 4.1.1.1), were resuspended 
in 3 × 40 mL 20 mM Tris/HCl pH 8.5. Sodium dithionite was added to a final 
concentration of 2 mM. The cells were lysed on ice by sonication for 3 × 30 s using a 
Satorius Labsonic P at 80% amplitude. The cell extract was centrifuged (Eppendorf 
5810R) at 4˚C and 18000 × g for 20 min. The supernatant was collected and filtered 
through 0.45 μm GHP Acrodisc GF syringe filters from Pall. Water flushed with argon 
(on ice) was used to dilute the supernatant to a conductivity of approximately 1 
mS/cm. The supernatant was loaded onto a Q Sepharose High Performance 26/10 
column, which was equilibrated in 20 mM Tris/HCl pH 8.5, 2 mM sodium dithionite. 
Prior to equilibration this buffer and the salt buffer 20 mM Tris/NaOH, 0.8 M 
(NH4)2SO4, pH 8.5 were flushed with argon for one hour per L buffer.  The column was 
washed with 1.5 CV of 20 mM Tris/HCl pH 8.5, 2 mM sodium dithionite. A linear 
gradient of 0-15% buffer B over 6 CV was applied to the column. The fractions 
containing ferrous-cgTPH1 were collected and pooled. 20 mM Tris/NaOH, 2 M 
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(NH4)2SO4 pH 8.5 was added to the collected fractions to reach an (NH4)2SO4 
concentration of 0.1 M. The collected fractions were then concentrated by ultrafiltration 
in an Amicon stirred pressure cell with an Ultracel PL-3 membrane. Approximately 7 
mL of concentrated cgTPH1 solution was then filtered through a 0.45 μm filter and 
loaded onto a HiLoad Superdex 75 26/60 prep grade column. Prior to loading, the 
column was equilibrated in 20 mM Tris/NaOH, 100 mM (NH4)2SO4, pH 8.5. Fractions 
containing cgTPH1 were collected. The cgTPH1 concentration was determined using 
the theoretical absorption coefficient [245] of ε280 = 37820 M-1 cm-1.  
To the solution of purified cgTPH1, glycerol and 2 M (NH4)2SO4, 20 mM Tris/NaOH, 
pH 8.5 was added to a concentration of 10% (w/v) glycerol and 100 mM (NH4)2SO4.  
Samples for enzyme kinetic experiments were stored in aliquots of 1 mL at -80˚C. 
cgTPH1 for crystallisation experiments was concentrated by ultrafiltration in an 
Amicon stirred pressure cell and subsequently stored at -80˚C in aliquots of 100 μL.  
4.1.2.2 Purification of chTPH2 
Cells from 3 × 650 mL culture containing chTPH2 (see section 4.1.1.2) were resus-
pended in 3 × 40 mL 20 mM Bis Tris Propane/HCl, 5%(w/v) glycerol, pH 7.2. Sodium 
dithionite was added to a final concentration of 2 mM. The cells were lysed on ice by 
sonication for 3 × 30 s using a Satorius Labsonic P at 80% amplitude. The cell extract 
was centrifuged at 4˚C and 18000 × g for 20 min. The supernatant was collected and 
filtered through 0.45 μm GHP Acrodisc GF syringe filters. The supernatant was loaded 
onto a Q Sepharose High Performance 26/10 column which was equilibrated in buffer 
A: 20 mM Bis Tris Propane/HCl, 5%(w/v) glycerol, pH 7.2, 2 mM sodium dithionite. 
Buffer A and buffer B: 20 mM Bis Tris Propane/HCl, 5% (w/v) glycerol, 0.8 M 
(NH4)2SO4, pH 7.2, were flushed with argon for one hour per L buffer prior to column 
equilibration.  The column was washed with 1.5 CV of buffer A. A linear gradient of 0-
4% buffer B (0-32 mM (NH4)2SO4) over one CV was applied to the column followed by 
a gradient from 4-12% buffer B (32-96 mM (NH4)2SO4) over 5 CV. The selected fractions 
containing chTPH2 were collected and pooled. The collected fractions were then 
concentrated by ultrafiltration in an Amicon stirred pressure cell with an Ultracel PL-3 
membrane. Approximately 7 mL of concentrated chTPH2 solution was then filtered 
through a 0.45 μm filter and loaded onto a HiLoad Superdex 75 26/60 prep grade 
column. Prior to loading the column was equilibrated in 20 mM HEPES/NaOH, 100 
mM (NH4)2SO4, 5%(w/v) glycerol, pH 7.2. Fractions containing chTPH2 were collected. 
The chTPH2 concentration was determined using the theoretical absorption coefficient 
[245] of ε280 = 39310 M-1 cm-1.  
Samples for enzyme kinetic experiments were stored in aliquots of 500 μL at -80˚C. 
chTPH2 for crystallisation experiments was concentrated by ultrafiltration in an 
Amicon stirred pressure cell and subsequently stored at -80˚C in aliquots of 100 μL.  
4.1.2.3 Purification of cthTPH2 
Cells containing cthTPH2 (see section 4.1.1.3) from 3 × 650 mL culture were 
resuspended in 3 × 40 mL 20 mM Tris/HCl, 10% (w/v) glycerol, pH 8.2. Sodium 
dithionite was added to a final concentration of 2 mM. The cells were lysed on ice by 
sonication for 3 × 30 s using a Satorius Labsonic P at 80% amplitude. The cell extract 
was centrifuged at 4˚C and 18000 × g for 20 min. The supernatant was collected and 
filtered through 0.45 μm GHP Acrodisc GF syringe filters. The supernatant was loaded 
onto a Q Sepharose High Performance 26/10 column, which was equilibrated in buffer 
4 Expression and purification of tryptophan hydroxylase variants 
 
38 
A: 20 mM Tris/HCl, 10%(w/v) glycerol, pH 8.2, 2 mM sodium dithionite. Prior to 
equilibration, buffer A and buffer B: 20 mM Tris/NaOH, 0.8 M (NH4)2SO4, 10%(w/v) 
glycerol, pH 8.2 was flushed with argon for one hour per L buffer.  The column was 
washed with 1.5 CV of 97% buffer A and 3 % buffer B. A linear gradient from 3-10% 
buffer B (24-80 mM (NH4)2SO4) was applied over 0.8 CV followed by a linear gradient 
from 10-24% buffer B (80 - 190 mM (NH4)2SO4) over 5 CV. The selected fractions 
containing cthTPH2 were collected and pooled. The collected fractions were then 
concentrated by ultrafiltration in an Amicon stirred pressure cell with an Ultracel PL-3 
membrane. Approximately 7 mL of concentrated cthTPH2 solution was then filtered 
through a 0.45 μm filter and loaded onto HiLoad Superdex 200 26/60 prep grade 
column. Prior to loading the column was equilibrated in 20 mM Tris/NaOH, 200 mM 
(NH4)2SO4, 10%(w/v) glycerol, pH 8.2. Fractions containing cthTPH2 were collected. 
The cthTPH2 concentration was determined using the theoretical absorption coefficient 
[245] of ε280 = 40800 M-1 cm-1. 
Samples for enzyme kinetic experiments were stored in aliquots of 500 μL at -80˚C. 
cthTPH2 for crystallisation experiments was concentrated by ultrafiltration in an 
Amicon stirred pressure cell and subsequently stored at -80˚C in aliquots of 100 μL. 
4.1.3 Activity measurements 
The purification was followed by TPH activity measurements of samples from the 
supernatant and collected fractions from the anion exchange and the gel filtration. Each 
sample of 200 μL was mixed with 200 μL 60 mM HEPES/NaOH, 15 % w/v glycerol, 
300 mM (NH4)2SO4, 4 mM DTT, 0.1 g/L catalase, 1.25 mM tryptophan, pH 7.0. The 
mixture was stored in eppendorf tubes and closed under an argon flow. The activity 
measurements were done as described in sections 6.1-6.3, using 70 μM tryptophan, 300 
μM BH4 and 500 μM O2. The activity measurements were done directly after the 
purification. 
4.1.4 SDS-PAGE and Western blot analysis 
SDS-PAGE was done using 12% Tris-HCl gels as described in section 3.4.3. Western 
blot analysis was done using PVDF membranes and chemicals (Immun-blot kit 170-
6461) from Bio-Rad. The primary antibody was the murine monoclonal PH8 antibody 
against TPH, TH and PAH, from Chemicon, Victoria, Australia. 50 μL PH8 antibody 
was added to 5 mL 20 mM Tris, 500 mM NaCl, 0.05% (v/v) Tween-20, 1% (w/v) 
gelatine, pH 7.5.  The secondary antibody was the goat anti-mouse alkaline phophatase 
(GAM-AP). 3.3 μL GAM-AP were added to 10 mL 20 mM Tris, 500 mM NaCl, 
0.05%(v/v) Tween-20, 1%(w/v) gelatine, pH 7.5. Treatment of the membrane and 
colour development were done as described in the instructions manual for the Immun-
blot kit [246]. 
4.2 Results and discussion of expression and purification of TPH 
variants 
4.2.1 Expression and purification of cgTPH1 
cgTPH1 was expressed in large amounts (see figure 4.1A, lane 2) as a soluble and active 
enzyme. The expression of cgTPH1 was verified by SDS-PAGE and Western blot 
analysis shown in figure 4.1. 
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Figure 4.1 (A) SDS-PAGE and Western blot of cgTPH1. Lane 1 is the marker. Lane 2 is 
supernatant from cells containing cgTPH1 expressed at 30˚C. Lane 3 is Western blot of same 
sample as in lane 2.  (B) SDS-PAGE from purification of cgTPH1 expressed at 20˚C. Lane 1 is 2 
μL raw extract from the cells. Lane 2 is the supernatant. Lane 3 is collected fractions from anion 
exchange (see figure 4.2). Lane 4 is the molecular weight standard.  Lane 5 is fractions C6-C8 
from gel filtration (see figure 4.3). Lane 6 is fractions C9-C12 from the gel filtration.   
The cgTPH1 is expressed as a fusion protein with ubiquitin. A small amount of the 
uncleaved fusion protein is present in the cells upon harvesting. The amount of 
ubiquitin-cgTPH1 was larger at 30˚C expression for 4 hours than at 20˚C expression for 
14 hours and the latter was therefore chosen [15]. The presence of ubiquitin-cTPH1 
from a 30˚C expression is shown in figure 4.1A by SDS-PAGE and Western blot. 
cgTPH1 could be purified without ubiquitin-cgTPH1 contamination. In addition to 
ubiquitin-cgTPH1 (44.6 kDa) and cgTPH1 (36.1 kDa) some cgTPH1 degradation 
products are also visible in the Western blot (figure 4.1A lane 3). Results presented 
later indicate that these degradation products do not seem to be a problem in the 
further purification.  
A chromatogram for the anion exchange of cgTPH1 is shown in figure 4.2. The cgTPH1 
eluted at 7 mS/cm and fractions C7-D3 were collected. Two other major peaks are seen 
in the chromatogram eluting at 5 and at 10 mS/cm respectively. These two peaks also 
contain minor amounts of cgTPH1 [15]. The cgTPH1 eluted in these fractions must 
have a different charge to surface ratios compared to the one eluting at 7 mS/cm. 
Experiments testing the effect of reducing conditions (dithionite and argon flushed 
buffers) and the effect of ethylenediamine tetraacetate (EDTA) showed that the 
reducing conditions lead to more cgTPH1 eluting at 7 mS/cm, compared to non-
reducing conditions. Adding EDTA gave more cgTPH1 eluting at 10 mS/cm [15]. 
Therefore different charges are ascribed to the presence of iron or the oxidation state of 
the iron. The cgTPH1 eluting at 5 mS/cm is assigned to contain Fe3+, cgTPH1 eluting at 
7 mS/cm is assigned to contain Fe2+ and cgTPH1 eluting at 10 mS/cm is assigned to be 
the apoenzyme.  
A chromatogram for the gel filtration of cgTPH1 is shown in figure 4.3. By omitting the 
first fractions in the cgTPH1 peak at 150 mL from the gel filtration, the ubiqutin-
cgTPH1 impurity can be avoided in the final sample (data not shown). Fractions C6-
C12 were collected from the gel filtration. Judging by the SDS-PAGE in figure 4.1B 
(lane 5 and 6) the purity of the cgTPH1 in fractions from the gel filtration is high and 
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suitable for crystallisation experiments. The cgTPH1 purification followed by activity 
measurements is summarised in table 4.1. 
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Figure 4.2 Anion exchange chromatogram of cgTPH1 on a Q Sepharose HP 26/10 column. 
Buffers were A: 20 mM Tris/HCl pH 8.5, 2 mM sodium dithionite, B: 20 mM Tris/NaOH, 0.8 M 
(NH4)2SO4, pH 8.5. Fractions C7-D3 were collected. 
The cTPH1 from rabbit is reported to be unstable at low ionic strength [87]. This is also 
the case for cgTPH1, but cgTPH1 is stable in cell lysate prior to the anion exchange. If 
cgTPH1 solution collected from the gel filtration is diluted to 1 mS/cm as in the initial 
cell lysate, significant amount of cgTPH1 is lost. Therefore a high resolution anion 
exchange following the gel filtration is not possible. This is compensated for by using a 
medium resolution anion exchange (Sepharose HP) in the first purification step. 
Thereby high purity is achieved without a third purification step.  
The cgTPH1 for crystallisation experiments was concentrated to 12-15 mg/mL and 
above this concentration a tendency for precipitation is observed. 
The yield of cgTPH1 per L culture is 10.9 mg, with a specific activity of 0.60 μM 5-
hydroxytryptophan per min per mg cgTPH1. These values are similar to those reported 
on rabbit cTPH1 [87]. The published procedure for purification of rabbit cTPH1 
consists of four steps. The first step is an anion exchange on a Q Sepharose column at 
pH 8. This is followed by (NH4)2SO4 fractionation. The rabbit cTPH1 was then 
redissolved in a MES buffer pH 7 and loaded onto a hydroxyapatite column and eluted 
with 150-200 mM phosphate [87]. The rabbit cTPH1 was then again precipitated with 
(NH4)2SO4 and redissolved in the final buffer 50 mM MES, 200 mM (NH4)2SO4, 10% 
glycerol, 2 mM DTT, pH 7.0. The purification of cgTPH1 consists of only 3 steps (anion 
exchange, ultrafiltration and gel filtration) and is therefore more simple and faster than 
the purification of rabbit cTPH1.  
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Figure 4.3 Gel filtration chromatogram of cgTPH1 on a Superdex 75 26/60 column. The buffer 
used was 20 mM Tris/NaOH, 100 mM (NH4)2SO4, pH 8.5. Fractions C6-C12 were collected.  
Table 4.1 cgTPH1 activity measured on samples from the different purification steps, purified 
from cells from 1.95 L culture. Measurements were done as described in section 4.1.3.  
Purification 
step 
Units* of 
enzyme 
Yield (%) cgTPH1 
(mg)** 
Specific activity 
(Units/mg) 
Supernatant 63.4 100   
From anion 
exchange 
24.8 39.1   
From gel 
filtration 
12.8 20.2 21.4 0.60 
* One unit is defined as the amount of enzyme that produces 1 μmole product/min. 
** Determined using ε280 = 37820 M-1 cm-1. 
 
As seen in table 4.1 approximately 50% of the enzyme units are lost during ultrafil-
tration and gel filtration. This may either be caused by a loss of cgTPH1 or by a 
decrease in the specific activity. This loss is larger than the ones observed for chTPH2 
and cthTPH2 (tables 4.2 and 4.3). Small aggregates of cgTPH1 could form during the 
ultrafiltration and be caught in the subsequent filtration. Since no visible aggregation 
was observed in the solution from the ultrafiltration, the observed loss of enzyme units 
is more likely to be caused by a decrease in the specific activity. In either case this 
indicates that cgTPH1 is not as stabilised in its buffer solution as chTPH2 and cthTPH2 
are in their respective buffer solutions. Addition of different concentrated buffer 
solutions to the collected fractions from the anion exchange should be tried. The gel 
filtration should subsequently be done in the new equivalent buffer solution. I would 
start by trying a gel filtration buffer of 20 mM HEPES, 200 mM (NH4)2SO4, 10%(w/v) 
glycerol, pH 7-7.5. 
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4.2.2 Expression and purification of chTPH2 
The expression of chTPH2 is verified by SDS-PAGE shown in figure 4.4. By comparing 
the intensities of the chTPH2 band in the raw extract and the supernatant in figure 4.4 
(lane 1 and 2) approximately 90% of the chTPH2 is in the soluble fraction.  If one 
compares the intensities of the raw extract of cgTPH1 expressing cells (figure 4.1B lane 
1) to the intensities of the raw extract chTPH2 expressing cells (figure 4.4 lane 1), it is 
clear that the expression of chTPH2 is significantly stronger than that of cgTPH1. A 
reason for this could be that the gene sequence for chTPH2 is codon optimised for E.coli 
expression while the cgTPH1 is the gene sequence isolated from chicken. It could also 
be caused by increased mRNA stability for the chTPH2 sequence. In the anion 
exchange in figure 4.5 chTPH2 elutes at 9.5 mS/cm and fractions C4-C12 were collected 
for further purification. This is the only major peak in the chromatogram, while three 
peaks are seen in the cgTPH1 ion exchange chromatogram (figure 4.2). This is probably 
due to the change in pH causing fewer proteins bind to anion exchange media at pH 
7.2 than at pH 8.5. A chromatogram for the gel filtration of chTPH2 is shown in figure 
4.6., in which chTPH2 eluted at approximately 137 mL and fractions B7-C1 were 
collected. The chTPH2 purification followed by enzyme activity measurements is 
summarised in table 4.2. 
The chTPH2 purification was originally done at pH 8.2, but the purified chTPH2 was 
not stable in the final solution. Different additives and buffers with different pH were 
tested on purified chTPH2. Buffers with pH 7.2 and pH 6.5 were found to improve the 
stability of chTPH2 significantly. Purification at pH 7.2 was subsequently tested and 
proved to be successful.  
The chTPH2 for crystallisation is concentrated to 20-32 mg/mL by ultrafiltration 
without any signs of precipitation. 
 
 
Figure 4.4 SDS-PAGE from chTPH2 purification. Lane 1 is 2 μL raw extract. Lane 2 is 2 μL 
supernatant of raw extract. Lane 3 is the molecular weight standard. Lane 4 is 20 μL flow-
through from the anion exchange column. Lane 5 is 2 μL of fraction C4 from the anion exchange 
chromatogram. Lane 6 is fraction C9. Lane 7 is 2 μL of pooled fractions C4-C12 from the anion 
exchange. Lane 8 is 2 μL from fractions B7-C1 from the gel filtration. Lane 9 is the molecular 
weight standard. Lane 10 is purified chTPH2 from another purification batch and this chTPH2 
was used for crystallisation experiments. 
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Figure 4.5 Anion exchange chromatogram of chTPH2 on a Q Sepharose HP 26/10 column. 
Buffers were A: 20 mM Bis Tris Propane/HCl, 5% glycerol, pH 7.2, 2 mM sodium dithionite, B: 
20 mM Bis Tris Propane/HCl, 5% glycerol, 0.8 M (NH4)2SO4, pH 7.2. Fractions C4-C12 were 
collected.  
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Figure 4.6 Gel filtration chromatogram of chTPH2 on a Superdex 75 26/60 prep grade column. 
The buffer used was 20 mM HEPES/NaOH, 5% glycerol, 100 mM (NH4)2SO4, pH 7.2. Fractions 
B7-C1 were collected.  
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Table 4.2 chTPH2 activity measured on samples from the different purification steps, purified 
from cells from 1.95 L culture. The activity measurements were done as describe in section 4.1.3. 
Step  Units* of 
enzyme 
Yield (%) chTPH2 
(mg)** 
Specific activity 
(units/mg enzyme) 
Supernatant 2235 100 - - 
From anion 
exchange 
1168 52 - - 
From gel 
filtration 
796 36 135 5.90 
* One unit is defined as the amount of enzyme that produces 1 μmole product/min. 
** Determined using ε280 = 39310 M-1 cm-1. 
 
The strong expression of chTPH2 combined with a good purification yield (36%) give 
69 mg purified protein per L culture. This makes it possible to produce large amounts 
of enzyme for crystallographic and comprehensive enzymatic characterisation. Judged 
from the SDS-PAGE (figure 4.4 lane 8 and 10) the purity of chTPH2 is higher and 
suitable for crystallisation experiments. The purity can be optimised by collecting 
fractions in a narrower interval of the anion exchange. 
The specific activity for chTPH2 of 5.90 μmole 5-hydroxytryptophan/min/mg is 
almost a factor 10 higher than that of 0.60 μmole/min/mg for cgTPH1 and rabbit 
cTPH1 [87]. A specific activity of 5 μmole/min/mg is reported on TPH1 purified from 
mouse mastocytoma P815 cells by Hasegawa and Ichiyama [158], and 5.28 
μmole/min/mg is reported by Nakata and Fujisawa also on TPH1 from mouse 
mastocytoma P815 [36]. There is only one report on expression of the chTPH2 (residues 
151-466) and they do not report the specific activity. Instead the Vmax,tryptophan of  
0.242±0.0219 μmol/min/mg is given [22], which is even lower than the specific activity 
for cgTPH1 in this study. 
4.2.3 Expression and Purification of cthTPH2 
Expression of cthTPH2 was done at 20˚C for 14 hours to get high amounts of soluble 
cthTPH2. Judging from the intensities of the chTPH2 and cthTPH2 SDS-PAGE bands 
for raw extract in figure 4.4 lane 1 and figure 4.7 lane 1, respectively, the expression 
level of these two variants is approximately the same.  
A chromatogram for the anion exchange of cthTPH2 is shown in figure 4.8. cthTPH2 
elutes at 18 mS/cm and fractions E5-F5 were collected. A chromatogram for the gel 
filtration of cthTPH2 is shown in figure 4.9. cthTPH2 elutes at 172 mL and fractions C3-
C8 were collected. According to the column specifications this elution volume is 
approximately equal to a protein size of 150 kDa which indicates that cthTPH2 elutes 
as a tetramer. This is in accordance with the report by Carkaci-Salli et al. on cthTPH2 
(residues 151-490) [22]. The cthTPH2 purification is followed by SDS-PAGE in figure 
4.7 and by enzyme activity measurements summarised in table 4.3. 
The cthTPH2 for enzyme kinetics measurements was stored at -80˚C in aliquots of 500 
μL. The cthTPH2 for crystallisation was concentrated by ultrafiltration to 39-44 mg/mL 
with no sign of precipitation, and was stored at -80˚C in aliquots of 100 μL. 
The UV-Vis spectrum of 12 μM and 270 μM cthTPH2 in 20 mM Tris/NaOH, 200 mM 
(NH4)2SO4, 10% glycerol, pH 8.2 is shown in figure 4.10. The UV-Vis spectrum of 
concentrated cthTPH2 shows a broad shoulder from the ordinary 280 nm absorption 
toward 450 nm. This yellowish colour is also seen in concentrated solution of chTPH2, 
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but not in cgTPH1. This difference between the hTPH2s and cgTPH1 is also visible by 
inspecting the 416 nm absorption in the chromatograms. The reason for this colour 
difference has not been identified. Iron is believed to be bound in the active site of all 
three variants. The colour may be due to subtle changes in the active site structure or 
binding of a coloured compound somewhere in the chTPH2/cthTPH2 structures.  
 
 
Figure 4.7 SDS-PAGE of samples from the purification of cthTPH2. Lane 1 is 2 μL raw extract 
from the cells. Lane 2 is 2 μL unfiltered supernatant of the raw extract. Lane 3 is 20 μL flow-
through when the supernatant was applied to the column. Lane 4 is 2 μL of fractions E5-F5 from 
the anion exchange. Lane 5 is 2 μL from fractions C3-C8 of the gel filtration. Lane 6 is the 
molecular weight standard. Lane 7 is 2 μL from the concentrated sample for crystallisation.  
 UV2_280nm  UV3_416nm  Cond  Conc  Fractions
   0
 200
 400
 600
 800
1000
mAU
0.0
5.0
10.0
15.0
20.0
mS/cm
10.0
20.0
30.0
40.0
mAU
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
%B
150 200 250 300 350 400 ml
X6 X7 X
8
W
as
te
A
3
A
6
A
9
A
12
B3 B6 B9 B1
2
C3 C6 C9 C1
2
D
3
D
6
D
9
D
12
E3 E6 E9 E1
2
F3 F6 F9 F1
2
W
as
te
 
Figure 4.8 Anion exchange chromatogram of cthTPH2 on a Q sepharose HP 26/10 column. 
Buffers used were A: 20 mM Tris/HCl, 10 % (w/v) glycerol, pH 8.2, 2 mM sodium dithionite, B: 
20 mM Tris/NaOH, 0.8 M (NH4)2SO4, 10% glycerol, pH 8.2. Fractions E5-F5 were collected.  
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Figure 4.9 Gel filtration chromatogram of cthTPH2 on a Superdex 200 26/60 column. The buffer 
was 20 mM Tris/NaOH, 10 % (w/v) glycerol, 200 mM (NH4)2SO4, pH 8.2. Fractions C3-C8 were 
collected.  
Table 4.3 cthTPH2 activity measured on samples from the different purification steps, purified 
from cells from 1.95 L culture. Measurements were done as described in section 4.1.3. 
Sample Units* of  
enzyme 
Yield  
(%) 
cthTPH2 
(mg)** 
Specific activity 
(units/mg enzyme) 
Supernatant 1115 100   
From anion 
exchange 
404 36   
From gel 
filtration 
256 23 74.7 3.42 
* One unit is defined as the amount of enzyme that produces 1 μmole product/min. 
** Determined using ε280 = 40800 M-1 cm-1. 
 
As seen in the SDS-PAGE in figure 4.11A, a few impurities are visible when a very 
large quantity of cthTPH2 was loaded on the gels. The Western blot in figure 4.11B 
shows that some of the high molecular weight impurities are TPH, probably oligomers 
of cthTPH2, which were not separated properly into monomers by SDS. Minor 
amounts of degradation products are also seen in the western blot. The cthTPH2 
protein sample is still believed to be pure enough for crystallisation trials. 
The specific activity of cthTPH2 is 3.42 μmole/min/mg which is a bit lower than the 
5.90 μmole/min/mg for chTPH2. Still this is much higher than the Vmax,BH4 of 
0.1236±0.0223 μmol/min/mg reported by Carkaci-Salli et al. for cthTPH2 (residues 151-
490) [22].  
Judging from the raw extracts the amount of expressed cthTPH2 (see figure 4.7 lane 1) 
is similar to that of chTPH2 (see figure 4.4 lane 1), but the amount of soluble TPH is 
different (lane 2, respectively). Almost no change is observed in the intensity of 
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chTPH2 between raw extract and supernatant, while there is an obvious decrease from 
cthTPH2 raw extract to supernatant. It is also seen that some cthTPH2 is found in the 
flow-through from the column. This is also reflected in the yield after the anion 
exchange where 52% is obtained for chTPH2 (see table 4.2) while only 36% for cthTPH2 
(see table 4.3). The reason for some of the cthTPH2 not to bind to the column is likely to 
be caused by incorrectly folded cthTPH2, which form aggregates that can be filtered 
through 0.45 μm filter. These aggregates do not bind to the column caused either by 
having no charge or by being larger than the exclusion limit of the column. The 
recovery of cthTPH2 is lower than that of chTPH2, but the 38 mg of purified cthTPH2 
per L culture is still better than that obtained in the cgTPH1 purification.  
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Figure 4.10 The UV-Vis spectrum of 12 μM (black) and 270 μM (red) cthTPH2 in 20 mM 
Tris/NaOH, 200 mM (NH4)2SO4, 10% glycerol, pH 8.2.  
 
 
Figure 4.11 (A) SDS-PAGE and (B) Western blot of same samples of purified cthTPH2. The 
loaded amount of purified cthTPH2 in μg is as follows, lane 1-6:  4.2, 12.5, 20.9, 41.7, 62.6, 83.4. 
Lane 7 is the molecular weight standard. 
Prior to the anion exchange purification the supernatant was filtered through 0.45 μm 
syringe filters. The volume that could be filtered before the filter was clogged was quite 
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low and 12 filters were needed for 120 mL supernatant. Protein aggregates that could 
not be precipitated by centrifugation are probably caught in the filters. The SDS-PAGE 
in figure 4.7 lane 3 shows that cthTPH2 is present in the flow-through from the column 
when the supernatant was loaded onto the column. This indicates that some of the 
cthTPH2 is in the partly soluble form discussed in section 3.4.2 and 3.5.1. When 
cgTPH1 and chTPH2 supernatants were filtered less than half the number of filters 
were used compared to filtration of cthTPH2. This also suggests that a higher portion 
of cthTPH2 is in an aggregated form, than in the case of cgTPH1 and chTPH2. When 
comparing the intensity of cthTPH2 band for raw extract and supernatant in figure 4.7 
it is also visible that a portion of cthTPH2 is not in a soluble form.  
During the optimisation of the chTPH2 purification it was observed that the 
supernatant produced at pH 8.2 also clogged the filters very quickly, but changing the 
pH to 7.2 significantly reduced the clogging of filters. This suggests that chTPH2 had a 
tendency to aggregate at pH 8.2 but not at pH 7.2. This might also be the case for 
cthTPH2. An anion exchange of cthTPH2 at pH 7.2 should be possible since cthTPH2 
elutes at relatively high conductivity (18 mS/cm) at pH 8.2. It is unlikely that dramatic 
changes in cthTPH2 would be observed by this pH change and I would suggest the 
change in pH to be tested in future purifications of cthTPH2.  
4.3 Conclusion 
Three variants of TPH: cgTPH1, chTPH2 and cthTPH2 have been expressed and 
purified to homogeneity. cgTPH1 gave a yield of 10.9 mg/L, while chTPH2 and 
cthTPH2 gave 69 mg/L and 38 mg/L, respectively. All three proteins seemed stable in 
the respective solutions. The specific activities of all three enzymes were high 
compared to other published results, especially the specific activity of 5.90 
μmole/min/mg for chTPH2. 
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CHAPTER FIVE 
5 Enzyme kinetics 
 
 
Enzyme kinetics deal with the factors affecting the rate of the enzyme-catalysed 
reaction. From studying the enzyme kinetics of an enzyme it is possible to deduce the 
kinetic mechanism of the enzyme. The kinetic mechanism is the order of which 
substrates add to the enzyme and products leave the enzyme [247]. Knowing the 
kinetic mechanism of an enzyme is useful in studying the molecular reaction 
mechanism, i.e. which chemical steps are involved in the enzymatic reaction [248]. The 
kinetic parameters (Km, Ki and Vmax) obtained through enzyme kinetics give 
information on the likely substrate concentrations in vivo and the possibility to 
differentiate isoenzymes from different tissues of the same organism [247]. In this 
chapter selected aspects of enzyme kinetics will be presented, which will be useful 
when proceeding to the following chapters dealing with enzyme kinetics of TPH. 
5.1 Definitions and nomenclature for enzyme catalysed reactions 
Various expressions and definitions are used to describe the reactions catalysed by 
enzymes. The nomenclature of Cleland [249] will be used in this and the following 
chapters. 
Substrates will be designated A, B, and C. Products will be designated P, Q and R. The 
enzyme forms will be designated E, F, and G, where E is the least complex or free form 
of the enzyme. The number of substrates and products are described by the use of 
syllables uni, bi, ter and quad. A reaction like that of TPH with three substrates and 
two products is therefore described as a ter bi reaction [249].  
The kinetic mechanism can be described in various terms. Two or more substrates can 
add to the enzyme in various ways. If all the binding and dissociation steps of the 
substrates are much faster than the catalytic reaction, then all forms of the enzyme are 
in a rapid equilibrium and the reaction is said to follow a rapid equilibrium mecha-
nism. If the catalytic reaction is not the rate limiting step, all forms of the enzyme 
reaches a steady-state concentration shortly after the mixing of enzyme and substrates. 
This is then called a steady-state reaction. A steady-state reaction can follow either a 
sequential mechanism or a ping pong mechanism [250]. In a sequential mechanism all 
substrates must add before a reaction happens and products are released. A sequential 
reaction can further be classified as ordered if the substrates add to the enzyme in an 
obligatory order and random if the substrates bind in a random order. In the ping pong 
mechanism one or more products leave the enzyme before all substrates have added to 
the enzyme [249].  
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5.2 Determining Km and Vmax for terreactant enzymes 
In multi-substrate enzymes the true Vmax is the maximum reaction rate of the enzyme 
when saturated with all substrates. The true Km is the substrate concentration at the 
true Vmax/2. In practise it might not be possible to saturate the enzyme ([S]>100 Km) 
with all substrates and often apparent Km and apparent Vmax values are determined 
instead, using more accessible substrate concentrations. Usually the apparent Km and 
Vmax values are quite dependent on the concentration of the fixed substrates, which 
makes it difficult to compare different published Km and Vmax values determined at 
different concentrations of the fixed substrates [251].  
The determination of Km and Vmax is done most accurately by fitting the Michaelis-
Menten equation (equation 5.1) to the measured initial rates (Vi) using non-linear 
regression instead of using for example the linear double reciprocal (equation 5.2) 
Lineweaver-Burk plot [251]. The double reciprocal plot can be useful in the 
presentation of series of measurements or in detection of patterns for different 
mechanisms and inhibition types, but should not be used for determination of Km and 
Vmax because the data points will be weighted differently [251]. 
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5.3 Substrate inhibition 
At high concentrations substrates will often function as dead-end inhibitors. This 
inhibition does usually not occur at physiological concentrations of the substrates and 
therefore gives information on the upper limits of substrate concentrations in vivo 
[252]. Substrate inhibition is also a good diagnostic tool when studying the kinetic 
mechanism. Different types of substrates inhibition are usually observed for different 
kinetic mechanisms. Competitive substrate inhibition shown in scheme 5.1 is 
characteristic of a ping pong mechanism. In this mechanism the substrate B can 
combine with enzyme E to form a dead-end complex EB [252]. 
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Scheme 5.1 
For the ordered sequential mechanism, uncompetitive substrate inhibition is the 
expected inhibition type. For the uncompetitive inhibition the substrate B combines 
with the EQ complex to form a dead-end complex as shown in scheme 5.2.  
When the inhibitory substrate resulting in a dead-end complex is varied at fixed 
concentrations of the other substrates equation 5.1 does no longer apply. Instead the 
extended form in equation 5.3 applies, where Ki is the inhibition constant for the 
inhibitory substrate and [S]=[B]. 
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Scheme 5.2 
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One can usually determine whether competitive or non-competitive substrate inhibi-
tion is observed from inspecting the effect of varying the concentration of a non-
inhibitory substrate at different inhibitory levels of the inhibitory substrate [252]. 
5.4 Ter bi kinetic mechanisms 
The reaction catalysed by TPH is a ter bi reaction. The possible ter bi mechanisms will 
be described and illustrated in schemes using the Cleland nomenclature [249] already 
seen in scheme 5.1-5.2. 
The ordered mechanism with A, B and C added in this order, is illustrated in scheme 
5.3. 
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Scheme 5.3 
The ordered addition of substrates in a steady-state fashion is called the ordered 
mechanism, while the ordered addition in an ordered equilibrium fashion is called 
rapid equilibrium ordered.  
The bi uni uni uni ping pong ter bi mechanism is shown in scheme 5.4. In this 
mechanism substrates A and B bind to the enzyme, a reaction occurs and product P 
leaves. Substrate C then binds and reacts with the modified enzyme and Q is produced 
and released [256].  
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Scheme 5.4 
Then there is a random A-B ordered C ter bi mechanism where A and B can add in any 
order in the rapid equilibrium or steady-state fashion. C then adds in the steady-state 
fashion. 
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Scheme 5.5 
In a similar way A can add in the steady-state followed by random addition of B and C 
in either steady-state or rapid equilibrium as shown in scheme 6.6. This is called the 
ordered A random B-C ter bi mechanism [256].  
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Scheme 5.6 
Finally all three substrates can add randomly in rapid equilibrium as shown in scheme 
5.7. This is called the rapid equilibrium random ter bi mechanism [257]. 
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Scheme 5.7 
The rate equations for these different kinetic mechanisms are presented in the 
following section. 
5.4.1 The rate equations of ter bi reactions 
Generally the rate equation for multisubstrate enzymes can be constructed using the 
method of King and Altman [253]. The general rate equation of a terreactant 
mechanism without the presence of products and assuming Michaelis-Menten kinetics 
is shown in equation 5.4 [250,254]. The rate equations of different mechanisms have 
different terms of the general rate equation present. The methods used to determine 
the kinetic mechanism (see section 5.5) will establish the presence or absence of 
different terms of the general rate equation [250]. The constant and coefficients (Coef) 
will consist of different mechanism dependent combinations of individual rate 
constants [255]. 
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The rate equation (equation 5.4) can be expanded to contain product terms, but since 
the rate equations will only be used for initial rate studies on reactions in the forward 
direction, only the rate equations in the absence of products will be presented. The 
following rate equations for the different ter bi mechanisms are from Segel’s book 
[256]. 
The rate equation for the ordered mechanism in scheme 5.3 is equation 5.5.   
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Kma, Kmb and Kmc are the Michaelis constants for substrate A, B and C respecttively. Kia 
and Kib are the inhibition constant for substrates A and B respectively. In this case Kia is 
also equal to the dissociation constant of substrate A, with Kia = k2/k1, and likewise 
Kib= k4/k3 and Kic = k6/k5.  
The rate equation for the rapid equilibrium ordered ter bi mechanism is equation 5.6.  
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The rate equation for the bi uni uni uni ping pong ter bi mechanism is equation 5.7. 
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Random sequences in fully steady-state mechanism introduce squared concentration 
terms in the rate equation. Theoretically this should give non-linear double reciprocal 
plots. In the case of the random A-B ordered C and the ordered A random B-C 
mechanisms, linear plots are still expected even though the enzyme forms might not be 
at equilibrium [256]. The rate equation for the random A-B ordered C mechanism is 
equation 5.8, and the rate equation for the ordered A random B-C mechanism is 
equation 5.9. 
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The rate equation for the rapid equilibrium random mechanism [257] is equation 5.10. 
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 The interaction factors α, β and γ are factors by which the dissociation constant of a 
given substrate changes when other substrates are bound [257].   
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5.5  Methods for investigating terreactant mechanisms 
Several graphical methods have been developed for investigating the kinetic 
mechanisms of terreactant reactions. In the method by Dalziel the concentrations of all 
substrates are varied simultaneously [258]. This method demands a high degree of 
accuracy and might therefore be less attractive. In the method of Viola and Cleland one 
substrate is held at saturation (>100Km) while the other two substrates are varied [255]. 
This method demands that the enzyme can be saturated with the three substrates, 
which might not always be possible because of substrate inhibition or limitations in the 
substrate solubility. High concentrations of substrates might also interfere with the 
sensitivity of the assay method used. In the method of Rudolph and Fromm the 
concentration of one substrate is varied at different fixed concentrations of the two 
others, maintaining a constant ratio between these two [259,260]. The concentration of 
each substrate is then varied, leading to three sets of experiments. The method of 
Rudolph and Fromm is chosen for the steady-state investigation of TPH, since it would 
be difficult to saturate with the different substrates and high accuracy might be 
difficult to obtain. The Rudolph and Fromm method will therefore be described in 
greater detail in the following section.  
5.5.1 The method of Rudolph and Fromm 
The graphical method of Rudolph and Fromm makes it possible to discriminate 
between different kinetic mechanisms. First of all the ping pong mechanism will give 
parallel lines in one or more of the double reciprocal plots of the initial rate data, while 
the sequential mechanism will exhibit intersecting lines in all reciprocal plots [260]. The 
point of intersection can either be on the y-axis or to the left of the y-axis [260]. The 
intercepts with the y-axis and the slopes of the lines in the double reciprocal plot can be 
plotted against the different reciprocal concentrations of one of the fixed substrates. 
The shapes of these replots depend upon the mechanism. The rate equation for the 
ordered mechanism (equation 5.5) is used as an example and is rewritten to the double 
reciprocal form when [C] is varied in equation 5.11. 
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If the concentration of substrate C is varied at concentrations [A] = x[B] the slope in the 
double reciprocal plot will be given by equation 5.12. 
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In this case the concentration of the fixed substrates A or B will appear as a squared 
term giving a parabolic replot [256]. The shapes of the slope and intercept replots will 
allow differentiation between different kinetic mechanisms. The predicted shapes of 
the replots for the different mechanisms are listed in table 5.1 below.  
5.5.2 Fitting rate equations to data 
The graphical methods for investigating terreactant mechanisms were developed at a 
time where the access to computational calculations was limited. Since then it has 
become an easy task to fit the different rate equations to the initial rate data, by global 
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curve fitting. This method is widely used and is considered a more robust method than 
the graphical methods [261,262,263,264]. 
Table 5.1 The shapes of the different replots for terreactant mechanisms when one substrate is 
varied at different fixed concentrations of the other two, maintained in a constant ratio 
[260,265]. Abbreviations used: N refers to nonlinear replots with nonzero intercepts on the y-
axis, NO refers to nonlinear replots that intersect the origin, L refers to linear replots with 
nonzero intercepts on the y-axis, A refers to a case in which the reciprocal plot intersects on the 
axis, pp refers to ping pong. 
Varied substrate Substrate A Substrate B Substrate C 
Mechanism Slope Intercept Slope Intercept Slope Intercept 
Rapid equilibrium 
random  
N N N N N N 
Ordered  N N N L N N 
Random AC N N NO L N N 
Random A N N NO N N L 
Random  (no EAC) N N  NO N N N 
Random AB NO N NO N N A 
Random BC, rapid 
equilibrium A 
NO N N L N L 
Random BC, steady-
state A 
N N N L N L 
Rapid equilibrium 
ordered 
NO N NO L N A 
Hexa uni pp L L L L L L 
Ordered bi uni uni bi pp L L L L L N 
Ordered bi uni uni bi pp L N L L L L 
Random bi uni uni bi pp L L  L L L N 
Random uni uni bi bi pp L N L L L L 
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CHAPTER SIX 
6 Determination of enzyme kinetic 
parameters of TPH variants 
 
 
Tryptophan hydroxylase catalyses the reaction tryptophan + BH4 + O2 to give 5-
hydroxytryptophan and 4a-hydroxy-BH4. In order to study this reaction and enzymatic 
properties of the enzyme, one needs to measure the initial rates of 5-hydroxy-
tryptophan formation (or substrate consumption). The initial rates are measured at 
different concentrations of all three substrates. Controlling the concentration of 
tryptophan and BH4 is straight forward since the concentration in stock solutions can 
be determined using UV-Vis spectrophotometry. Controlling the concentration of O2 is 
on the other hand not so easy. The O2 concentration in an aqueous solution is 
dependent on several factors. Most important factors are temperature, the ionic 
strength and the partial pressure of O2 above the solution. In this chapter I will 
describe the assay and procedure used to measure the initial rates at controlled 
concentrations of all three substrates and the determination of the apparent enzyme 
kinetic parameters for cgTPH1, chTPH2 and cthTPH2 will be presented. 
6.1 The tryptophan hydroxylase assay 
The formation of 5-hydroxytryptophan can be monitored using fluorescence spectro-
photometry [266]. This is based on different spectral properties of tryptophan and 5-
hydroxytryptophan shown in figure 6.1.  
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Figure 6.1 Absorbance spectra of tryptophan (black) and 5-hydroxytryptophan (red) in 10 mM 
HCl. 
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By using an excitation wavelength of 300 nm 5-hydroxytryptophan is almost selec-
tively excited. The emission is measured at 330 nm. A continuous assay for TPH based 
on fluorescence spectrophotometry was developed by Moran and Fitzpatrick [235] and 
this assay is used in this study. The assay will be described in the following sections, 
while the procedures for controlling the O2 concentration and measuring the initial 
rates are described in section 6.2 and 6.3, respectively. 
6.1.1 Composition of the assay solution 
(6R)-5,6,7,8-tetrahydro-L-biopterin dihydrochloride (BH4) was from Schircks Labora-
tories, Jona, Switzerland. All other chemicals used were analytical grade obtained from 
Sigma-Aldrich. All solutions were prepared using 18.2 MΩ cm water from a Milli-Q 
synthesis A10 Q-Gard system (Millipore). 
The assay volume was 2500  μL and contained 200 mM (NH4)2SO4, 50 mM 
HEPES/NaOH, pH 7.0, 7 mM dithiothreitol (DTT), 25 μg/mL catalase, 25 μM 
(NH4)2Fe(SO4)2, and standard substrate concentrations were 70 μM tryptophan, 300 μM 
BH4 and 500 μM O2. All measurements were done at 15˚C. Stock solutions of the 
different components were prepared as seen in table 6.1. Tryptophan, BH4, DTT and 
(NH4)2Fe(SO4)2 were prepared freshly prior to each measuring session. Catalase was 
dissolved in water in a larger batch and frozen (-20˚C) in aliquots of 1.2 mL until use. 
Tryptophan, DTT and (NH4)2Fe(SO4)2 were dissolved in water, while BH4 was 
dissolved in 10 mM HCl in order to protonate N5 and prevent autooxidation [235] (see 
section 2.4). The DTT and BH4 solutions were kept on ice. A stock solution mixture was 
usually made from the stock solutions of DTT and (NH4)2Fe(SO4)2.  
Table 6.1 Concentration of compounds in the stock solutions and concentrations used in the 
assay. 
Compound Concentration in assay 
500 mM (NH4)2SO4 
125 mM HEPES/NaOH pH 7.0 
200 mM  
50 mM  
175 mM DTT 7 mM 
1.27 mM (NH4)2Fe(SO4)2 25 μM 
1.25 mg/mL catalase 25 μg/mL 
3.0 mM tryptophan 70 μM 
15 mM BH4 300 μM 
 
The tryptophan concentration was determined in 10 mM HCl using ε278 = 5500 M-1cm-1. 
The concentration of BH4 was determined in 2 M HCl using ε266 = 18,000 M-1 cm-1 [235].  
The components in the assay have the following functions: the (NH4)2SO4 stabilises 
TPH, (NH4)2Fe(SO4)2 is a source of Fe2+ required by TPH for activity, catalase removes 
any peroxide that could be formed for example from autooxidation of BH4 and DTT is 
a reductant which keeps the iron in ferrous state and it also reduces qBH2 to BH4. qBH2 
is a product of the decomposition of 4a-hydroxy-BH4 (see section 2.4) and from the 
autooxidation of BH4. Accumulation of qBH2 is unwanted because it disturbs the 
fluorescence signal from 5-hydroxytryptophan having a higher absorbance at 330 nm 
than BH4, as seen in figure 6.2 [235].  
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Figure 6.2 The absorption spectra of BH4 at pH 7 (full line) and qBH2 (dashed line) [235]. 
6.1.2 Standard curves for 5-hydroxytryptophan 
The absorption spectrum for BH4 at pH 7.0 is shown in figure 6.2. At pH 7.0 BH4 
absorbs at 300 nm which is used as the excitation wavelength. The fluorescence signal 
from 5-hydroxytryptophan is therefore reduced by the attenuation of the incoming 
light. Consequently it is necessary to make 5-hydroxytryptophan standard curves for 
all the BH4 concentrations used. 
The fluorescence of 5-hydroxytryptophan for the standard curves, at concentration 
from 0.4 to 20 μM 5-hydroxytryptophan, was measured in 50 mM HEPES/NaOH, 200 
mM (NH4)2SO4, pH 7.0. The standard curves can be seen in appendix 1. The 
concentration of 5-hydroxytryptophan was determined in 10 mM HCl using ε278 = 5500 
M-1 cm-1 [235].  
6.1.3 Instrument and instrument settings 
Measurements were done on a Varian Cary Eclipse fluorescence spectrophotometer. 
The excitation wavelength was 300 nm and emission was measured at 330 nm. 
Excitation and emission slits were 5 nm. The photomultiplier tube (PMT) voltage was 
650 V for most measurements. A few measurements were done at 585 V when low BH4 
concentrations were used in combination with high tryptophan and O2 concentrations. 
The measurements were done in 10.00 mm × 10.00 mm QS quartz cuvettes from 
Hellma. The fluorescence spectrophotometer was equipped with a temperature 
controlled four cuvette holder with magnetic stirring. All measurements were done at 
15˚C. 
6.2 Controlling the O2 concentration 
The O2 concentration in solutions saturated with O2 can be found in reference works. 
The solubility of O2 in water at 15˚C is 1528 μM at an O2 partial pressure of 101.325 kPa 
[267]. In all the following measurements the value of 1528 μM will be used as equal to 
100 % O2. This is an approximation since the measurements were done in 50 mM 
HEPES/NaOH, 200 mM (NH4)2SO4, pH 7.0 and not in pure water.   
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Another complication in the controlling the O2 concentration is that the assay mixture 
contains 7 mM DTT which reacts with O2 [268]. The reaction at pH 7.0 between DTT 
and O2 is not fast, but it is faster than the diffusion of O2 from the gas above the 
solution and fast enough to disturb the oxygen concentration in the assay mixture.  
To solve this problem it was necessary to use an O2 sensing electrode so that the O2 
concentration could be measured at the time of the reaction. It was impractical having 
the O2 electrode in the cuvette where the measurements were done (due to protein 
binding to the electrode membrane, bigger chance of polluting the samples and slower 
mixing when adding substrates). Therefore two cuvettes, one reaction cuvette and a 
reference cuvette, were used for each measurement. The reference cuvette contained 
the same solution as the reaction cuvette except that enzyme and BH4 was not added to 
the reference cuvette. The O2 concentration was measured in the reference cuvette. 
6.2.1 Mixtures of O2 and N2  
To obtain the desired O2 concentration in the reaction solution, the solutions in the 
reaction and reference cuvettes were flushed with different N2/O2 mixtures. The 
desired N2/O2 ratios were produced using Mass Flow controllers model 5850 TR from 
Brooks Instruments B.V. Veenendaal, Holland. These were calibrated for N2 and O2 
respectively. The flow controllers were operated through a monitor model 0152 from 
Brooks Instruments. 
6.2.2 The O2 electrode 
The O2 concentration was determined using a MI-730 Oxygen electrode and OM-4 
Oxygen Meter from Microelectrodes, Inc., Londonderry, NH, USA. The electrode was 
calibrated in 50 mM HEPES/NaOH, 200 mM (NH4)2SO4, pH 7.0, in a cuvette at 15˚C. 
The zero set point was obtained by flushing the solution with N2 until saturation. The 
100% O2 set point (equal to 1528 μM in water at 15˚C, PO2 = 101.325 kPa [267]) was 
obtained by flushing with O2 until saturation. The flushing tube was lifted out of the 
solution but still keeping 100% O2 above the solution surface and after a few minutes 
the oxygen meter was set to 100% O2. This was done to ensure that the solution was not 
supersaturated with O2. Corrections were not made for fluctuations in the ambient air 
pressure.  
6.3 Procedure for measuring the initial rate of 5-
hydroxytryptophan formation 
From stock solutions HEPES (NH4)2SO4 pH 7.0, DTT, (NH4)2Fe(SO4)2, tryptophan (see 
table 6.1) and water were added to the cuvettes containing cylindrical magnetic stir 
bars. Lids with holes for gas tubes, O2 electrode and enzyme/substrate addition were 
sealed to the cuvettes with parafilm. The cuvettes with gas tubes and O2 electrode were 
placed in temperature controlled cuvette holder in the fluorescence spectrophotometer 
and flushed with a desired gas mixture of O2 and N2 with magnetic stirring. Care was 
taken to ensure the same gas flow from the two tubes. The oxygen concentration was 
monitored and at a desired O2 concentration the tubes were pulled up still keeping 
constant gas mixture above the solutions. Flushing time was dependent on the desired 
O2 concentration and usually varied from 2-12 min.  
Catalase and TPH (both kept on ice) were then added to the reaction cuvette and an 
equal volume of water (kept on ice) was added to the reference cuvette. BH4 was added 
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to reaction cuvette to initiate the reaction and the equal volume of 10 mM HCl was 
added to the reference cuvette. 
The initial rate slope (intensity/min) was determined using the fluorescence spectro-
photometer software. The software performs linear regression on an interval of the 
progression curve. The selection of the interval was done manually usually with an 
interval of minimum 0.04 min. The initial rate was converted to μM 5-hydroxytryp-
tophan/min from standard curves for 5-hydroxytryptophan at different concentrations 
of BH4 (appendix 1). When the initial rates had been measured the appropriate 
equation was fitted to the data using OriginPro 7.5 from OriginLab Corp. For each fit 
to the presented in the following sections a SS/DoF is presented. This is the sum of 
squares divided by the number of degrees of freedom. The closer SS/DoF is to zero the 
better. The coefficient of determination (R2) is also presented in the figures showing the 
data points and fitted equation [269]. 
6.4 Activity measurements of cgTPH1 
The enzyme activity measurements on cgTPH1 were done using the assay described in 
section 6.1 and the procedure in section 6.3. The enzyme solution was prepared as 
follows: Stocks of cgTPH1 stored at -80˚C were thawed and 1700 μL was mixed with 
680 μL 140 mM HEPES/NaOH, 450 mM (NH4)2SO4, 10% glycerol, pH 7.0, 7 mM DTT, 
46 μM tryptophan, 0.1 g/L catalase. The mixture was stored in 3 eppendorf tubes 
closed under an argon flow. This was done to prevent loss of activity. The cgTPH1 
concentration in the assay was 1.7 μM. The standard substrate concentrations were 70 
μM tryptophan, 300 μM BH4 and 500 μM O2. An extra experiment was carried out with 
varied BH4 concentration at 10 μM tryptophan and 133 μM O2. All data points were 
measured twice. Vmax, Km and Ki for the substrates were determined by fitting 
equations to the direct initial rates. The kinetic data for varied concentrations of BH4 
and O2 were fitted to the Michaelis-Menten equation 5.1. Data for varied tryptophan 
concentrations were fitted to equation 5.3 taking substrate dead-end inhibition into 
account. 
6.4.1 Results of activity measurements of cgTPH1 
The measured initial rates of cgTPH1 with varied tryptophan concentrations are shown 
in figure 6.3A, varied BH4 concentration in figure 6.3B, varied O2 concentration in 
figure 6.3C and varied BH4 concentration with 10 μM tryptophan 133 μM O2 in figure 
6.4. The fitted curve is shown in red. The enzyme kinetic parameters are also sum-
marised in table 6.2. From the results here the specific activity of cgTPH1 is 0.58 
μmol/mg/min.  
Table 6.2 Summary of enzyme kinetic parameters for cgTPH1 determined at 15˚C with 70 μM 
tryptophan, 300 μM BH4 and 500 μM O2 except for the measurements with varied concentration 
of BH4 with 10 μM tryptophan and 133 μM O2. 
Varied substrate Vmax, (min-1) Km (μM) Ki (μM) kcat (min-1) 
Tryptophan 54.9±2.4 7.7±0.7 164±24 32.3 
BH4 73.4±1.5 324±10 - 43.2 
O2 38.7±0.4 39±2 - 22.8 
BH4 (10 μM 
tryptophan) 
33.3±0.5 71±3  - 19.6 
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Figure 6.3 Initial rate as a function of substrate concentrations of cgTPH1. (A) Varied concen-
tration of tryptophan. (B) Varied concentration of BH4. (C) Varied concentration of O2.  
Equation 5.3 was fitted to the data for varied tryptophan concentration. Equation 5.1 was fitted 
to the data from varied BH4 and O2 concentrations. The fitted equations are shown in red. The 
kinetic parameters obtained from fitting equation 5.1 and 5.2 are listed in table 6.2. 
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Figure 6.4 Initial rates at varied BH4 concentrations for cgTPH1, with 10 μM tryptophan and 133 
μM O2. Equation 5.1 was fitted to data and is shown as the red curve.  
6.4.2 Discussion of the cgTPH1 kinetic parameters 
Since this is the first characterisation of cgTPH1 it is not possible to compare the kinetic 
constants obtained in this study with other published data of this enzyme. The rabbit 
cTPH1 [87] and chTPH1 [64] have been characterised with determined kinetic 
constants. In the case of chTPH1 the assay conditions are not described and data points 
not shown which makes it difficult to judge the validity of the data. In the case of 
rabbit cTPH1 the parameters were determined at 15˚C, air saturated (≈ 300 μM O2) 50 
mM MES, 100 mM (NH4)2SO4, 50 μM (NH4)2Fe(SO4)2 25 μg/mL catalase, pH 7.0, 150 
μM BH4 (for tryptophan variation), 200 μM tryptophan (for BH4 variation). Km,tryptophan 
determined here is 7.7±0.7 μM versus 7.8±2.2 μM for chTPH1 and 47.9±4.2 μM for 
rabbit cTPH1. The differences between the Km,tryptophan values of cgTPH1 and rabbit 
cTPH1 are significant and can not likely be ascribed to the differences in BH4 
concentration, since the lower BH4 concentration used with rabbit cTPH1 should yield 
a lower Km,tryptophan.  
For cgTPH1 substrate inhibition by tryptophan is observed above 15 μM, which is 
lower than that of >70 μM reported for chTPH1 (a Ki,tryptophan was not reported)[64]. The 
Ki,tryptophan of 146±14 μM for rabbit cTPH1 [87] is comparable to the Ki,tryptophan of 163±24 
μM determined here.  
The Km,BH4 value of 324±10 μM is quite high compared to Km,BH4 of 135±16 μM 
determined at 200 μM tryptophan for rabbit cTPH1 and very high compared to 26.5±2 
μM of chTPH1. Substrate inhibition by tryptophan is probably one reason for the high 
Km,BH4 value, but this can not be the only explanation since the Km,BH4 for rabbit cTPH1 
was measured at 200  μM tryptophan and was also influenced by tryptophan inhibition 
[87]. When the Km,BH4 was determined at 10 μM tryptophan and 133 μM O2 the Km,BH4 
should not be influenced by tryptophan inhibition. At these conditions Km,BH4 is 71±3 
μM which is significantly lower than the 324±10 μM. The Km,BH4 for chTPH2 at 10 μM 
tryptophan, 133 μM O2 has been measured to 20.5±1.7 μM (figure 7.7C) which also is 
significantly lower than the 71±3 μM. This indicates that there may be some structural 
differences in the BH4 binding site which can explain the lower affinity of cgTPH1 
toward BH4 compared to chTPH2.  
The Km,O2 value of 39±2 μM is low compared to the oxygen concentration in pure water 
at equilibrium with atmospheric air, which is approximately 300 μM. It is difficult to 
determine the in vivo O2 concentration where TPH is found. In the brain the average 
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PO2 value is 20 -30 torr, which is equal to 30-40 μM [270]. This value is similar to the 
Km,O2 of cgTPH1. In three studies Km,O2 has been determined for TPH partially purified 
from natural sources. A Km,O2 of 2.5% at 37˚C (approximately 27 μM) was determined 
using TPH (probably isoform 2) from rabbit hindbrain [266]. Km,O2 of TPH (probably 
isoform 1) partially purified from human carcinoid tumor was determined to 1.2% at 
37˚C (approximately 13 μM) using 6MePH4 and 7.1% (approximately 78 μM) when 
DMPH4 was used [47]. Km,O2 of TPH (probably TPH1) from neoplastic murine mast 
cells was determined to 6.5% at 37˚C (approximately 70 μM) [153]. These values are in 
the same range as those determined for cgTPH1.  
As mentioned in section 2.7 the kinetic mechanism for the aromatic amino acid 
hydroxylases is believed to be an ordered sequential mechanism. The expected 
inhibition pattern for this mechanism is uncompetitive substrate inhibition where the 
second substrate can add to the enzyme complex EQ (e.g. TPH-4a-hydroxy-BH4) to 
form a dead-end complex EQB (see section 5.3, scheme 5.2). Tryptophan is generally 
believed to be the second substrate to bind in TPH prior to the reaction [97], which 
supports the uncompetitive inhibition mechanism. Two other mechanisms of 
tryptophan inhibition can be envisioned. Tryptophan could bind to the free enzyme 
hindering the binding of substrate A (e.g. BH4) (similar to scheme 5.1). Another 
possibility is that tryptophan is the first substrate to bind (substrate A) and binding of a 
second tryptophan, hinders the binding of substrate B (e.g. BH4). The Km,BH4 is lowered 
significantly (from 324 to 71 μM) by lowering the tryptophan concentration. The 
greatest effect on Km,BH4 by lowering the tryptophan concentration is likely to be seen in 
the inhibition mechanism where tryptophan binds to the free enzyme. Further 
experiments have to be done to verify the order of substrate binding and mechanism of 
substrate inhibition for cgTPH1. 
6.5 Activity measurements of chTPH2 
The enzyme activity measurements of chTPH2 were done using the assay described in 
section 6.1 and the procedure in section 6.3. The enzyme solution was prepared as 
follows: Stocks of chTPH2 stored at -80˚C were thawed. The chTPH2 was diluted with 
the gel filtration buffer (20 mM HEPES/NaOH, 100 mM (NH4)2SO4, 5% (w/v) glycerol, 
pH 7.2) to give a concentration of 125 μM. Equal volumes of the chTPH2 solution and 
1.2 mM tryptophan, 4 mM DTT, 0.1 g/L catalase in 60 mM HEPES/NaOH, 15%(w/v) 
glycerol, 300 mM (NH4)2SO4, pH 7.0 were mixed. The mixture was stored in 3-6 
eppendorf tubes closed under an argon flow. The purpose of diluting the chTPH2 
sample with buffer solution containing tryptophan, DTT, catalase, extra (NH4)2SO4, 
extra glycerol was to prevent loss of activity. If chTPH2 was just stored in the gel 
filtration buffer loss of activity was observed during the measurements. In all the 
experiments 0.256 units (measured at 60 μM tryptophan, 300 μM BH4 and 300 μM O2) 
of chTPH2 was used which in average was equal to 0.50±0.05 μM. The standard 
substrate concentrations were 70 μM tryptophan, 500 μM O2 and 300 μM BH4. All data 
points were measured in triplicate. Vmax, and Km for the substrates were determined by 
fitting the Michaelis-Menten equation (equation 5.1) to the initial rates.  
6.5.1 Results of activity measurements of chTPH2 
The initial rates measured at varied tryptophan, BH4 and O2 concentrations are shown 
in figure 6.5A, B and C respectively. A summary of the enzyme kinetic parameters are 
listed in table 6.3. The specific activity of chTPH2 is calculated to 6.87 μmol/mg/min.  
6.5 Activity measurements of chTPH2
 
65 
0 20 40 60 80 100
0
20
40
60
80
100
120
140
 
[BH4] = 300 μM
[O2] = 500 μM 
SS/DoF = 3.61
R2 =  0.998
  
Vmax = 151±1 min
-1
Km = 15.0±0.4 μM
V
i (
μM
/m
in
)
Tryptophan (μM)
A
 
0 50 100 150 200 250 300 350
0
20
40
60
80
100
120
140
 
[Trp] = 70 μM
[O2] = 500 μM 
SS/DoF = 8.50
R2 =  0.992
  
Vmax = 137±2 min
-1
Km = 26.5±1.3 μM
V i
 (μ
M
/m
in
)
BH4 (μM)
B
 
0 100 200 300 400 500
0
20
40
60
80
100
120
140
 
[Trp] = 70 μM
[BH4] = 300 μM 
SS/DoF = 2.97
R2 =  0.998
  
Vmax = 202±3 min
-1
Km = 273±9 μM
V i
 (μ
M
/m
in
)
O2 (μM)
C
 
Figure 6.5 Initial rates measured at varied substrate concentrations using chTPH2. (A) Varied 
tryptophan concentration. (B) Varied BH4 concentration. (C) Varied O2 concentration. Equation 
5.1 was fitted to the data and the fitted equations are shown in red. The non-varied substrate 
concentrations were 70 μM tryptophan, 300 μM BH4 and 500 μM O2.  
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Table 6.3 A summary of enzyme kinetic parameters for chTPH2. These were determined at 15˚C 
and the concentrations of the non-varied substrates were 70 μM tryptophan, 300 μM BH4 and 
500 μM O2. 
Substrate Vmax (min-1) Km (μM) kcat (min-1) 
Tryptophan 151±1 15.0±0.4 302 
BH4 137±2 26.5±1.3 274 
O2 202±3 273±9 404 
6.5.2 Discussion of the chTPH2 enzyme kinetic parameters 
The initial rate data for chTPH2 follows Michaelis-Menten kinetics as seen in figures 
6.5A-C. The kinetic parameters for chTPH2 have been determined from fitting equation 
5.1 to the data. Kinetic parameters of chTPH2 have been published recently by Carkaci-
Salli et al. [22]. The chTPH2 used by Carkaci-Salli et al. contained amino acids 151-466 
with an N-terminal 6His tag.  The assay used was a radioenzymatic 3H2O release assay 
and conditions were not described in detail except that 50 μM tryptophan was used for 
Km,BH4 determination and 50 μM BH4 was used for Km,tryptophan determination [22]. In 
this study Km,tryptophan has been determined to 15.0±0.4 μM which is higher than the 
7.7±0.7 μM  of cgTPH1 but lower than the 41.79±3.12 μM by Carkaci-Salli et al. [22].  
The Km,BH4 was determined to 26.5±1.3 μM which is significantly lower than the 324±10 
μM of cgTPH1, but higher than the 6.22±1.4 μM by Carkaci-Salli et al. [22]. The Km,O2 
was here determined to 273±9 μM which is in the range of the O2 concentration in pure 
water in equilibrium with atmospheric air. This differs from the 39±2 μM determined 
for cgTPH1 and from the approximate O2 concentration in brain of 30-40 μM [270]. 
Substrate inhibition by tryptophan was not observed but concentrations higher than 
100 μM were not tested. It is possible that substrate inhibition will be observed at 
concentrations above 100 μM tryptophan. 
6.6 Activity measurements of cthTPH2 
The enzyme activity measurements on cthTPH2 were done using the assay described 
in section 6.1 and the procedure in section 6.3. The enzyme solution was prepared as 
follows: Stocks of cthTPH2 stored at -80˚C were thawed. Equal volume of the cthTPH2 
solution was mixed with 1.2 mM tryptophan, 4 mM DTT, 0.1 g/L catalase in 60 mM 
HEPES/NaOH, 10%(w/v) glycerol, 200 mM (NH4)2SO4, pH 7.0. The mixture was 
stored in 3 eppendorf tubes closed under an argon flow. The dilution with buffer 
containing tryptophan, DTT and catalase was done to prevent loss of activity. In all the 
experiments 0.179 units (measured at 70 μM tryptophan, 300 μM BH4 and 500 μM O2) 
of chTPH2 was used which was equal to 0.50±0.01 μM cthTPH2. The standard substrate 
concentrations were 70 μM tryptophan, 500 μM O2 and 300 μM BH4. All data points 
were measured twice. Vmax, and Km for the substrates were determined by fitting the 
Michaelis-Menten equation (equation 5.1) to the initial rates.  
6.6.1 Results of activity measurements of cthTPH2 
The initial rates measured at varied tryptophan, BH4 and O2 concentrations are shown 
in figure 6.8A, B and C respectively. A summary of the enzyme kinetic parameters are 
listed in table 6.4. The specific activity of cthTPH2 is calculated to 3.60 μmol/mg/min. 
6.6 Activity measurements of cthTPH2
 
67 
0 20 40 60 80 100
0
10
20
30
40
50
60
70
80
90
 
[BH4] = 300 μM
[O2] = 500 μM 
SS/DoF = 1.46
R2 =  0.998
  
Vmax = 109±2 min
-1
Km = 37.4±1.4 μM
V
i (
μM
/m
in
)
Tryptophan (μM)
A
 
0 50 100 150 200 250 300
0
10
20
30
40
50
60
70
80
 
[Trp] = 70 μM
[O2] = 500 μM 
SS/DoF = 1.41
R2 =  0.997
  
Vmax = 76.3±0.8 min
-1
Km= 22.9±1.1 μM
V i
 (μ
M
/m
in
)
BH4 (μM)
B
0 100 200 300 400 500
0
10
20
30
40
50
60
70
80
 
[Trp] = 70 μM
[BH4] = 300 μM 
SS/DoF = 1.61
R2 =  0.997
  
Vmax = 98±2 min
-1
Km = 185±10 μM
V i
 (μ
M
/m
in
)
O2 (μM)
C
 
Figure 6.6 Initial rates measured at varied substrate concentration using cthTPH2. (A) Varied 
tryptophan concentration. (B) Varied BH4 concentration. (C) Varied O2 concentration.  The 
Michaelis-Menten equation (equation 5.1) was fitted to the data and is shown in red. The non-
varied substrate concentrations were 70 μM tryptophan, 300 μM BH4 and 500 μM O2.  
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Table 6.4 A summary of enzyme kinetic parameters of cthTPH2. The non-varied substrate 
concentrations were 70 μM tryptophan, 300 μM BH4 and 500 μM O2. The parameters were 
determined at 15˚C. 
Substrate Vmax (min-1) Km (μM) kcat (min-1) 
Tryptophan 109±2 37.4 ±1.4 218 
BH4 76.3±0.8 22.9 ±1.1 153 
O2 98±2 185±10 196 
6.6.2 Discussion of the enzyme kinetic parameters of cthTPH2 
The Michaelis-Menten equation (equation 5.1) was fitted to the initial rates giving the 
parameters in table 6.4. Kinetic parameters have been determined for cthTPH2  by 
Carkaci-Salli et al. (residues 151-490) with assay conditions described in 6.5.2 [22] and 
for cthTPH1 (residues 91-444 with N-terminal His-tag) McKinney et al. [92]. Assay 
conditions used by McKinney et al. were 40 mM HEPES pH 7.0, 0.05 mg/mL catalase, 
10 μM (NH4)2Fe(SO4)2, 2.5 mM DTT, 50 μM tryptophan and 250 μM BH4, done at 30˚C 
[92]. The Km,tryptophan value determined here is 37.4±1.4 μM which is in the same range 
as the 20.1±3.4 μM by Carkaci-Salli et al. [22], and close to the 33±4.5 determined for 
cthTPH1 [92]. The Km,BH4 was determined to 22.9±1.1 μM which is close to the 16.88±3.9 
μM determined by Carkaci-Salli et al. [22]. The Km,BH4 of 50.8±16 μM determined for 
cthTPH1 is a bit higher but not significantly [92]. The Km,O2 was determined to 185±10 
μM which is a bit lower than the one determined for the catalytic domain alone. 
6.7 Overall summary and discussion 
The kinetic parameters are determined using the same assay conditions for all three 
variants. This makes it possible to compare the kinetic data without taking the different 
assay conditions into account.  
The Km,tryptophan values for chTPH2  is a factor two higher than the Km,tryptophan for 
cgTPH1 indicating that cgTPH1 has a higher affinity for tryptophan than chTPH2. In 
the same way Km,tryptophan for cthTPH2 is a factor two higher than that of the chTPH2, 
indicating that the tetramerisation domain has an influence on the affinity for 
tryptophan.  
Table 6.5 Summary of Km and kcat values for the TPH variants determined using 70 μM 
tryptophan, 300 μM BH4 and 500 μM O2, at 15˚C. 
Enzyme Substrate Km (μM) kcat (min-1) 
cgTPH1 Tryptophan 7.7±0.7 32.3 
chTPH2 Tryptophan 15.0±0.4 302 
cthTPH2 Tryptophan 37.6 ±1.4 218 
    
cgTPH1 BH4 324±10 43.2 
chTPH2 BH4 26.5±1.3 274 
cthTPH2 BH4 22.9 ±1.1 153 
    
cgTPH1 O2 39±2 22.8 
chTPH2 O2 273±9 404 
cthTPH2 O2 185±10 196 
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The Km,BH4 values for the TPH2 variants are similar while the Km,BH4 for cgTPH1 is more 
than a factor 10 higher. This difference is likely to be caused by both the substrate 
inhibition by tryptophan and a lower affinity of cgTPH1 for BH4. The 3-dimensional 
structure of cgTPH1 and chTPH2 will possibly give a structural explanation of these 
different properties. The Km,O2 values of chTPH2 and cthTPH2 are in the same range 
while the Km,O2 for cgTPH1 is lower. It is possible that the low Km,O2 of cgTPH1 is a 
result of the tryptophan inhibition or that cgTPH1 simply has a much higher affinity 
for O2 than chTPH2 and cthTPH2. From the brain oxygen concentration of 30-40 μM 
one would have expected the Km,O2 for chTPH2 and cthTPH2 to be in this range. 
Possibly the regulatory domain of hTPH2 can affect the affinity for O2.  
The specific activities were calculated from the initial rates at 70 μM tryptophan, 300 
μM BH4 and 500 μM O2. These were calculated for comparison to the specific activities 
obtained from the variants directly after purification (see chapter 4) to check if activity 
was lost by freezing and thawing. The specific activity of cgTPH1 was 0.60 
μmol/min/mg before freezing and 0.58 μmol/min/mg after thawing. The specific 
activity of chTPH2 was 5.90 μmol/min/mg before freezing and 6.87 μmol/min/mg 
after thawing and for cthTPH2 it was 3.42 μmol/min/mg before freezing and 3.60 
μmol/min/mg after thawing. The specific activities of cgTPH1 and cthTPH2 are not 
significantly changed by freezing. The specific activity of chTPH2 actually increases, 
which I currently have no explanation for, but it can be concluded that chTPH2 as well 
as cgTPH1 and cthTPH2 can be frozen and thawed without significant loss of activity. 
From the kcat values it can be concluded that chTPH2 is a more effective enzyme than 
cthTPH2 and much more effective than cgTPH1. The large difference in kcat between 
cgTPH1 and chTPH2 is likely to be due to the substrate inhibition by tryptophan. The 
substrate inhibition may again be due to small structural differences in the active sites 
of these enzymes. The difference in kcat between chTPH2 and cthTPH2 may be due to a 
slightly restrained structure of the catalytic domain upon tetramerisation. 
6.8 Conclusion 
The apparent kinetic parameters Km and Vmax have successfully been determined for 
three TPH variants: cgTPH1, chTPH2 and cthTPH2. This is the first time any kinetic 
parameters have been determined for cgTPH1 and to my knowledge it is also the first 
time the Km,O2 values have been determined for any fully purified recombinant TPH. 
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CHAPTER SEVEN 
7 Steady-state kinetics of chTPH2 
 
 
In chapter 5 enzyme kinetics for ter reactant enzymes were introduced and the method 
of Ruldolph and Fromm was presented. In this chapter I will explain how experiments 
with chTPH2 were done using the method of Rudolph and Fromm and present the 
results of these experiments. The assay and the procedure for measuring the initial 
rates are described in chapter 6. The data obtained from the experiments was analysed 
by two methods. First plotting analysis was used followed by a global curve fit 
analysis. All Km and Vmax values in this chapter are apparent values, unless otherwise is 
stated. 
7.1 Substrate concentrations 
As described in chapter 6 the method of Rudolph and Fromm consists of three sets of 
experiments. In each set one substrate is varied at different fixed concentrations of the 
other two, maintaining a constant ratio between these two [260]. The concentrations of 
the substrates and the ratios between the fixed substrates used are listed in table 7.1. 
Table 7.1 Concentrations of the changing fixed substrates for the different experiment series. 
Tryptophan variation BH4 variation Oxygen variation 
[O2] = 3[BH4] [O2]=13.33[Trp] [BH4]=4.286[Trp] 
BH4 (μM) O2 (μM) Trp (μM) O2 (μM) Trp (μM) BH4 (μM) 
20 60 6.7 90 7 30 
30  90 8.2 109.3 14 60 
40 120 10 133 23.3 100 
60 180 15 200 35 150 
100 300 22.5 300 70 300 
150 450 33.8 450   
300 900 52.5 700   
  75 1000   
 
The decisions made on concentrations and the ratios between the fixed substrates were 
based on the approximate Km values for the three substrates obtained from some initial 
test experiments. Practical considerations were also taken into account, as for example 
the fact that high tryptophan concentrations will give high background fluorescence 
level and high concentrations of BH4 will significantly attenuate the incoming light. 
Substrate concentrations should usually be varied in the range of Km values [260]. The 
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initial estimates of the Km values for tryptophan, BH4 and O2 are 14 μM, 50 μM and 170 
μM, respectively.  
In the following an experiment series is defined as the measurements of initial rates 
when one substrate concentration is varied and the other two are fixed. Varied 
tryptophan concentration at 30 μM BH4 and 90 μM O2 will for instance be one series. 
For each experiment series the initial rate was measured at minimum 4 different 
concentrations of the varied substrate, and each different concentration was measured 
in triplicate. In some cases a large spread was observed in the initial rates and more 
than 3 measurements were done for each substrate concentration.  
7.2 Enzyme concentration in the measurements 
To eliminate small variations in enzyme activity, caused by differences in specific 
activity of each enzyme sample, a fixed amount of units of enzyme was used in each 
set of measurements. 0.254 units was used in the experiments with varied tryptophan 
while 0.256 units was used when BH4 and O2 were varied (1 unit is the amount of 
enzyme that produces 1 μmole product/min). chTPH2 from two purification batches 
was used in these experiments. The activity of each enzyme sample was determined as 
the average activity from 4 measurements with 60 μM tryptophan, 300 μM BH4 and 300 
μM O2. 0.256 units of chTPH2 was in average equal to 0.50±0.05 μM.  
7.3 Data analysis using the plotting methods 
7.3.1 Analysis of the primary data 
In one experiment series only one substrate concentration is changed. The reaction can 
therefore be treated as a mono substrate reaction and should follow the Michaelis-
Menten equation (equation 5.1). The Km and Vmax values were obtained by non-linear 
regression using the program OriginPro 7.5. The data will be presented in a double 
reciprocal plot (Lineweaver-Burk plot, see equation 5.2) with the straight line construc-
ted from the determined Km and Vmax values. The data will also be presented in Vi 
versus the substrate concentration plots in section 7.5.1. 
7.3.2 Generation and analysis of replots 
The Km and Vmax values obtained are used to construct replots.  In the double reciprocal 
plot the slope is equal to Km/Vmax and the intercept equal to 1/Vmax. Km/Vmax and 
1/Vmax are plotted against the different reciprocal concentration of one of the fixed 
substrates. The replots should be either linear or parabolic upwards as described in 
section 5.5.1. Statistics can be used to determine whether the points follow a straight 
line or a parabolic curve. This is done using an F-test [269]. 
7.4 Results presented in double reciprocal plots and correspon-
ding replots 
The initial rates measured at varied tryptophan concentration at fixed levels of BH4 and 
O2 are presented in a double reciprocal plot in figure 7.1A. The replots of Km/Vmax and 
1/Vmax are presented in figure 7.1B and C. Similarly the initial rates at varied concen-
tration of BH4 and O2 and corresponding replots are presented in figure 7.2 and 7.3, 
respectively. 
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Figure 7.1 Results from the varied tryptophan concentration. (A) The double reciprocal plot. (B) 
Km/Vmax (the slopes of the lines in A) plotted against the reciprocal concentration of O2. (C) 
1/Vmax (the intercepts of the lines in A) plotted against the reciprocal concentration of O2.  
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Figure 7.2 Results from the varied BH4 concentration. (A) The double reciprocal plot 1/Vi 
versus 1/[BH4]. (B) Km/Vmax (the slopes of the lines in A) plotted against the reciprocal 
concentration of tryptophan. (C) 1/Vmax (the intercepts of the lines in A) plotted against the 
reciprocal concentration of tryptophan.  
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Figure 7.3 Results from the varied O2 concentration. (A) The double reciprocal plot 1/Vi versus 
1/[O2]. (B) Km/Vmax (the slopes of the lines in A) plotted against the reciprocal concentration of 
BH4. (C) 1/Vmax (the intercepts of the lines in A) plotted against the reciprocal concentration of 
BH4.  
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7.4.1 Analysis of the plots 
From the line patterns in the double reciprocal plots in figure 7.1A, 7.2A and 7.3A one 
should be able to determine whether the mechanism is a ping pong or a sequential 
mechanism. If the lines in all three double reciprocal plots intersect, the mechanism is 
sequential. The mechanism is a ping pong mechanism if parallel lines are observed in 
at least one of the replots. The lines in figure 7.1A and 7.2A intersect far to the left. The 
general trend for these lines in figure 7.1A and 7.2A is that the slopes (Km/Vmax) 
decrease as the concentrations of the substrates kept in a constant ratio are increased. 
This trend is not observed for the lines in figure 7.3A. Here lines intersect to the right of 
the y-axis, which is not in agreement with the theory (see section 5.5.1). Three lines, the 
60, 100 and 300 μM BH4, seem to follow the trend of a decreasing slope (see table 7.2) 
when the BH4 and tryptophan concentrations are increased. While the other two lines, 
30 and 150 μM BH4 do not fit into this trend.  
From the mixed pattern in figure 7.3A, it is difficult to confidently conclude that the 
lines intersect. This again makes it difficult to conclude whether the mechanism is a 
ping pong or a sequential mechanism.  
Table 7.2 The Km and Vmax parameters obtained from the experiments with varied O2 
concentration. 
Trp (μM) BH4 (μM) Km (μM) Vmax (min-1) Km/Vmax 1/Vmax 
7 30 52.5 29.3 1.79 0.0342 
14 60 157.9 69.5 2.27 0.0144 
23.3 100 187.3 109.2 1.71 0.00916 
35 150 323.9 167.8 1.93 0.00596 
70 300 248.5 192.1 1.29 0.00521 
 
The different possible patterns of the replots for the different mechanisms are shown in 
table 5.1. The replots can be linear, intersecting the y-axis at the origin or above. The 
replots can also be parabolic upwards with or without intersecting the origin.  
The replots were treated statistically. Both replots of the varied tryptophan concen-
tration experiments are linear. For varied BH4 concentration the Km/Vmax replot is 
parabolic upwards (p = 0.037) while the 1/Vmax is linear. In the case of varied O2 
concentration 1/Vmax is parabolic upwards (p = 0.036), while the Km/Vmax replot is 
neither linear nor parabolic upwards.  
All together this replot pattern does not fit with the possible patterns in table 5.1. Since 
it could not be concluded that any of the replots fit a certain mechanism, no conclusion 
could be drawn on the type of mechanism by analysing the data this way. 
7.5 Analysis using global curve fitting 
As analysing the data by the plotting method was inconclusive, the more robust 
method of global curve fitting was applied. In this method one may fit the full rate 
equation (equation 5.5-5.10) for different possible mechanisms to the data points (see 
section 5.5.2)[261,263] using OriginPro 7.5. The different rate equations can be entered 
in the software programme. The directly measured concentrations of the substrates 
[A], [B] and [C] are defined as independent variables while Vi is defined as a 
dependent variable. Vmax and the different K parameters are entered as parameters, 
with the possibility of constraining these. Usually only one constraint being K>0 was 
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enforced on the parameters, which is reasonable since all the K parameters are ratios of 
rate constants k which can not be negative.  
When the different rate equations have been fitted to the data, one may compare how 
well the different rate equations fit the data. Since it is easier to fit a complicated model 
(more parameters) than a simpler model (fewer parameters), one should always choose 
the simpler model unless the more complicated model is significantly better as 
determined by the F-test [269]. When the numbers of fitted parameters in the two rate 
equations are the same, the sum of squares of deviations of the data points from the 
model (SS) can be compared directly. If one rate equation has fewer fitted parameters 
than the other rate equation, the complexities of the rate equations have to be 
quantified with the degrees of freedom (DF). The degree of freedom is the number of 
data points minus the number of fitted parameters.  If the simpler rate equation (null 
hypothesis) is correct, the relative increase in the sum of squares should be 
approximately equal to the relative increase in degrees of freedom. This is calculated in 
the F ratio (equation 7.1). 
 ( )
( ) altaltnull
altaltnull
/DFDFDF
SS/SSSSF −
−=  
(7.1) 
If the more complicated rate equation (alternative) is correct, one expect the relative 
increase in SS to be greater than the relative increase in degrees of freedom [269]. 
In the global curve fitting all 534 data points were used. The initial rates measured with 
varied tryptophan concentration were corrected for the small difference in the amount 
of enzyme used in the measurements.  
7.5.1 Results from global curve fitting 
The different rate equations were fit to all the data points with all combinations of 
tryptophan, BH4 and O2 as A, B and C. The lowest sum of squares for each rate 
equation is listed in table 7.3. 
Table 7.3 Sum of squares for the fitting of rate equations to the initial rates. SS is the sum of 
squares and DF is the degrees of freedom. 
Mechanism (equation number) SS DF Substrate (A,B,C) F ratio 
Rapid equilibrium ordered (5.6) 21605 530 (BH4, O2, Trp)  
Bi uni uni uni ping pong (5.7) 9773 529 (Trp/BH4, O2) 
Random A-B ordered C (5.8) 9583 528 (BH4, Trp/O2) 
Rapid equilibrium random (5.10) 9560 527 (-,-,-) 
10.5 
 
1.3 
Ordered (5.5) 9515 528 (Trp/O2, BH4, Trp/O2)  
Ordered A random B-C (5.9) 9478 528 (Trp, BH4/O2)  
 
The rapid equilibrium ordered rate equation does not fit data very well as the sum of 
squares is much higher than for any of the other rate equations. The ping pong rate 
equation has a higher sum of squares than the random A-B ordered C but they have 
different degrees of freedom. When comparing the random A-B ordered C fit with the 
ping pong fit, the calculated F ratio is 10.5. This says that the random A-B ordered C 
rate equation fits significantly better than the ping pong mechanism. The rapid 
equilibrium random rate equation has a lower sum of squares than the random A-B 
ordered C, but the F ratio of 1.3 (p = 0.0013) tells that the rapid equilibrium random 
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rate equation fit is better. The fit of the remaining rate equations (5.5, 5.8 and 5.9) can 
be compared directly since the degrees of freedom are the same for all three. The 
lowest sum of squares of 9478 is obtained when fitting the rate equation for the ordered 
A random B-C mechanism, where substrate A is tryptophan. The sum of squares of 
9515 for the ordered mechanism with BH4 as substrate B is close to that of the ordered 
A random B-C, while the sum of squares of the random A-B ordered C equation fit is 
somewhat worse.  
Data points for each series of data are presented in figures 7.5-7.10, with the fitted 
curves for both the ordered A (A = tryptophan), random B-C rate equation (dashed 
blue curve) and the ordered rate equation with substrate B being BH4 (red curve). 
Parameter values for these two best fits are listed in table 7.4. 
Initially some of the series were done with O2 concentrations up to 1000 μM. When O2 
concentrations above 500 μM were used a deviations from the Michaelis-Menten 
equation were observed which was similar to substrate inhibition. Examples of this 
observation are shown in figure 7.4 with the globally fit rate equations for the ordered 
A random B-C mechanism.  This deviation might be caused by O2 inactivation of the 
enzyme in different ways than ordinary substrate inhibition. All measurements done 
with O2 concentrations above 500 μM have therefore not been used in the data analysis. 
Table 7.4 Kinetic parameters obtained from the global curve fitting of the rate equations for the 
ordered A random B-C and ordered mechanism. 
Ordered A random B-C Ordered  
A= tryptophan A = tryptophan, B = BH4, C = O2 
Vmax 379±19 min-1 Vmax 358±17 min-1 
Km,tryptophan 43.7±2.7 μM Km,tryptophan 40.1±2.7 μM 
Km,BH4 114±10 μM Km,BH4 90.2±8.4 μM 
Km,O2 497±37 μM Km,O2 467±33 μM 
Ki,tryptophan 80±137 μM Ki,tryptophan 4.52±1.20 μM 
Ki,BH4, (BH4 = C) 
Ki,O2, (O2 = C) 
1.6±2.5 μM 
7.0±11.3 μM 
Ki,BH4 6.3±2.0 μM 
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Figure 7.4 Initial rates measured at different O2 concentrations. From the top the data is of 100 
μM BH4/23.3 μM tryptophan, 60 μM BH4/14 μM tryptophan and 30 μM BH4/7 μM tryptophan. 
The data points measured at 1000 μM are shown in red and these data points were not used in 
the fitting of the rate equation. The curves are the rate equations for the ordered A random B-C 
mechanism fitted to the data shown in figures 7.5-7.10.  
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Figure 7.5 Initial rates measured at varied tryptophan concentration with the concentrations of 
BH4 and O2 in: (A) 20 μM and 60 μM, (B) 30 μM and 90 μM, (C) 40 μM and 120 μM. The red 
curve is the fitted ordered rate equation with BH4 as substrate B. The dashed blue curve is the 
fitted ordered A random B-C rate equation with tryptophan as substrate A. 
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Figure 7.6 Initial rates measured at varied tryptophan concentration with the concentrations of 
BH4 and O2 in: (A) 60 μM and 180 μM, (B) 100 μM and 300 μM, (C) 150 μM and 450 μM. The red 
curve is the fitted ordered rate equation with BH4 as substrate B. The dashed blue curve is the 
fitted ordered A, random B-C rate equation with tryptophan as substrate A. 
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Figure 7.7 Initial rates measured at varied BH4 concentration with the concentrations of 
tryptophan and O2 in: (A) 6.7 μM and 90 μM, (B) 8.2 μM and 109 μM, (C) 10 μM and 133 μM. 
The red curve is the fitted ordered rate equation with BH4 as substrate B. The dashed blue curve 
is the fitted ordered A, random B-C rate equation with tryptophan as substrate A. Equation 5.1 
has been fitted (black) to this data alone for comparison with the cgTPH1 data in figure 6.4. 
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Figure 7.8 Initial rates measured at different BH4 concentration. The tryptophan and O2 
concentrations are in: (A) 15 μM and 200 μM, (B) 22.5 μM and 300 μM, (C) 33.8 μM and 450 μM. 
The red curve is the fitted ordered rate equation with BH4 as substrate B. The dashed blue curve 
is the fitted ordered A random B-C rate equation with tryptophan as substrate A. 
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Figure 7.9 Initial rates measured at varied O2 concentration. The concentrations of tryptophan 
and BH4 are in: (A) 7 μM and 30 μM, (B) 14 μM and 60 μM, (C) 23.3 μM and 100 μM. The red 
curve is the fitted ordered rate equation with BH4 as substrate B. The dashed blue curve is the 
fitted ordered A random B-C rate equation with tryptophan as substrate A. 
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Figure 7.10 Initial rates measured at varied O2 concentrations. The concentrations of tryptophan 
and BH4 are in: (A) 35 μM and 150 μM, (B) 70 μM and 300 μM. The red curve is the fitted 
ordered rate equation with BH4 as substrate B. The dashed blue curve is the fitted ordered A 
random B-C rate equation with tryptophan as substrate A. 
7.5.2 Discussion of the results of the global curve fitting 
Since the four rate equations (equations 5.5, 5.8, 5.9 and 5.10) that fit the data the best 
are all sequential mechanisms it can be concluded that chTPH2 follows a sequential 
mechanism. 
As can be seen in figures 7.5-7.10 the curves of the two rate equations fitting best to the 
data are quite similar, but since the sum of squares is lower for the ordered A, random 
B-C equation fit, this is the best fit. This means that the chTPH2 mechanism probably 
follows an ordered binding of tryptophan as the first substrate followed by a random 
binding of BH4 or O2 either in the rapid equilibrium or in the steady-state fashion 
(scheme 5.6). The reaction then proceeds when all three substrates are bound in 
chTPH2.  
7.6 Overall discussion
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7.6 Overall discussion 
In the literature there are no reports of steady-state mechanism analysis of TPH, but 
comparable studies have been made on rat TH [95] and CvPAH [96,97]. Fitzpatrick 
used the same method with rat TH as used in this study and concludes that the 
mechanism is ordered with 6MePH4 binding as the first substrate (based on inhibitions 
studies), O2 binding as the second (binding in a rapid equilibrium fashion) and 
tryptophan as the last substrate [95]. Volner et al. uses the method for CvPAH used in 
this study. Additionally Volner et al. also uses the method where one of the substrates 
is held at a saturating level, and inhibition studies. Volner et al. concludes that the 
mechanism is ordered with DMPH4 binding first, followed by phenylalanine and O2 as 
the last substrate [97]. Pember et al. also used the method use here with CvPAH and 
also concluded an ordered A random B-C mechanism but with O2 as substrate A [96]. 
As mentioned in section 2.7 Pember et al. at the time thought that CvPAH was a Cu 
protein [98]. As seen, several different steady-state mechanisms have been reported 
and the results here support the mechanism determined by Pember et al. but with 
tryptophan as substrate A instead of O2. These examples show that there is no general 
consensus on the binding order of the substrates, but the mechanism is a sequential 
mechanism in all cases.  
The inhibition by O2 has also been reported for bovine TH by Oka et al. [101]. Oxygen 
inhibition of bovine TH was observed already at 40 - 90 μM being dependent on the 
BH4 concentration [101]. The inhibition observed in this study is at much higher O2 
concentrations and the mechanism of inhibition in bovine TH and chTPH2 might not 
be the same. The O2 inhibition in bovine TH observed by Oka et al. could not be 
confirmed by Fitzpatrick using rat TH [95].  The O2 inhibition observed in this study 
could be caused by O2 binding in the reactive site preventing the other substrates in 
binding correctly. It might also bind directly to the iron, probably oxidising Fe2+ to Fe3+. 
The oxidation of iron is a possible explanation for the inhibition, since the iron then has 
to be reduced to Fe2+ to be in the catalytic active state.  
Further investigations will be needed to determine whether the kinetic mechanism in 
cgTPH1 and chTPH2 is the same or not. If the substrate inhibition by tryptophan in 
cgTPH1 is uncompetitive, which is typical for a sequential mechanism [252], this 
indicates that tryptophan is the second substrate to bind in cgTPH1 (see section 5.3 and 
6.4.2). This would then imply a different kinetic mechanism for cgTPH1 than the one 
proposed in this study for chTPH2 where tryptophan binds as the first substrate.  
7.6.1 Further kinetic analyses of chTPH2 
The results from the enzyme kinetic measurements above indicate that the kinetic 
mechanism is an ordered A random B-C mechanism with tryptophan as substrate A. 
This result should be supported by inhibition studies [252,259], which unfortunately 
could not be done within the time limit of this project. The inhibition studies could for 
example be performed with BH2 which is a non-reactive BH4 analogue, and should be a 
competitive inhibitor towards BH4. Phenylalanine or 5-fluorotryptophan should be a 
competitive inhibitor towards tryptophan and should also be tested. 
The measurements with varied tryptophan should also be extended to higher 
concentrations of tryptophan to explore if substrate inhibition is observed. In case of 
observed substrate inhibition, the type of substrate inhibition should be identified (see 
section 5.3).  
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Product inhibition by 5-hydroxytryptophan should also be studied in order to 
determine which product leaves the enzyme as the first. 
7.7 Conclusion 
Since it could not be concluded that any of the replots fit a certain mechanism, no 
conclusion could be drawn on the type of mechanism by analysing the data this way. 
From the global curve analysis it can be concluded that the chTPH2 kinetic mechanism 
is a sequential mechanism. It can also be concluded that the ordered A random B-C 
mechanism with tryptophan as substrate A fits the data best. The fit of ordered 
mechanism with BH4 as substrate B is close to the fit for the ordered A random B-C.  
None of these mechanisms have BH4 as the substrate bound first.   
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CHAPTER EIGHT 
8 Crystallisation of proteins 
 
 
Determination of the three-dimensional structure of a protein by X-ray crystallography 
requires growth of suitable crystals. This is the major obstacle in protein X-ray 
crystallography. This chapter will serve as a short introduction to some aspects of 
protein crystallisation and crystal annealing, which will be useful when proceeding to 
the next chapter.  
8.1 Nucleation and growth of protein crystals 
Protein crystals grow from a supersaturated solution of the protein [271]. Before a 
crystal can grow, stable nuclei have to be formed. Stable nuclei are small more or less 
ordered aggregations of protein molecules with a size large enough not to 
spontaneously dissolve [272]. Different degrees of protein supersaturation can be 
obtained as illustrated in the phase diagram in Figure 8.1. The degree of 
supersaturation necessary for nucleation is higher than that for crystal growth. The 
probability of nucleation is dependent on the degree of supersaturation, so if a high 
degree of supersaturation is reached a large number of nucleations might occur [272].    
When stable protein nuclei have formed in the supersaturated state, protein molecules 
will start to order themselves in a crystal lattice. Because of the interactions formed in 
the crystal lattice, the crystal form is an energetically more favourable state than the 
supersaturated state of the protein. The crystals will grow until the protein concen-
tration is decreased to the point of saturation [272]. The growth rate is dependent on 
the degree of supersaturation. Since the risk of crystal growth defects tends to be 
higher at higher growth rate, the desired degree of supersaturation should be just high 
enough for nucleation to occur. In this way fewer and better crystals should be 
obtained [272].  
If the degree of supersaturation becomes too high the protein may form spherulites or 
phase separations, but more commonly the protein will form non-specific aggregates 
seen as amorphous precipitation (see Figure 8.1). If the supersaturation is too high the 
rate of precipitate formation is higher than that of crystal formation. The crystal form is 
still a lower energy state than the precipitate and this is why protein crystals 
sometimes grow concomitantly with the dissolution of precipitate [272].  
The solubility of a protein in solution is dependent on various factors such as pH, 
temperature and the concentration of different precipitants (see section 8.3). Many 
other factors can also influence the crystallisation of a protein. Some examples are: 
purity of the protein, organism source of the protein, substrates, co-factors, reducing or 
oxidising environment, surfaces of the crystallisation vessel, vibration and sound and 
many more [272,273].  
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Figure 8.1 A phase diagram showing the different states of the protein phases [274]. This is an 
example phase diagram and all the states might not exist for a given protein and the sizes of the 
phases might vary greatly. 
The interactions formed between the protein molecules in a crystal are essential for 
crystal growth. Proteins are sensitive and dynamic macromolecules that might easily 
loose their native structure. Therefore, it is generally accepted that the solution (the 
mother liquor) optimal for crystal growth supports the most structurally homogeneous 
state of the protein, which at the same time optimises the possible intermolecular 
interactions [272]. To determine the optimal conditions for crystal growth of a given 
protein is not an easy task. Currently, the conditions for crystallisation can not be 
predicted and are usually determined by screening a large number of possible 
conditions.
8.2 Crystallisation screens 
The process of screening for crystallisation conditions is commonly done by using 
sparse matrix screens. Sparse matrix screens contain different solutions that have 
proven successful in the crystallisation of numerous proteins. The first sparse matrix 
screen was described by Jancarik and Kim [275]. Several companies sell this screen and 
small variations may exist, for example in whether the buffer pH is reached by using 
HCl or acetic acid [276].  
Another sparse matrix screen is the commercially available JCSG+ screen, which is 
developed through experience gained from a structural genomics project [277].  
More systematic (grid) screens are also used in the initial screening [277,278,279]. Some 
of these are the PEG/Ion screens or the PACT screen [277], while the Index screen from 
Hampton Research is a combination of sparse matrix and grid screening [280].  
8.3 Precipitants 
Precipitants are compounds that decrease the protein solubility. The supersaturation 
necessary for nucleation and crystal growth is usually obtained by increasing the 
precipitant concentration in the protein solution. This can be done momentarily using 
batch crystallisation or in a more gradual manner using dialysis or the vapour 
diffusion method [281]. In the vapour diffusion method the initial precipitant 
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concentration in the non-equilibrated drop is typically half of that in the reservoir. This 
causes water vapour to diffuse from the drop to the reservoir until equilibrium is 
reached. In the vapour diffusion method the precipitant serves to increase the protein 
concentration and to decrease the protein solubility [272]. 
Different types of precipitants are used in protein crystallisation and these are usually 
categorised in four groups: salts, organic solvents, long-chain polymers and low-
molecular-mass polymers/non-volatile organic compounds [272]. Examples of organic 
solvents used as precipitants are ethanol, propanol and dioxane, while examples of 
low-molecular-mass polymers are polyethylene glycol (PEG) with a molecular weight 
of 200 or 400 g/mol. A typical non-volatile organic compound would be 2-methyl-2,4-
pentanediol [272]. Salts and PEGs are the most successful precipitants used in protein 
crystallisation and a short description will be given in the following sections. 
8.3.1 Salts as precipitants 
The ionic strength of a solution greatly affects the solubility of proteins [272]. At very 
low ionic strength no ions are available to satisfy the electrostatic requirements of the 
protein molecules. The protein molecules will then seek to balance the electrostatic 
requirements with themselves which leads to aggregation or to crystals if it happens in 
an order fashion. This process is called salting-in [272].  
As the ionic strength is increased the electrostatic requirements are satisfied and the 
solubility of the protein is increased. If the concentration of salts with strongly 
hydrated ions is further increased the protein solubility is decreased by the process 
called salting-out. The salting-out process is more complicated and can be explained in 
two ways whether one looks at the polar or non-polar surface of a protein 
[271,282,283,284]. For a typical protein 50-60% of the surface is non-polar [285]. The 
surface tension of the solvent is increased by strongly hydrated anions such as 
sulphate. The increased surface tension strongly affects the non-polar surface and will 
force the protein to decrease its surface accessible area by either crystallisation or 
aggregation [284]. For the polar surface of a protein, the solubility is highly dependent 
on the effectiveness of the hydration layers. The second hydration layer is disturbed by 
strongly hydrated anions making the bulk solution a less good solvent for the protein. 
The protein will therefore try to decrease the solvent accessible surface [284]. The effect 
of different ions on the solubility and of salting-out proteins was observed already in 
1888 by F. Hofmeister and the order of the ions are therefore called the Hofmeister 
series [284]. Some of the ions are listed here in their efficiency in lowering the solubility 
of a negatively charged protein. For anions: HPO42-/H2PO4¯ > SO42- > CH3COO¯ >> Cl¯ 
> NO3¯ and for cations: Li+ > Na+ ≈ K+ > NH4+ > Cs+[284]. 
For a positively charged protein this order is reversed [283]. Both inorganic and 
organic salts are used extensively in crystallising proteins [272,286]. Some specific ions, 
for example different divalent cations may have essential roles in the stabilisation of 
the protein structure or in crystal lattice and are often tested as additives in a concen-
tration of a few mM [287].  
8.3.2 Polyethylene glycols as precipitants 
PEGs with molecular weights ranging from 400 Da to 20 kDa have been used 
successfully in the crystallisation of many proteins [271,288,289].  PEGs have a random 
and flexible structure which occupies a large volume. The addition of PEGs to a protein 
solution reduces the solvent volume available for the protein resulting in favoured 
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attraction between the protein molecules [271,290]. The solubility of a protein decreases 
exponentially with the increasing concentration (%w/v) of the PEG and the typical 
concentration range used for crystallisation is 4-25% (w/v) [289]. An advantage of 
using PEG is that the PEG concentration interval yielding crystals is larger for a given 
protein, than that typically observed for salts [271]. This is valuable both in the 
screening and optimisation process, since crystals may form even though the PEG 
concentration differs a bit from the optimal concentration opposed to salts where the 
concentration often has to be spot-on for crystal formation. Polypropylene glycol and 
polyethylene glycol monomethyl ether (MPEG) are also used for crystallisation, but in 
a lesser extent than PEGs [291].  
8.4 Additives used in crystallising proteins  
Addition of certain ions or small organic molecules to the mother liquor may in some 
cases be necessary to establish the stabilising contacts between protein molecules in a 
crystal [287,292,293,294]. Typical additives would be substrates or substrate analogues, 
co-factors, linker molecules and osmolytes. Reports by McPherson et al. and Larson et 
al. suggest that screening additives may be a successful alternative to the more 
common buffer/precipitant screening [293,294]. Neutral detergents are usually used in 
the crystallisation of membrane proteins, but have also been reported to improve the 
crystallisation for some soluble proteins [295]. 
8.5 Annealing of protein crystals 
Protein crystals are very seldom perfect crystals, but are instead made of mosaic blocks 
of ordered molecules. The mosaic blocks are generally well aligned but upon flash-
freezing the mosaic blocks might rearrange relative to each other. If the mosaic blocks 
are not well aligned the crystal is said to have a high mosaicity. 
Annealing of protein crystals is done to decrease the mosaicity. The term annealing is 
borrowed from metallurgy. Protein crystal annealing refers to a flash-frozen protein 
crystal being transferred from liquid nitrogen to a small drop of mother liquor with 
added cryo-protectant typically at 4˚C or room temperature [296]. After 3 minutes in 
the cryo-protectant buffer the crystal is remounted in the loop and flash-frozen in 
liquid nitrogen or cold nitrogen gas stream. This process may be repeated several 
times. It is essential that a suitable cryo-protectant is found so that the crystal is stable 
in the cryo-protectant buffer [296]. The purpose of the cryo-protectant is to prevent the 
formation of ice crystals in the mother liquor when the protein crystal is flash-frozen. 
Examples of typical cryo-proctectants are glycerol, ethylene glycol and PEG 400 [297]. 
It is believed that the annealing heal dislocation defects from the flash-freezing by 
recrystallisation at the dislocations [296]. This will decrease the mosaicity of the crystal. 
Resolution improvement is sometimes also observed upon annealing and this is 
believed to be caused by diffraction peak sharpening allowing detection of peaks that 
prior to annealing were too diffuse. Annealing is recommended for all flash-frozen 
crystals that do not diffract satisfactorily [296].  
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CHAPTER NINE 
9 Crystallisation of TPH variants 
 
 
As described in chapter 4 it is possible to obtain cgTPH1, chTPH2 and cthTPH2 in 
purities and amounts suitable for crystallographic characterisation. In this chapter I 
will describe the crystallisation experiments done with these three variants. The results 
from the crystallisation as well as collected diffraction data and structure solution will 
be presented. The crystallisation conditions of cgTPH1 were found by Charlotte R. 
Petersen in her M.Sc. project, in which I was a co-supervisor [15].  
9.1 Crystallisation of cgTPH1 
9.1.1 The initial crystallisation of cgTPH1  
Initial screenings were done with Stura Footprint Screens (appendix 2.1), Index Screen 
from Hampton Research (appendix 2.2), JCSG+ screen from Qiagen (appendix 2.3) and 
PACT screen from Qiagen (appendix 2.4). The results from Index, JCSG+ and PACT 
screens will be described first. 
9.1.1.1 Crystallisation trials using Index, JCSG+ and PACT screens 
The cgTPH1 for the crystallisation experiments was purified as described in section 
4.1.2.1. A cgTPH1 sample of 100 μL was mixed with 50 μL of ice cold 20 mM 
Tris/NaOH, 100 mM (NH4)2SO4, pH 8.5. The solution was filtered through a 0.22 μm 
Ultrafree-MC durapore membrane centrifugal filter from Millipore at 8000 × g and 4˚C 
for 4 min. The protein concentration was determined using ε280 = 37820 M-1 cm-1. The 
cgTPH1 solution was further diluted to the desired concentration with 20 mM 
Tris/NaOH, 100 mM (NH4)2SO4, pH 8.5. 
The Index, JCSG+ and PACT screens were set up at the Department of Chemistry at 
University of Copenhagen using an Oryx 8 robot from Douglas Instruments. The 
screens were set up with three drops per well. The cgTPH1 concentrations in the non-
equilibrated drops were 4.2 mg/mL with 8 times molar excess of BH4, 6.2 mg/mL with 
8 times excess of BH4 and 4.3 mg/mL without any BH4, respectively. The trays were 
stored at 6˚C.  
Precipitation was observed in most drops. Crystals were observed in several drops, but 
most of these drops contained calcium which could form CaSO4 crystals with the 
sulphate from the cgTPH1 buffer (see section 4.1.2.1). The conditions containing 
calcium were tested with the sulphate containing buffer. Crystals appeared in all these 
drops and we concluded that these were most likely CaSO4 crystals. The crystals from 
drops without calcium did not diffract and could furthermore not be reproduced. 
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9.1.1.2 Crystallisation trials using Stura Footprint screens 
The Stura Footprint screens 1 and 2 were set up as sitting drop experiments. The trays 
were placed on ice during addition of 500 μL crystallisation solutions to the wells and 
during drop set up. The drops were set up with 2 μL crystallisation solution + 2 μL 
protein solution. The concentration of cgTPH1 in the protein solution was 3.5 mg/mL. 
The trays were sealed with clear sealing tape and stored at 4˚C. 
9.1.2 The initial crystals of cgTPH1 and data collection 
Semi crystalline assemblies were observed in the drop containing 1.32 M 
NaH2PO4/K2HPO4 pH 7.0. Trials to optimise these conditions were unsuccessful [15].  
Protein crystals were observed after 40 days in the drop containing 0.2 M imidazole 
malate pH 8.5, 22.5 % PEG 10000. The larger crystals were flash-frozen in the mother 
liquor for testing at a synchrotron. The smaller crystals left in the drop were stained 
with methylene blue (Izit) (see figure 9.1). The crystals were brought to MAX-lab in 
Lund, Sweden, beamline 911-5. The crystals flash-frozen in the mother liquor diffracted 
to 8 Å and ice rings from the mother liquor were observed. At the synchrotron, cryo-
protectant solutions were tested on the remaining crystals in the drop. Some crystals 
were successfully flash-frozen in a cryo-protectant solution with PEG 400 added to 
approximately 20% (v/v). Unfortunately these did not diffract. At this point it was 
unclear whether it was because of deterioration from storage in the drop for several 
weeks or if they were destroyed by cryo-protectant. 
 
Figure 9.1 Crystals of cgTPH1 stained with methylene blue, crystallised with 0.2 M imidazole 
malate pH 8.5, 22.5% PEG 10000, cgTPH1 concentration was 3.5 mg/mL and the drops were 
stored at 4˚C [15].  
Reproducing the crystallisation was successful only with the solution 0.2 M imidazole 
malate pH 8.5, 22.5% PEG 10000 from Molecular Dimensions. Drops setup with this 
solution in the sitting drop manner yielded new crystals after 70 days. Few crystals 
were present and we were afraid that the crystals would be destroyed in testing cryo-
protectant solutions. These crystals were therefore flash-frozen in the mother liquor, 
and stored in liquid nitrogen. A data set was collected to 3.0 Å at the European 
Synchrotron Radiation Facility (ESRF), beam line ID 14-3. Ice rings were observed in 
the diffraction pattern. 
After data collection several crystals were annealed in a cryo-solution of 20%(v/v) PEG 
400, 0.2 M imidazole malate pH 8.5, 22.5% PEG 10000. Two crystals dissolved in the 
cryo-solution while one crystal was successfully transferred and flash-frozen. Through 
this annealing, the mosaicity of the crystal decreased and the diffraction limit 
improved from 5 Å to 3.5 Å. Diffraction patterns from the crystal, before and after 
transfer to the cryo-solution are shown in figure 9.2.  
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Figure 9.2 The diffraction patterns of the same crystal. (A) Before annealing. (B) After annealing. 
The middle ring of the three ice rings indicates 3.7 Å. 
Data processing, structure solution and refinement were done by Associate Professor 
Pernille Harris. The reflections could be indexed to a lattice with the dimensions 61.5 
Å, 79.2 Å, 86.8 Å and 62.9˚, 89.9˚and 89.9˚. The ice rings were cut out of the data, giving 
a reduced completeness of data. The data statistics for the possible space groups are 
listed in table 9.1.  
Table 9.1 Data collection and processing statistics for the possible space groups for the cgTPH1 
crystal. 
Space group P1 P21 C2 C2221 
Crystallisation 
conditions 
0.2 M imidazole malate pH 8.5, 22.5% PEG 10000 
Hanging drop, 4˚C 
X-ray source ID14-3, ESRF 
Detector ADSC Quantum CCD 
Wavelength (Å) 0.931 
Data collection temp.  
(K) 
100 
Resolution limit (Å) 20- 3.0 (3.2-3.0) 
No. reflections 48427(9318) 48342 (9311) 48371 (9331) 46441 (9291) 
Unique reflections 24728(4759) 13344 (2528) 13470 (2566) 6833 (1291) 
Redundancy 1.96 (1.96) 3.62 (3.68) 3.59 (3.64) 6.80 (7.20) 
Completeness (%) 84.3 (91.5) 87.8 (94.9) 89.6 (97.0) 90.4 (99.9) 
Rmerge 11.4 (30.5) 14.7 (38.4) 15.3 (38.4) 16.4 (39.9) 
<I/σ(I)>  5.67 (2.37) 7.08 (3.06) 6.98 (2.97) 9.55 (4.24) 
Unit cell parameters 
a (Å) 
b (Å) 
c (Å) 
α (˚) 
β (˚) 
γ (˚) 
 
61.5 
79.2 
86.8 
62.9 
89.9 
89.9 
 
79.2 
61.5 
86.9 
90.0 
117.2 
90.0 
 
154.5 
79.2 
61.5 
90.0 
90.1 
90.0 
 
78.1 
152.4 
60.6 
90.0 
90.0 
90.0 
Solvent content (%) 52.8    
Matthews coef. (Å3 Da-1) 2.61    
a Values in parentheses are for the outermost resolution shell. 
b Rmerge = ∑i |Ii-<Ii>|/∑i Ii , where <Ii> is the average of Ii over all symmetry equivalents.  
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The structure could be solved by molecular replacement in space group P1 with four 
molecules in the asymmetric unit using the structure of the catalytic domain of 
phenylalanine hydroxylase (PDB entry 1J8U) [84]. The structure could be refined to an 
Rfree = 32.7%. Even though the model is not of superior quality, differences in the 
overall structure compared to the structure of chTPH1 are observed and will be 
presented and discussed in section 9.4. 
9.1.3 Further crystallisation of cgTPH1 
To optimise the crystallisation of cgTPH1 a 0.2 M imidazole malate pH 8.5, 22.5 % PEG 
10000 solution, a 50 % PEG 10000 solution and a 2 M imidazole malate pH 8.5 solution 
were bought from Molecular Dimensions. 
9.1.3.1 Trials to optimise crystallisation of cgTPH1 
Several conditions were tested in trials to optimise the crystallisation of cgTPH1. A full 
list of tested conditions is presented in appendix 3. In summary the cgTPH1 concen-
tration was varied between 0.94 – 6.1 mg/mL. cgTPH1 from a new purification batch 
was tested. The PEG 10000 concentration was varied between 5 - 29%. A 0.2 M 
malonate imidazole borate (MIB) buffer [298] pH 7.0, 7.5, 8.0, 8.5 was tried instead of 
imidazole malate buffer. Addition of BH4 or BH2 to the drops was tested. DTT, β-
mercaptoethanol and EDTA added to the reservoir solution of 0.2 M imidazole malate 
pH 8.5 and 22.5% PEG 10000 were tested. In addition to this the non-volatile additives 
from (the old version) Hampton’s additive screens 1, 2 and 3 (appendix 2.5) and 
Hampton’s detergent screens 1-3 (appendix 2.6) were tested with the condition 0.2 M 
imidazole malate, 22.5% PEG 10000. All trays were stored at 4˚C.   
9.1.4 Results of optimisation trials and data collection  
9.1.4.1 Crystals from the optimisation trials 
The crystals proved difficult to reproduce and very few were observed. In a few drops 
with 17-22.5% PEG 10000 very small stacks of needles appeared. In one drop with 0.2 
M imidazole malate pH 8.5, 18% PEG 10000 three crystals appeared after 3 months. 
These crystals were flash-frozen in the cryo-protectant solution determined earlier 
(section 9.1.2) [15] and stored in liquid nitrogen. These crystals were tested at the ESRF 
synchrotron (see section 9.1.4.2).  
Crystals (see figure 9.3) also appeared after 3 weeks, in drops set up with 0.2 M MIB 
buffer pH 8.5, 22.5% PEG 10000 with a protein concentration of 3.5 mg/mL. These 
were flash-frozen in the mother liquor, thawed in 0.2 M MIB buffer pH 8.5, 20% PEG 
400, 22.5% PEG 10000 and flash-frozen again, and stored in liquid nitrogen. These 
crystals appeared close to the end of this project and the crystals could not be tested 
before the deadline. 
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Figure 9.3 Crystals of cgTPH1 grown in 0.2 M MIB buffer pH 8.5, 22.5% PEG 10000, cgTPH1 
concentration 3.5 mg/mL.  One square in the mesh is 90 × 90 μm. 
9.1.4.2 Data collection on crystals from optimisation trials 
Three crystals grown in 0.2 M imidazole malate pH 8.5, 18% PEG 10000 (see section 
9.1.4.1) were brought to ESRF, beamline ID-14.1. The diffraction quality of the three 
crystals was tested. The best crystal diffracted to approximately 6 Å. It was determined 
earlier that annealing in the cryo-protectant solution decreased the mosaicity of the 
crystals (section 9.1.2). Therefore each crystal was annealed 1-3 times. The crystals were 
tested again and the annealing significantly improved the diffraction quality. A data 
set was collected on the best crystal diffracting to approximately 4 Å. Examples of the 
diffraction patterns are shown in figure 9.4. 
     
Figure 9.4 Diffraction patterns of the cgTPH1 crystal described in section 9.1.4 and 9.1.5 
collected on ID 14-1 at ESRF.  (A) Rotation angle 0˚. (B) Rotation angle 90˚. The third ring from 
the centre is 4 Å.  
The data could be processed in space group P21 with the cell dimensions 185.8 Å, 49.9 
Å, 139.6 Å and β = 110.9˚. The structure was attempted solved by molecular 
replacement using either the structure of chTPH1 (PDB entry 1MLW) or the catalytic 
domain of PAH as a search model. For unknown reasons the crystal packing in all 
solutions were unrealistic with approximately half of the expected molecules missing. 
It was not possible to do any refinement of these structure solutions. Similar problems 
were observed for a data set collected the same day on a crystal of another protein. 
This crystal diffracted to 2 Å and had low mosaicity but the structure could not be 
refined. This indicates that some settings might have been wrong on the beam-line. 
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Many problems were encountered with automatic sample changer that day but this 
should not interfere with the data collection.  
9.1.5 Discussion of the crystallisation of cgTPH1 
It has proven difficult to optimise and even reproduce crystals of cgTPH1. The crystal 
formation usually takes from 40 to 120 days. This slow crystal growth is likely to 
involve the concomitant dissolution of precipitated cgTPH1 (see section 8.1).  
A new batch of purified cgTPH1 should be prepared, and purity should be checked by 
SDS-PAGE and Western blot analysis. The structural homogeneity should be verified 
by dynamic light scattering [299]. 
Many conditions were tested in the initial screenings and none except the 0.2 M 
imidazole malate pH 8.5, 22.5% PEG 10000 proved successful. In the further experi-
ments (section 9.1.4.1) crystals were formed in similar conditions (0.2 M imidazole 
malate pH 8.5, 18% PEG 10000 and in 0.2 M MIB, 22.5% PEG 10000). Therefore new 
grid screens should be set up testing the conditions around the initial conditions. More 
crystals combined with an optimised cryo-protectant solution will likely result in better 
data leading to a high resolution structure of cgTPH1.  
9.2 Crystallisation experiments of chTPH2 
Initial crystallisation experiments were done with chTPH2 purified and stored in a Tris 
buffer with pH 8.2. The pH 8.2 of this buffer proved not to be optimal for the stability 
and crystallisation of chTPH2 and will not be described here. chTPH2 purified in 
buffers with pH 7.2 proved more stable and suitable for crystallisation experiments. A 
few crystallisation experiments described in the following were done with chTPH2 
from a purification where the gel filtration was done in 20 mM MES/NaOH, 100 mM 
(NH4)2SO4, 5% glycerol, pH 6.5. Also one crystallisation test was done to test if there 
was any difference in the tendency to precipitate between purified chTPH2 from 
expression at 20˚C and 30˚C respectively. If nothing is noted the chTPH2 used was 
from 20˚C expression in 20 mM HEPES/NaOH, 100 mM (NH4)2SO4, 5% glycerol, pH 
7.2. 
9.2.1 Experimental 
9.2.1.1 Preparation of trays and the chTPH2 sample 
The first screens showed that chTPH2 had a very high tendency to precipitate even at 
very low protein concentrations. It was also observed that chTPH2 is sensitive to 
temperature. Crystallisation experiments were set up with chTPH2 (25 mg/mL), with 
20 mM HEPES/NaOH, 100 mM (NH4)2SO4, 5%(w/v) glycerol, pH 7.2, as the 
crystallisation solution. This crystallisation solution is the same as the gel filtration 
buffer (see section 4.1.2.2). If this experiment was set up at room temperature and kept 
at room temperature, precipitation was observed after one hour. When the same 
experiment was set up on ice and the tray moved to 4˚C immediately after, no 
precipitation was observed. Consequently, trays containing the crystallisation solutions 
were cooled at 4˚C prior to set up and the following set up were done on ice. Sitting 
drops were also used instead of hanging drops, since these are faster to set up and the 
drop is closer to the ice. 
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When thawed a sample of 100 μL chTPH2 was centrifuged at 15000 x g for 8 min at 4˚C. 
The supernatant was transferred to a sterile eppendorf tube. The chTPH2 concentration 
was determined using ε280 = 39310 M-1 cm-1. The chTPH2 was further diluted to the 
desired concentration using 20 mM HEPES, 100 mM (NH4)2SO4, pH 7.2. Buffer without 
glycerol was used for dilution to decrease the glycerol concentration in the protein 
sample.  
9.2.1.2 The chTPH2 crystallisation experiments 
The crystallisation experiments done with chTPH2 are listed in table 9.2. Composition 
of the Stura Footprint 1 and 2 screens can be seen in appendix 2.1. Composition of 
Crystal Screen from Hampton Research is seen in appendix 2.7. Sigma’s Crystallisation 
Basic Kit for Proteins contains the same solutions as Hampton’s Crystal Screen and is 
therefore not listed in the appendix. Composition of Sigma’s Crystallisation Extension 
Kit for Proteins is listed in appendix 2.8. The composition of the TPH screen which was 
designed for chTPH2 can be seen in appendix 2.9. 
Several additives have been tested in the crystallisation experiments. The function or 
role of some of the additives might need an explanation. BH4, tryptophan and 5-
hydroxytryptophan are substrates and product respectively. BH2 is a substrate 
analogue and inhibitor. DL-4-chlorophenylalanine is an inhibitor. Hexaethylene glycol 
monododecylether (C12E6), octaethylene glycol monododecylether (C12E8) and dodecyl 
β-D-maltoside are detergents. Different metal ions are added to possibly stabilise the 
structure or crystal packing. Glycine, 1,3-diaminopropane and 1,4-diaminobutane are 
added to function as linkers.  
BH4 and BH2 were dissolved in 10 mM HCl. Tryptophan, 5-hydroxytryptophan, DL-4-
chlorophenylalanine, C12E6, C12E8 and dodecyl β-D-maltoside were dissolved in 20 mM 
HEPES, 100 mM (NH4)2SO4, pH 7.2. NiCl2, CoCl2, [Ru(NH3)6]Cl3, [Co(NH3)6]Cl3 and 
CsCl were dissolved in water. Glycine, 1,3-diaminopropane and 1,4-diaminobutane 
were dissolved in water and pH adjusted to pH 7. In the experiments, the additives 
were added in one of three different ways. Some additives were added to the chTPH2 
solution prior to set up, other additives were added to the mixed drop while others 
again were added to the reservoir solution prior to set up. When an additive was 
added to the reservoir solution in the TPH screen a concentrated stock solution was 
used so that the dilution of the other components was minimised. The method used for 
adding the additive is also listed in table 9.2. 
9.2.2 Results of the crystallisation experiments of chTPH2 
No crystals of chTPH2 were observed in any of the drops. The following description 
and discussion will be on the properties observed from the crystallisation experiments 
and an explanation for the composition of the TPH screen. The first screens showed 
that chTPH2 had a very high tendency to precipitate even at very low protein 
concentrations. For example precipitation was observed in all drops of the Crystal 
Screen with a chTPH2 concentration of 1.2 mg/mL.  
For a protein to crystallise it has to be supersaturated. If the degree of supersaturation 
is too high precipitation occurs. If precipitation occurs in the majority of the drops in a 
screen one would usually decrease the protein concentration. In the case of chTPH2 it 
could be concentrated to 32 mg/mL without any sign of precipitation (at 4˚C) 
indicating that it can be stored in high concentrations. A protein concentration below 1 
mg/mL is usually not recommended for crystallisation. 
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Table 9.2 List of crystallisation experiments with chTPH2. Most of the screens were designed for 
the experiment, while Stura, Crystal Screen, Sigma Extension Kit are commercial screens with 
compositions found in appendix 2. +/- means with and without the following additive. “In 
chTPH2” means that the additive was added to the protein solution prior to drop set up. “In 
reservoir” means that a small volume of concentrated additive was added to the crystallisation 
solution.  
Screen chTPH2 conc. 
(mg/mL) 
Additive 
Stura Footprint 1+2 1.5 +/- BH4, 0.7 mM in chTPH2 
Crystal Screen 1.2 +/- Trp, 0.13 mM in chTPH2 
Crystal Screen 8, MES pH 6.5 none 
Sigma screen 4 BH2, 1 mM in chTPH2 
Sigma Extension Kit 4 BH2, 1 mM in chTPH2 
5-18% glycerol; 0.1 M (NH4)2SO4; 
HEPES pH 7.2 
3, 25 
4  
None 
+/- BH2, 8 μM in chTPH2 
0.2-1.2 M (NH4)2SO4; 
HEPES pH 7.0 
1.3, 3  
4   
None 
+/- BH2, 8 μM in chTPH2 
2-8% PEG 400, 4000, MPEG 5000; 
0.1 M (NH4)2SO4;  
MES pH 6.5, HEPES 7.5 
1.5  +/- BH4, 0.7 mM in chTPH2  
3-5% PEG 400, 1500, 4000, MPEG 
550, 5000; 0.15 M (NH4)2SO4; MES 
pH 6.0, 6.5, HEPES pH 7.0, 7.5 
1.2    +/- Trp, 0.13 mM in chTPH2 
3-7% PEG 400, 1500, 4000, 8000;  
0.15 M (NH4)2SO4; MES pH 6.5 
1.3   
3  
+/- BH4, 0.36 mM in chTPH2 
None 
3-7% PEG 400, 1500, 4000, 8000; 
0.15 M (NH4)2SO4; MES pH 6.5 
4, MES pH 6.5 +/- BH2, 8 μM in chTPH2  
10, 12, 14% MPEG 5000; 
HEPES, MIB pH 7.5 
1.2, 4  C12E8, 0.1 mM in chTPH2 
TPH screen 4, 20˚C/30˚C 
expression 
None 
TPH screen 4 None 
TPH screen 4 NiCl2, 9.5 mM in reservoir 
TPH screen 4 CoCl2, 9.5 mM in reservoir 
TPH screen 4 [Ru(NH3)6]Cl3, 0.3 μL added to the 
drop 
TPH screen 4 CsCl, 38 mM in reservoir 
TPH screen 4 Trp, 0.8 mM in reservoir 
TPH screen 4 [Co(NH3)6]Cl3, 0.3 μL 0.1 M added to 
the drop 
TPH screen 4 C12E6, 0.16 mM in chTPH2  
TPH screen 4 C12E8, 0.22 mM in chTPH2 
TPH screen 4 Dodecyl-m., 0.34 mM in chTPH2 
TPH screen 4 5-OH-Trp, 1.1 mM in chTPH2 
TPH screen 4 BH4, 1 mM in chTPH2 
TPH screen 4 BH2, 1 mM in chTPH2 
TPH screen 4 Glycine (pH 7), 0.1 M in reservoir 
TPH screen 4 Diaminopropane, diaminobutane 
both 50 mM, pH 7, in reservoir 
TPH screen 4 DL-4-Cl-Phe, 1 mM in chTPH2  
TPH screen 5 BH2, 1 mM, in chTPH2 
C12E8, 0.22 mM, in chTPH2 
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Therefore I decided to decrease the concentration of the precipitation agent instead of 
the protein in order to obtain a more appropriate degree of supersaturation. In most 
commercial screens the concentration of the precipitation agent was too high for 
chTPH2 and dilution of the screen to a desired precipitant concentration would lead to 
an undesired low buffer capacity. Consequently I made my own TPH screen 
containing 24 conditions. The TPH screen spans a pH from 5.5 - 8.5 using different 
buffers. Several different PEGs in low concentrations were used. Prior to the final 
screen composition different PEG concentrations were tested with a chTPH2 
concentration of 4 mg/mL and the concentration giving only light precipitation was 
selected. The selected salts are the ones that seemed to stabilise chTPH2 and which are 
also used in commercial screens. One condition with 2-methyl-2,4-pentanediol (MPD) 
and one with dioxane are included. Most conditions contain both a buffer and a salt. 
The composition of the TPH screen can be seen in appendix 2.9. The screen contains 24 
conditions which made it possible to test several different additives in combination 
with the screen. Many drops have been set up and unfortunately none of the 
experiments yielded crystals or any crystalline precipitate that could be optimised to 
crystals. This does not mean that the protein can not crystallise, just that the right 
conditions have not yet been found. In the following section I will discuss new 
strategies for the crystallisation of chTPH2.  
9.2.3 New strategies for the crystallisation of chTPH2 
High purity of the protein sample used for crystallisation experiments is very 
important and when a protein will not crystallise one of the first things to check is the 
protein purity. The chTPH2 used for crystallisation is very pure as judged from SDS-
PAGE (see figure 4.4, lane 10) but there are small amounts of impurities. It might be 
necessary to optimise the purification to yield even purer protein. As mentioned in 
section 4.2.2 this is possible by collecting fractions in a narrower interval in the anion 
exchange. If this is not enough incorporating a third purification step is necessary. This 
could for example be hydrophobic interaction chromatography [300] or affinity 
chromatography using DMPH4 adsorbent [155]. The latter method has been used 
successfully by several research groups [143,156,158]. Some of the impurities are also 
likely to be degradation products and including protease inhibitors in the lysis buffer 
might also improve homogeneity of the purified sample.  
Judging from the elution profile of chTPH2 from gel filtration (see figure 4.6) purified 
chTPH2 is structurally homogeneous, but it has not been tested if this changes upon 
freezing and thawing. Therefore the structural homogeneity of chTPH2 should be 
tested with dynamic light scattering [299].  
Optimising the storage buffer of the protein to optimal solubility has been reported to 
significantly increase the likelihood of obtaining crystals [301,302,303]. That chTPH2 is 
stable in 20 mM HEPES/NaOH, 100 mM (NH4)2SO4, 5% glycerol, pH 7.2 does not 
necessarily mean that it is the optimal condition of chTPH2. Maybe the purification 
should be done at a slightly different pH or the (NH4)2SO4 and glycerol concentration 
in the gel filtration should be increased to 200 mM and 10%, respectively.  
When the purity and homogeneity of the chTPH2 sample have been optimised or 
checked, new crystallisation experiments should be done with various screens for 
example JCSG+ and PACT screens, maybe with different degrees of dilution of the 
screens (even though it might change the buffer capacity). The drops should be set up 
in a cold room (4-6˚C) and stored at this temperature. Glycerol is known to stabilise 
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protein structures but it is commonly believed that glycerol hinders crystallisation or 
reduces crystalline order. This might be true in some cases but for some proteins 
addition of glycerol (10-30% v/v) has proven necessary in the crystallisation [304]. It 
might very well be that the structure of chTPH2 needs to be stabilised by for example 
glycerol in order to form crystals instead of precipitate. Addition of glycerol to the 
crystallisation solutions should therefore be tested. 
9.3 Crystallisation experiments of cthTPH2 
9.3.1 Experimental  
9.3.1.1 Preparation of the cthTPH2 sample  
A sample of 100 μL cthTPH2 was centrifuged at 15000 x g for 8 min at 4˚C when 
thawed. The concentration was determined using ε280 = 40800 M-1 cm-1. Dilution to the 
desired protein concentration was done with 20 mM Tris/HCl, 150 mM (NH4)2SO4, pH 
8.2.  
9.3.1.2 Crystallisation experiments done with cthTPH2 
Initial screening was done with Stura Footprint screen 1 and 2 (see appendix 2.1) set up 
as hanging drops with and without BH4. These screens showed that cthTPH2 also had 
a high tendency to precipitate. Extensive screening was done using the Index, JCSG+ 
and PACT screens (see appendix 2.2-2.4). These were set up with an Oryx 8 robot at the 
Department of Chemistry, University of Copenhagen. The drop size was 150 nL+150 
nL with three sitting drops per well. The cthTPH2 concentrations in the solution used 
for drop 1, 2 and 3 were 1.3, 10 and 20 mg/mL respectively. The drops were set up at 
room temperature and subsequently stored at 6˚C.  
When these experiments had been evaluated, follow-up experiments were done to test 
conditions where possible crystals or promising precipitates were observed. The test 
was set up as 2+2 μL sitting drops. For each original condition three experiments were 
done. One was identical to the original condition. In another experiment the 
precipitant concentration was lower than the original and in the third experiment it 
was higher than in the original condition. In addition to the above mentioned screens 
Hampton’s Crystal Screen, Sigma’s Crystallisation Extension Kit and the TPH screen 
were set up as 2+2 μL sitting drops as listed in table 9.3. All the trays except for the 
Index, JCSG+ and PACT were set up on ice and stored at 4˚C. 
9.3.2 Results and discussion of the crystallisation experiments 
with cthTPH2 
In general cthTPH2 behaved similar to chTPH2. It was temperature sensitive and had a 
high tendency to precipitate even at low cthTPH2 concentrations. 
Many conditions for crystallisation of cthTPH2 were tested and unfortunately no 
cthTPH2 crystals were obtained. The drops of the Index, JCSG+ and PACT screens are 
very small and it can be difficult to determine whether things that look like small 
crystals really are crystals. Possible crystals were observed in some conditions in the 
Index, JCSG+ and PACT screens. I tried to reproduce these. Unfortunately no crystals 
could be reproduced.  
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Table 9.3 List of crystallisation experiments with cthTPH2. The composition of Stura, Crystal, 
Sigma Extension, Index, PACT, JCSG+ and TPH screens is listed in appendix 2. +/- means with 
and without the following additive. The additives were added to the protein solution prior to 
drop set up. 
Screen cthTPH2 concentration Additives 
Stura screen 1 + 2 7 and 20 mg/mL None 
Stura screen 1 + 2 5 mg/mL +/- BH4, 1 mM 
Stura 1, (partial) 1, 2 mg/mL None 
Crystal screen  4 mg/mL +/- BH4, 1 mM  
Sigma extension 4 mg/mL None 
Index 1.3, 10 and 20 mg/mL None 
PACT 1.3, 10 and 20 mg/mL None 
JCSG+ 1.3, 10 and 20 mg/mL None 
Follow up on Index, PACT 
and JCSG+ screens 
2, 5, 10, 15 and 20 mg/mL None 
TPH screen 4 mg/mL None,  
C12E6, 0.16 mM 
C12E8, 0.22 mM  
Dodecyl maltoside, 0.34 mM 
9.3.3 Future experiments with cthTPH2 
The ideas suggested for chTPH2 are applicable to cthTPH2. Especially experiments to 
find the optimal storage buffer. It was seen during the purification that some enzyme 
activity was lost when stored at pH 8.2 but not in buffers with pH 7. Unfortunately this 
was observed at the end of the project and the crystallisation experiments above had 
been performed. Performing the purification at pH 7-7.2 would be the first things to try 
in improving the crystallisation of cthTPH2. 
9.4 Presentation of the overall structure of cgTPH1 
The structure of cgTPH1 determined from data described in section 9.1.2 could be 
refined to an Rfree = 32.7%. The model contains residues 109-125, 134-345, 357-392 and 
400-412. The overall structure is shown in figure 9.5 and structurally aligned with the 
catalytic domain of PAH (PDB entry 1PAH)[69] and chTPH1 with bound BH2 (PDB 
entry 1MLW)[64] in figure 9.6. Electron density is observed for the iron coordinated by 
His273, His279 and Glu318 (see figure 9.7A).  
The largest differences between the structures of cgTPH1 and chTPH1 are observed in 
the β-sheet of Phe319-Gly332 (see figure 9.6 and enlarged in 9.7B) and in the BH4/BH2 
binding region (see figure 9.6 and enlarged in 9.8). 
In cgTPH1 the BH4 binding loop (Arg231-Leu243) has moved into the space where BH4 
would be positioned. The loop would have to move back if BH4 was to bind as in the 
chTPH1 structure.  The aligned structure of PAH (shown in green in figure 9.6 and 9.8) 
does not contain BH2/BH4 and here the BH4 binding loop moves away from the BH4 
position. When comparing different structures of PAH with and without bound BH4 
(PDB entries 1J8T, 1J8U and 1PAH) one also observes differences in the position of this 
loop. 
The position of the BH4 binding loop also affects the structure of the neighbouring N-
terminal part of cgTPH1 having quite different structures in chTPH1 and PAH (see 
figure 9.6). This part is not visible in the cgTPH1 structure but can not be positioned as 
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in chTPH1 and PAH because it then would crash with the N-terminal of the 
neighbouring molecule. In PAH this N-terminal part is known to be flexible as 
illustrated in figure 2.8 where large movement of Tyr138 is observed upon binding of 
thienylalanine and BH4 (see section 2.5.1).  
 
Figure 9.5 Overall structure of cgTPH1 determined at 3 Å resolution. His273 and His279 and 
Glu318 are shown with sticks and the iron as a brick red sphere. The figure was made using 
Pymol [72]. 
 
Figure 9.6 Structural alignment of cgTPH1 shown in blue, chTPH1 (PDB entry 1MLW) shown in 
red and the catalytic domain of human PAH (PDB entry 1PAH) shown in green.  The structural 
alignment was done using Coot 0.1 [94]. The figure was made using Pymol [72]. 
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A   B  
Figure 9.7 (A) Electron density of the iron coordination by His273 and His278 and Glu318. (B) 
Alignment of the β-sheet of Phe319-Gly332 of cgTPH1 (blue) with PAH (1PAH, green) and 
chTPH1 (1MLW, red). The structural alignment was done using Coot 0.1 [94]. The figure was 
made using Pymol [72]. 
 
Figure 9.8 Structural alignment of cgTPH1 (blue) chTPH1 (1MLW, red) and PAH (1PAH, green) 
zoomed on the BH4 binding area with the BH4 binding loop and the neighbouring N-terminal 
part.  The iron (red sphere) and BH2 is part of the chTPH1 structure (red).  The loop in cgTPH1, 
which would bind BH4, has moved into the space where BH4 would be positioned. The PAH 
structure does not contain BH4/BH2 and the BH4 binding loop has moved further away. The 
position of the BH4 binding loop affects the structure of the protein chains equivalent to Lys118-
Lys138 in cgTPH1. In this region the structures of chTPH1 and catalytic domain of PAH (1PAH) 
are quite different while the structure of cgTPH1 is disordered from Tyr126-Asp133. The 
structural alignment was done using Coot 0.1 [94]. The figure was made using Pymol [72]. 
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Figure 9.9 Alignment of the C-terminals of cgTPH1 (blue) with catalytic domain of PAH (1PAH, 
green) and chTPH1 (1MLW, red). The last visible residue in the chTPH1 structure is Thr392. 
Residues Thr393-Gly399 were not visible in the cgTPH1 structure, but Val400 -Leu412 shows β-
sheet formation as seen in the structures of PAH and TH. The structural alignment was done 
using Coot 0.1 [94]. The figure was made using Pymol [72].  
The last residue visible in the chTPH1 structure is Thr392. In the cgTPH1 structure 
Thr393-Gly399 are not visible, but residues Val400-Leu412 are visible forming a β-
sheet, which aligns well with the C-terminal of the catalytic domain of PAH (1PAH) as 
illustrated in figure 9.9. In the tetrameric TH and PAH (see figure 2.6) this β-sheet is 
followed by the helix responsible for the coiled-coiled interactions. In chTPH2 the 
residues equivalent to the β-sheet were removed giving the xchTPH2 and ychTPH2 
variants discussed in section 3.5.3-3.5.5.  This β-sheet was removed in chTPH2 because 
I feared that it was very dynamic and interfered with the crystallisation. The results 
from cgTPH1 indicate that this is not the case. 
9.5 Conclusion 
Crystals of cgTPH1 were produced and data was collected on the best diffracting to 3 
Å. The data could be indexed in several space groups and the structure could be solved 
in space group P1 using molecular replacement. The structure was refined to an Rfree of 
32.7%. It was possible to build most of the protein chain and some overall structural 
differences are observed compared to the structures of the catalytic domains of hTPH1 
and human PAH.  
It was not possible to crystallise chTPH2 and cthTPH2, but suggestions for further 
experiments are given.  
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CHAPTER TEN 
10 Concluding remarks 
 
 
This project started shortly after the identification of the second gene for TPH. Since 
then, a few reports have since been published on the characterisation of TPH2 
[22,141,144]. It may be concluded that TPH2 is as difficult to express in E. coli as TPH1 
and also that the characterisation is hampered by the instability of TPH2. In this study 
two variants of TPH2 (chTPH2 and cthTPH2) and one variant of TPH1 (cgTPH1) have 
successfully been expressed and purified. All three enzymes were purified with a high 
yield and high specific activity (chapter 4). The yield of 60 mg purified chTPH2 per L 
culture allows the production of this enzyme in amounts necessary for mechanistic 
studies. 
The Km and Vmax parameters of cgTPH1, chTPH2 and cthTPH2 have been determined 
for all three substrates (chapter 6). This is the first report on Km,O2 determination on 
purified TPH. Substrate inhibition by tryptophan is observed for cgTPH1 at 
concentrations above 15 μM. Substrate inhibition was not observed for chTPH2 at 
concentrations up to 100 μM. Large differences are observed between Km values of 
cgTPH1 and chTPH2. These differences may to some extent be influenced by the 
tryptophan inhibition. The specific activity of chTPH2 is also 10 times higher than the 
one of cgTPH1. Additionally, it was observed that chTPH2 and cthTPH2 have a 
yellowish colour, while cgTPH1 appears to be colourless.  
The kinetic mechanism of chTPH2 was studied (chapter 7) using the method of 
Rudolph and Fromm (chapter 5). The data were furthermore analysed using global 
curve fitting. Rate equations for different kinetic mechanisms were fitted to the data. 
From the fitted models, it can be concluded that chTPH2 follows a sequential 
mechanism. The best model corresponds to the mechanism with ordered addition of 
tryptophan as the first substrate, followed by random addition of BH4 and O2. To my 
knowledge this is the first report of the kinetic mechanism of TPH. 
Screenings for crystallisation conditions have been done for cgTPH1, chTPH2 and 
cthTPH2. Crystallisation conditions were found for cgTPH1 and several crystals were 
grown. The best crystal diffracted to 3 Å and a data set was collected on this crystal. 
The structure was solved by molecular replacement and could be refined to an Rfree of 
32.8%. The structure has been presented and structural differences are observed when 
compared to the structure of chTPH1. The structure of chTPH1 by Wang et al. from 
2002 [64] is still the only published structure of TPH.  
Further research on TPH1 and TPH2 is necessary to get a full understanding of these 
enzymes. Knowledge on TPH1 and TPH2 will aid the understanding of the 
biochemical roles of serotonin. Further research on TPH1 and TPH2 may also lead to 
the development of drugs that can regulate the function of TPH1 and TPH2 which 
might be useful in the treatment of neuropsychiatric disorders. 
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APPENDIX ONE 
A.1 Standard curves of 5-hydroxytryptophan 
 
 
 
The standard curves for 5-hydroxytryptophan at different concentrations of BH4. 
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Slopes of the standard curves for 5-hydroxytryptophan at different concentrations of 
BH4 with a PMT of 650 V. 
BH4 (μM) Slope (f.i./ μM 5-hydroxytryptophan) R2 
20 122.65±0.72 0.9999 
30 105.81±0.23 0.9999 
40 88.36±1.84 0.9987 
60 71.625±0.567 0.9999 
100 44.635±0.607 0.9996 
150 27.552±0.453 0.9995 
200 18.015±0.046 0.9999 
300 7.7749±0.0835 0.9996 
400 4.5998±0.0356 0.9999 
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Slopes of the standard curves for 5-hydroxytryptophan at different concentrations of 
BH4 with a PMT of 585 V. 
BH4 (μM) Slope (f.i./ μM 5-hydroxytryptophan) R2 
20 41.296±0.900 0.9988 
30 35.950±0.703 0.9991 
40 32.939±0.457 0.9994 
60 25.374±0.278 0.9998 
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APPENDIX TWO 
A.2 Composition of crystallisation screens 
 
A.2.1 Stura Footprint 
The Stura Footprint screens are from Molecular Dimensions. 
A.2.1.1 Stura Footprint screen 1 
# Buffer Salt Other 
A1 0.2 M imidazole malate pH 5.5  15% PEG 600 
B1 0.2 M imidazole malate pH 5.5  24% PEG 600 
C1 0.2 M imidazole malate pH 5.5  33% PEG 600 
D1 0.2 M imidazole malate pH 5.5  42% PEG 600  
A2 0.2 M imidazole malate pH 7.0  10% PEG 4000 
B2 0.2 M imidazole malate pH 7.0  15% PEG 4000 
C2 0.2 M imidazole malate pH 7.0  20% PEG 4000 
D2 0.2 M imidazole malate pH 7.0  25% PEG 4000 
A3 0.2 M imidazole malate pH 8.5  7.5% PEG 10000 
B3 0.2 M imidazole malate pH 8.5  12.5% PEG 10000 
C3 0.2 M imidazole malate pH 8.5  17.5% PEG 10000 
D3 0.2 M imidazole malate pH 8.5  22.5% PEG 10000 
A4 0.15 M sodium citrate pH 5.5 0.75 M (NH4)2SO4  
B4 0.15 M sodium citrate pH 5.5 1.0 M (NH4)2SO4  
C4 0.15 M sodium citrate pH 5.5 1.5 M (NH4)2SO4  
D4 0.15 M sodium citrate pH 5.5 2.0 M (NH4)2SO4  
A5 0.8 M NaH2PO4 /K2HPO4 pH 7.0   
B5 1.32 M NaH2PO4 /K2HPO4 pH 7.0   
C5 1.6 M NaH2PO4 /K2HPO4 pH 7.0   
D5 2.0 M NaH2PO4 /K2HPO4 pH 7.0   
A6 10 mM sodium borate pH 8.5 0.75 M Citrate  
B6 10 mM sodium borate pH 8.5 1.0 M Citrate  
C6 10 mM sodium borate pH 8.5 1.2 M Citrate  
D6 10 mM sodium borate pH 8.5 1.5 M Citrate  
A.2.1.2 Stura Footprint screen 2 
# Buffer Salt Other 
A1 0.1 M HEPES pH 8.2  30% MPEG 550 
B1 0.1 M HEPES pH 8.2  40% MPEG 550 
C1 0.1 M HEPES pH 8.2  50% MPEG 550 
D1 0.1 M HEPES pH 8.2  60% MPEG 550 
A2 0.1 M HEPES pH 7.5  18% PEG 600 
B2 0.1 M HEPES pH 7.5  27% PEG 600 
C2 0.1 M HEPES pH 7.5  36% PEG 600 
Appendix 2 
 
 
128 
D2 0.1 M HEPES pH 7.5  45% PEG 600 
A3 0.1 M sodium cacodylate pH 6.5  18% PEG 2000 
B3 0.1 M sodium cacodylate pH 6.5  27% PEG 2000 
C3 0.1 M sodium cacodylate pH 6.5  36% PEG 2000 
D3 0.1 M sodium cacodylate pH 6.5  45% PEG 2000 
A4 0.2 M imidazole malate pH 6.0  8% PEG 4000 
B4 0.2 M imidazole malate pH 6.0  15% PEG 4000 
C4 0.2 M imidazole malate pH 6.0  20% PEG 4000 
D4 0.2 M imidazole malate pH 6.0  30% PEG 4000 
A5 0.1 M sodium acetate pH 5.5  12% MPEG 5000 
B5 0.1 M sodium acetate pH 5.5  18% MPEG 5000 
C5 0.1 M sodium acetate pH 5.5  24% MPEG 5000 
D5 0.1 M sodium acetate pH 5.5  36% MPEG 5000 
A6 0.1 M ammonium acetate pH 4.5  9% PEG 10000 
B6 0.1 M ammonium acetate pH 4.5  15% PEG 10000 
C6 0.1 M ammonium acetate pH 4.5  22.5% PEG 10000 
D6 0.1 M ammonium acetate pH 4.5  27% PEG 10000 
A.2.2 Index screen  
The Index screen is from Hampton Research 
# Buffer Salt  Other 
1 0.1 M Citric acid pH 3.5  2.0 M (NH4)2SO4  
2 0.1 M Na-acetate pH 4.5  2.0 M (NH4)2SO4  
3 0.1 M Bis-Tris pH 5.5  2.0 M (NH4)2SO4    
4 0.1 M Bis-Tris pH 6.5  2.0 M (NH4)2SO4   
5 0.1 M HEPES pH 7.5  2.0 M (NH4)2SO4   
6 0.1 M Tris pH 8.5  2.0 M (NH4)2SO4   
7 0.1 M Citric acid pH 3.5  3.0 M NaCl   
8 0.1 M Na-acetate pH 4.5  3.0 M NaCl  
9 0.1 M Bis-Tris pH 5.5  3.0 M NaCl  
10 0.1 M Bis-Tris pH 6.5  3.0 M NaCl  
11 0.1 M HEPES pH 7.5  3.0 M NaCl    
12 0.1 M Tris pH 8.5  3.0 M NaCl   
13 0.1 M Bis-Tris pH 5.5  0.3 M Mg-(formate)2   
14 0.1 M Bis-Tris pH 6.5  0.5 M Mg-(formate)2   
15 0.1 M HEPES pH 7.5  0.5 M Mg-(formate)2    
16 0.1 M Tris pH 8.5  0.3 M Mg-(formate)2  
17 
 
 None - pH 5.6  
 
1.26 M NaH2PO4,  
0.14 M K2HPO4   
18 
 
None - pH 6.9 
 
0.49 M NaH2PO4  
0.91 M K2HPO4  
19 
 
None - pH 8.2 
 
0.056 M NaH2PO4 
1.344 M K2HPO4   
20 0.1 M HEPES pH 7.5 1.4 M Na3-citrate   
21 None  1.8 M (NH4)3-citrate pH 7.0   
22 None  0.8 M succinic acid pH 7.0   
23 None  2.1 M DL-malic acid pH 7.0   
24 None  2.8 M Na-acetate pH 7.0   
25 None  3.5 M Na-formate pH 7.0   
26 None  1.1 M (NH4)2-tartrate pH 7.0   
27 None  2.4 M Na-malonate pH 7.0   
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28 None  35% v/v Tacsimate pH 7.0   
29 None  60% v/v Tacsimate pH 7.0  
30 0.1 M Bis-Tris pH 6.5  0.1 M NaCl 1.5 M (NH4)2SO4  
31 0.1 M Tris pH 8.5  0.8 M Na/K-tartrate  0.5% w/v M PEG 5000  
32 0.1 M Bis-Tris pH 5.5  1.0 M (NH4)2SO4 1% w/v PEG 3350  
33 
 
0.1 M HEPES pH 7.0  
 
1.1 M Na-malonate pH 7.0  
 
0.5% v/v Jeffamine 
ED-2001, reagent pH 7 
34 0.1 M HEPES pH 7.0  1.0 M succinic acid pH 7.0  1% w/v MPEG 2000  
35 0.1 M HEPES pH 7.0  1.0 M (NH4)2SO4  0.5% w/v PEG 8000  
36 0.1 M HEPES pH 7.0  15% v/v Tacsimate pH 7.0  2% w/v PEG 3350  
37 None   25% w/v PEG 1500  
38 
 
0.1 M HEPES pH 7.0  
  
30% v/v Jeffamine M-
600 reagent pH 7.0 
39 
 
M HEPES pH 7.0  
  
30% v/v Jeffamine 
ED-2001 reagent pH 7 
40 0.1 M Citric Acid pH 3.5   25% w/v PEG 3350  
41 0.1 M Na-acetate pH 4.5   25% w/v PEG 3350 
42 0.1 M Bis-Tris pH 5.5   25% w/v PEG 3350 
43 0.1 M Bis-Tris pH 6.5   25% w/v PEG 3350 
44 0.1 M HEPES pH 7.5   25% w/v PEG 3350 
45 0.1 M Tris pH 8.5   25% w/v PEG 3350  
46 0.1 M Bis-Tris pH 6.5   20% w/v MPEG 5000  
47 0.1 M Bis-Tris pH 6.5   28% w/v MPEG 2000  
48 0.1 M Bis-Tris pH 5.5  0.2 M CaCl2 45% v/v MPD  
49 0.1 M Bis-Tris pH 6.5  0.2 M CaCl2  45% v/v MPD  
50 0.1 M Bis-Tris pH 5.5  0.2 M (NH4)-acetate  45% v/v MPD  
51 0.1 M Bis-Tris pH 6.5  0.2 M (NH4)-acetate 45% v/v MPD 
52 0.1 M HEPES pH 7.5  0.2 M (NH4)-acetate 45% v/v MPD 
53 0.1 M Tris pH 8.5  0.2 M (NH4)-acetate  45% v/v MPD  
54 0.1 M Bis-Tris pH 6.5  0.05 M CaCl2  30% v/v MPEG 550  
55 0.1 M HEPES pH 7.5  0.05 M MgCl2  30% v/v MPEG 550  
56 
 
0.05 M HEPES pH 7.5  
 
0.2 M KCl  
 
35% v/v Penta-
erythritol propoxylate 
57 
 
0.05 M Bis-Tris pH 6.5  
 
0.05 M (NH4)2SO4  
 
30% v/v Penta-
erythritol ethoxylate  
58 0.1 M Bis-Tris pH 6.5  None  45% v/v PPG P 400  
59 
 
0.1 M HEPES pH 7.5  
 
0.02 M MgCl2  
  
22% w/v Polyacrylic 
Acid 5100 Na-salt  
60 
 
0.1 M Tris pH 8.5  
 
0.01 M CoCl2  
 
20% w/v Polyvinyl-
pyrrolidone K15  
61 0.1 M HEPES pH 7.5  0.2 M Proline  10% w/v PEG 3350  
62 0.1 M Tris pH 8.5  0.2 M TMAO 20% w/v MPEG 2000  
63 0.1 M HEPES pH 7.0  5% v/v Tacsimate pH 7.0 10% w/v MPEG 5000  
64 
 
 
 
0.1 M HEPES pH 7.5  
 
 
 
0.005 M CoCl2  
0.005 M NiCl2  
0.005 M CdCl2  
0.005 M MgCl2  
12% w/v PEG 3350  
 
 
 
65 0.1 M Bis-Tris pH 5.5  0.1 M (NH4)-acetate  17% w/v PEG 10000  
66 0.1 M Bis-Tris pH 5.5  0.2 M (NH4)2SO4  25% w/v PEG 3350  
67 0.1 M Bis-Tris pH 6.5  0.2 M (NH4)2SO4  25% w/v PEG 3350 
68 0.1 M HEPES pH 7.5  0.2 M (NH4)2SO4  25% w/v PEG 3350 
69 0.1 M Tris pH 8.5  0.2 M (NH4)2SO4  25% w/v PEG 3350 
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70 0.1 M Bis-Tris pH 5.5  0.2 M NaCl  25% w/v PEG 3350 
71 0.1 M Bis-Tris pH 6.5  0.2 M NaCl  25% w/v PEG 3350 
72 0.1 M HEPES pH 7.5  0.2 M NaCl  25% w/v PEG 3350 
73 0.1 M Tris pH 8.5  0.2 M NaCl  25% w/v PEG 3350 
74 0.1 M Bis-Tris pH 5.5  0.2 M Li2SO4 25% w/v PEG 3350 
75 0.1 M Bis-Tris pH 6.5  0.2 M Li2SO4  25% w/v PEG 3350 
76 0.1 M HEPES pH 7.5  0.2 M Li2SO4  25% w/v PEG 3350  
77 0.1 M Tris pH 8.5  0.2 M Li2SO4  25% w/v PEG 3350 
78 0.1 M Bis-Tris pH 5.5  0.2 M (NH4)-acetate  25% w/v PEG 3350 
79 0.1 M Bis-Tris pH 6.5  0.2 M (NH4)-acetate  25% w/v PEG 3350 
80 0.1 M HEPES pH 7.5  0.2 M (NH4)-acetate  25% w/v PEG 3350 
81 0.1 M Tris pH 8.5  0.2 M (NH4)-acetate  25% w/v PEG 3350 
82 0.1 M Bis-Tris pH 5.5  0.2 M MgCl2  25% w/v PEG 3350 
83 0.1 M Bis-Tris pH 6.5  0.2 M MgCl2  25% w/v PEG 3350 
84 0.1 M HEPES pH 7.5  0.2 M MgCl2  25% w/v PEG 3350 
85 0.1 M Tris HCl pH 8.5  0.2 M MgCl2  25% w/v PEG 3350 
86  0.2 M K/Na-tartrate  20% w/v PEG 3350 
87  0.2 M Na-malonate pH 7.0  20% w/v PEG 3350 
88  0.2 M (NH4)3-citrate pH 7.0  20% w/v PEG 3350 
89  0.1 M Succinic acid pH 7.0  15% w/v PEG 3350 
90  0.2 M Na-formate  20% w/v PEG 3350 
91  0.15 M DL-malic acid pH 7.0  20% w/v PEG 3350 
92  0.1 M Mg-(formate)2  15% w/v PEG 3350 
93  0.05 M Zn-(acetate)2  20% w/v PEG 3350 
94  0.2 M Na3-citrate 20% w/v PEG 3350 
95  0.1 M KSCN  30% w/v MPEG 2000  
96  0.15 M KBr  30% w/v MPEG 2000  
 
A.2.3 JCSG+ screen 
The JCSG+ screen is from Qiagen. 
 Buffer Salt  Other 
1 0.1 M Na-acetate pH 4.5  0.2 M Li2SO4 50% w/v PEG 400  
2 0.1 M Na3-citrate pH 5.5   20% w/v PEG 3000  
3 0.2 M (NH4)2-citrate pH 5.0  20% w/v PEG 3350  
4 0.1 M Na-acetate pH 4.6  0.02 M CaCl2  30% v/v MPD  
5 0.2 M Mg(formate)2 pH 5.9   20% w/v PEG 3350  
6 0.1 M Phosphate-citrate pH 4.2  0.2 M Li2SO4  20% w/v PEG 1000  
7 0.1 M CHES pH 9.5   20% w/v PEG 8000  
8 0.2 M NH4-formate pH 6.6  20% w/v PEG 3350  
9  0.2 M NH4Cl pH 6.3  20% w/v PEG 3350  
10 0.2 M K-formate pH 7.3   20% w/v PEG 3350  
11 0.1 M Tris pH 8.5  0.2 M NH4 H2PO4  50% v/v MPD  
12  0.2 M KNO3 pH 6.9  20% w/v PEG 3350  
13 0.1 M Na3-citrate pH 4  0.8 M (NH4)2SO4    
14  0.2 M NaSCN pH 6.9  20% w/v PEG 3350  
15 0.1 M BICINE pH 9   20% w/v PEG 6000  
16 
 
0.1 M HEPES pH 7.5  
  
10% w/v PEG 8000 
8% ethylene glycol  
17 
 
0.1 M Na-cacodylate pH 6.5  
  
40% v/v MPD  
5% w/v PEG 8000  
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18 
 
0.1 M Phosphate-citrate pH 4.2  
  
40% v/v ethanol  
5% w/v PEG 1000  
19 0.1 M Na-acetate pH 4.6   8% w/v PEG 4000  
20 0.1 M Tris pH 7  0.2 M MgCl2  10% w/v PEG 8000  
21 0.1 M Na3-citrate pH 5   20% w/v PEG 6000  
22 0.1 M Na cacodylate pH 6.5  0.2 M MgCl2  50% v/v PEG 200  
23  1.6 M Na3-citrate   
24  0.2 M K3-citrate pH 8.3  20% w/v PEG 3350  
25 0.1 M Phosphate-citrate pH 4.2  0.2 M NaCl  20% w/v PEG 8000  
26 0.1 M Na3-citrate pH 4  1 M LiCl  20% w/v PEG 6000  
27  0.2 M NH4NO3 pH 6.3  20% w/v PEG 3350  
28 0.1 M HEPES pH 7   10% w/v PEG 6000  
29 0.1 M HEPES pH 7.5  
0.8 M Na3PO4  
0.8 M K3PO4  
30 0.1 M Phosphate-citrate pH 4.2   40% v/v PEG 300  
31 0.1 M Na acetate pH 4.5  0.2 M Zn(acetate)2  10% w/v PEG 3000  
32 0.1 M Tris pH 8.5   20% v/v ethanol  
33 
 
0.1 M Na/K phosphate pH 6.2  
  
25% v/v 1,2 propan-
diol, 10% v/v glycerol  
34 
 
0.1 M BICINE pH 9  
  
10% w/v PEG 20000,  
2 %v/v dioxane  
35 0.1 M Na acetate pH 4.6  2 M (NH4)2SO4   
36 
   
10% w/v PEG 1000, 
10% w/v PEG 8000  
37 
   
24 %w/v PEG 1500, 
20% w/v glycerol  
38 0.1 M HEPES pH 7.5  0.2 M MgCl2 30% v/v PEG 400  
39 0.1 M Na/K phosphate pH 6.2  0.2 M NaCl  50% v/v PEG 200  
40 0.1 M Na-acetate pH 4.5  0.2 M Li2SO4 30% w/v PEG 8000  
41 0.1 M HEPES pH 7.5  0.2 M MgCl2  70% v/v MPD  
42 0.1 M Tris pH 8.5   20% w/v PEG 8000  
43 0.1 M Tris pH 8.5  0.2 M Li2SO4 40% v/v PEG 400  
44 0.1 M Tris pH 8   40% v/v MPD  
45 
  
0.17 M (NH4)2SO4 
 
25.5% w/v PEG 4000 
15% v/v glycerol  
46 0.1 M Na-cacodylate pH 6.5  0.2 M Ca(acetate)2  40% v/v PEG 300  
47 
 
0.07 M Na-acetate pH 4.6  
 
0.14 M CaCl2  
 
14% v/v isopropanol  
30% v/v glycerol  
48 
  
0.04 M K3-phosphate  
 
16% w/v PEG 8000, 
20% v/v glycerol  
49 0.1 M Na-cacodylate pH 6.5  1 M Na3-citrate   
50 
 
0.1 M Na-cacodylate pH 6.5  
 
0.2 M NaCl  
2 M (NH4)2SO4  
51 0.1 M HEPES pH 7.5  0.2 M NaCl 10% v/v isopropanol  
52 
 
0.1 M Tris pH 8.5  
 
0.2 M Li2SO4 
1.26 M (NH4)2SO4  
53 0.1 M CAPS pH 10.5   40% v/v MPD  
54 0.1 M Imidazole pH 8  0.2 M Zn(acetate)2  20% w/v PEG 3000  
55 0.1 M Na-cacodylate pH 6.5  0.2 M Zn(acetate)2  10% v/v isopropanol  
56 0.1 M Na-acetate pH 4.5  1 M (NH4)2HPO4  
57 0.1 M MES pH 6.5  1.6 M MgSO4   
58 0.1 M BICINE pH 9   10% w/v PEG 6000  
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59 
 
0.08 M Na cacodylate pH 6.5  
 
0.16 M Ca-(acetate)2  
 
14.4% w/v PEG 8000 
20% v/v glycerol  
60 0.1 M Imidazole pH 8   10% w/v PEG 8000  
61 
 
0.1 M MES pH 6.5  
 
0.05 M CsCl 
 
30% w/v Jeffamine 
M-600  
62 0.1 M Na3-citrate pH 5  3.15 M (NH4)2SO4  
63 0.1 M Tris pH 8   20% v/v MPD  
64 
 
0.1 M HEPES pH 6.5  
  
20% w/v Jeffamine 
M-600  
65 
 
0.1 M Tris pH 8.5  
 
0.2 M MgCl2 
 
50% v/v ethylene 
glycol  
66 0.1 M BICINE pH 9   10% v/v MPD  
67 0.8 M Succinic acid pH 7.0   
68 2.1 M DL-malic acid pH 7.0   
69 2.4 M Na-malonate pH 7.0   
70 
 
0.1 M HEPES pH 7.0 
 
1.1 M Na-malonate  
pH 7 
0.5 % v/v Jeffamine 
ED-2001 pH 7.0  
71 0.1 M HEPES pH 7.0 1 M Succinic acid pH 7 1% w/v MPEG 2000  
72 
0.1 M HEPES pH 7.0 
  
30% v/v Jeffamine M-
600 pH 7.0  
73 
 
0.1 M HEPES pH 7.0  
  
30% v/v Jeffamine 
ED-2001 pH 7.0  
74 
 
0.1 M HEPES pH 7.5  
 
0.02 M MgCl2 
 
22% w/v Polyacrylic 
acid 5100 sodium salt  
75 
0.1 M Tris pH 8.5  
 
0.1 M CoCl2  
 
20% w/v Polyvinyl-
pyrrolidone K15  
76 0.1 M Tris pH 8.5  0.2 M TMAO 20% w/v MPEG 2000 
77 
 
 
 
0.1 M HEPES pH 7.5  
 
 
 
0.005 M CoCl2 
0.005 M CdCl2 
0.005 M MgCl2 
0.005 M NiCl2  
12% w/v PEG 3350  
 
 
 
78 0.2 M Na-malonate pH 7.0  20% w/v PEG 3350  
79 0.1 M Succinic acid pH 7.0  15% w/v PEG 3350  
80 0.15 M DL-Malic acid pH 7.0  20% w/v PEG 3350  
81  0.1 M KSCN  30% w/v MPEG 2000  
82  0.15 M KBr 30% w/v MPEG 2000  
83 0.1 M bis-Tris pH 5.5  2 M (NH4)2SO4  
84 0.1 M bis-Tris pH 5.5  3 M NaCl  
85 0.1 M bis-Tris pH 5.5  0.3 M Mg-(formate)2   
86 0.1 M bis-Tris pH 5.5  1 M (NH4)2SO4 1% w/v PEG 3350  
87 0.1 M bis-Tris pH 5.5   25% w/v PEG 3350  
88 0.1 M bis-Tris pH 5.5  0.2 M CaCl2 45% v/v MPD  
89 0.1 M bis-Tris pH 5.5  0.2 M NH4 -acetate  45% v/v MPD  
90 0.1 M bis-Tris pH 5.5  0.1 M NH4 -acetate  17% w/v PEG 10000  
91 0.1 M bis-Tris pH 5.5  0.2 M (NH4)2SO4  25% w/v PEG 3350  
92 0.1 M bis-Tris pH 5.5  0.2 M NaCl 25% w/v PEG 3350  
93 0.1 M bis-Tris pH 5.5  0.2 M Li2SO4  25% w/v PEG 3350  
94 0.1 M bis-Tris pH 5.5  0.2 M NH4 -acetate  25% w/v PEG 3350  
95 0.1 M bis-Tris pH 5.5  0.2 M MgCl2 25% w/v PEG 3350  
96 0.1 M HEPES pH 7.5  0.2 M NH4 -acetate  45% v/v MPD  
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A.2.4 PACT screen 
The JCSG+ screen is from Qiagen. 
 Buffer Salt  Other 
1 0.1 M SPG buffer pH 4   25% w/v PEG 1500  
2 0.1 M SPG buffer pH 5   25% w/v PEG 1500  
3 0.1 M SPG buffer pH 6   25% w/v PEG 1500  
4 0.1 M SPG buffer pH 7   25% w/v PEG 1500  
5 0.1 M SPG buffer pH 8   25% w/v PEG 1500  
6 0.1 M SPG buffer pH 9   25% w/v PEG 1500  
7 0.1 M Na-acetate pH 5  0.2 M NaCl 20% w/v PEG 6000  
8 0.1 M Na-acetate pH 5  0.2 M NH4Cl 20% w/v PEG 6000  
9 0.1 M Na-acetate pH 5  0.2 M LiCl2   20% w/v PEG 6000  
10 0.1 M Na-acetate pH 5  0.2 M MgCl2  20% w/v PEG 6000  
11 0.1 M Na-acetate pH 5  0.2 M CaCl2  20% w/v PEG 6000  
12 0.1 M Na-acetate pH 5  0.01 M ZnCl  20% w/v PEG 6000  
13 0.1 M MIB buffer pH 4   25% w/v PEG 1500  
14 0.1 M MIB buffer pH 5   25% w/v PEG 1500  
15 0.1 M MIB buffer pH 6   25% w/v PEG 1500  
16 0.1 M MIB buffer pH 7   25% w/v PEG 1500  
17 0.1 M MIB buffer pH 8   25% w/v PEG 1500  
18 0.1 M MIB buffer pH 9   25% w/v PEG 1500  
19 0.1 M MES pH 6  0.2 M NaCl 20% w/v PEG 6000  
20 0.1 M MES pH 6  0.2 M NH4Cl 20% w/v PEG 6000  
21 0.1 M MES pH 6  0.2 M LiCl  20% w/v PEG 6000  
22 0.1 M MES pH 6  0.2 M MgCl  20% w/v PEG 6000  
23 0.1 M MES pH 6  0.2 M CaCl2  20% w/v PEG 6000  
24 0.1 M MES pH 6  0.01 M ZnCl2 20% w/v PEG 6000  
25 0.1 M PCB buffer pH 4   25% w/v PEG 1500  
26 0.1 M PCB buffer pH 5   25% w/v PEG 1500  
27 0.1 M PCB buffer pH 6   25% w/v PEG 1500  
28 0.1 M PCB buffer pH 7   25% w/v PEG 1500  
29 0.1 M PCB buffer pH 8   25% w/v PEG 1500  
30 0.1 M PCB buffer pH 9   25% w/v PEG 1500  
31 0.1 M HEPES pH 7  0.2 M NaCl  20% w/v PEG 6000  
32 0.1 M HEPES pH 7  0.2 M NH4Cl  20% w/v PEG 6000  
33 0.1 M HEPES pH 7  0.2 M LiCl  20% w/v PEG 6000  
34 0.1 M HEPES pH 7  0.2 M MgCl2  20% w/v PEG 6000  
35 0.1 M HEPES pH 7  0.2 M CaCl2 20% w/v PEG 6000  
36 0.1 M HEPES pH 7  0.01 M ZnCl2  20% w/v PEG 6000  
37 0.1 M MMT buffer pH 4   25% w/v PEG 1500  
38 0.1 M MMT buffer pH 5   25% w/v PEG 1500  
39 0.1 M MMT buffer pH 6   25% w/v PEG 1500  
40 0.1 M MMT buffer pH 7   25% w/v PEG 1500  
41 0.1 M MMT buffer pH 8   25% w/v PEG 1500  
42 0.1 M MMT buffer pH 9   25% w/v PEG 1500  
43 0.1 M Tris pH 8  0.2 M NaCl 20% w/v PEG 6000  
44 0.1 M Tris pH 8  0.2 M NH4Cl  20% w/v PEG 6000  
45 0.1 M Tris pH 8  0.2 M LiCl  20% w/v PEG 6000  
46 0.1 M Tris pH 8  0.2 M MgCl2  20% w/v PEG 6000  
47 0.1 M Tris pH 8  0.2 M CaCl2  20% w/v PEG 6000  
48 0.1 M Tris pH 8  0.01 M ZnCl2  20% w/v PEG 6000  
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49  0.2 M NaF  20% w/v PEG 3350  
50  0.2 M NaBr  20% w/v PEG 3350  
51  0.2 M NaI  20% w/v PEG 3350  
52  0.2 M KSCN  20% w/v PEG 3350  
53  0.2 M NaNO3 20% w/v PEG 3350  
54  0.2 M Na formate  20% w/v PEG 3350  
55  0.2 M Na acetate  20% w/v PEG 3350  
56  0.2 M Na2SO4 20% w/v PEG 3350  
57  0.2 M K/Na tartrate  20% w/v PEG 3350  
58  0.2 M Na/K phosphate  20% w/v PEG 3350  
59  0.2 M Na citrate  20% w/v PEG 3350  
60  0.2 M Na malonate  20% w/v PEG 3350  
61 0.1 M Bis Tris propane pH 6.5  0.2 M NaF  20% w/v PEG 3350  
62 0.1 M Bis Tris propane pH 6.5  0.2 M NaBr  20% w/v PEG 3350  
63 0.1 M Bis Tris propane pH 6.5  0.2 M NaI  20% w/v PEG 3350  
64 0.1 M Bis Tris propane pH 6.5  0.2 M KSCN  20% w/v PEG 3350  
65 0.1 M Bis Tris propane pH 6.5  0.2 M NaNO3  20% w/v PEG 3350  
66 0.1 M Bis Tris propane pH 6.5  0.2 M Na formate  20% w/v PEG 3350  
67 0.1 M Bis Tris propane pH 6.5  0.2 M Na acetate  20% w/v PEG 3350  
68 0.1 M Bis Tris propane pH 6.5  0.2 M Na2SO4 20% w/v PEG 3350  
69  0.1 M Bis Tris propane pH 6.5  0.2 M K/Na tartrate  20% w/v PEG 3350  
70 0.1 M Bis Tris propane pH 6.5  0.2 M Na/K phosphate  20% w/v PEG 3350  
71 0.1 M Bis Tris propane pH 6.5  0.2 M Na citrate  20% w/v PEG 3350  
72 0.1 M Bis Tris propane pH 6.5  0.2 M Na malonate  20% w/v PEG 3350  
73 0.1 M Bis Tris propane pH 7.5  0.2 M NaF  20% w/v PEG 3350  
74 0.1 M Bis Tris propane pH 7.5  0.2 M NaBr  20% w/v PEG 3350  
75 0.1 M Bis Tris propane pH 7.5  0.2 M NaI  20% w/v PEG 3350  
76 0.1 M Bis Tris propane pH 7.5  0.2 M KSCN  20% w/v PEG 3350  
77 0.1 M Bis Tris propane pH 7.5  0.2 M NaNO3  20% w/v PEG 3350  
78 0.1 M Bis Tris propane pH 7.5  0.2 M Na-formate  20% w/v PEG 3350  
79 0.1 M Bis Tris propane pH 7.5  0.2 M Na-acetate  20% w/v PEG 3350  
80 0.1 M Bis Tris propane pH 7.5  0.2 M Na2SO4  20% w/v PEG 3350  
81 0.1 M Bis Tris propane pH 7.5  0.2 M K/Na-tartarte  20% w/v PEG 3350  
82 0.1 M Bis Tris propane pH 7.5  0.2 M Na/K phosphate  20% w/v PEG 3350  
83 0.1 M Bis Tris propane pH 7.5  0.2 M Na citrate  20% w/v PEG 3350  
84 0.1 M Bis Tris propane pH 7.5  0.2 M Na-malonate  20% w/v PEG 3350  
85 0.1 M Bis Tris propane pH 8.5  0.2 M NaF  20% w/v PEG 3350  
86 0.1 M Bis Tris propane pH 8.5  0.2 M NaBr  20% w/v PEG 3350  
87 0.1 M Bis Tris propane pH 8.5  0.2 M NaI  20% w/v PEG 3350  
88 0.1 M Bis Tris propane pH 8.5  0.2 M KSCN  20% w/v PEG 3350  
89 0.1 M Bis Tris propane pH 8.5  0.2 M NaNO3  20% w/v PEG 3350  
90 0.1 M Bis Tris propane pH 8.5  0.2 M Na formate  20% w/v PEG 3350  
91 0.1 M Bis Tris propane pH 8.5  0.2 M Na acetate  20% w/v PEG 3350  
92 0.1 M Bis Tris propane pH 8.5  0.2 M Na2SO4  20% w/v PEG 3350  
93 0.1 M Bis Tris propane pH 8.5  0.2 M K/Na tartrate  20% w/v PEG 3350  
94 0.1 M Bis Tris propane pH 8.5  0.2 M Na/K phosphate  20% w/v PEG 3350  
95 0.1 M Bis Tris propane pH 8.5  0.2 M Na citrate  20% w/v PEG 3350  
96 0.1 M Bis Tris propane pH 8.5  0.2 M Na malonate  20% w/v PEG 3350  
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A.2.5 Additive screens 
These screens are from Hampton Research. 
A.2.5.1 Additive screen 1 
# Concentration Additive Class 
1 0.1 M barium chloride Divalent cation 
2 0.1 M cadmium chloride  Divalent cation 
3 0.2 M calcium chloride  Divalent cation 
4 0.1 M cobaltous chloride  Divalent cation 
5 0.1 M cupric chloride  Divalent cation 
6 0.1 M magnesium chloride  Divalent cation 
7 0.1 M manganese (II) chloride  Divalent cation 
8 0.1 M strontium chloride  Divalent cation 
9 0.1 M yttrium chloride  Trivalent cation 
10 0.1 M zinc chloride Divalent cation 
11 30 % v/v ethylene glycol Organic 
12 30 % v/v Glycerol anhydrous Organic 
13 30 % w/v 1,6 hexanediol Organic 
14 30 % v/v MPD Organic 
15 50 % v/v polyethylene glycol 400 Organic 
16 0.1 M trimethylamine HCl Chaotrope 
17 1.0 M guanidine HCl Chaotrope 
18 0.1 M urea Chaotrope 
19 15 % w/v 1,2,3-heptanetriol Amphiphile, micelle manipulator 
20 20 % w/v benzamidine HCl Amphiphile, micelle manipulator 
21 30 % v/v dioxane Organic, volatile 
22 30 % v/v ethanol Organic, volatile 
23 30 % v/v iso-propanol Organic, volatile 
24 30 % v/v methanol Organic, volatile 
A.2.5.2 Additive screen 2 
# Concentration Additive Class 
1 1.0 M NaI Ion 
2 0.1 M L-cysteine Reducing agent 
3 0.1 M EDTA sodium salt Chelator 
4 0.1 M NAD Co-factor 
5 0.1 M ATP disodium salt Co-factor 
6 30 % w/v D(+)-glucose monohydrate Carbohydrate 
7 30 % w/v D(+)-sucrose Carbohydrate 
8 30 % w/v xylitol Carbohydrate 
9 0.1 M spermidine Polyamine 
10 0.1 M spermine tetra-HCl Polyamine 
11 30 % v/v 6-aminocaproic acid Linker 
12 30 % v/v 1,5-diaminopentane di-HCl Linker 
13 30 % w/v 1,6-diaminohexane Linker 
14 30 % v/v 1,8-diaminooctane Linker 
15 1.0 M glycine Linker 
16 0.3 M glycyl-glycyl-glycine Organic 
17 0.1 M hexaminecobalt trichloride Polyamine 
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18 0.1 M taurine Linker 
19 0.1 M betaine monohydrate Linker 
20 5 % w/v polyvinylpyrrolidone K15 Polymer 
21 3.0 M non-detergent sulfo-betaine 195 Non-detergent solubilizing agent 
22 2 % v/v non-detergent sulfo-betaine 201 Non detergent solubilizing agent 
23 0.1 M phenol Chaotrope 
24 30 % v/v Dimethyl sulfoxide Dissociating agent, volatile 
A.2.5.3 Additive screen 3 
# Concentration Additive Class 
1 1.0 M ammonium sulfate Salt 
2 1.0 M cesium chloride Salt 
3 1.0 M potassium chloride Salt 
4 1.0 M lithium chloride Salt 
5 2.0 M sodium chloride Salt 
6 0.5 M sodium fluoride Salt 
7 2.0 M sodium thiocyanate Salt 
8 30 % w/v dextran sulfate sodium salt Polymer 
9 50 % v/v jeffamine M-600 Organic, non-volatile 
10 40 % v/v 2,5 Hexanediol Organic, non-volatile 
11 40 % v/v (+/-)-1,3 butanediol Organic, non-volatile 
12 40 % v/v polypropylene glycol P400 Organic, non-volatile 
13 40 % v/v 1,4 butanediol Organic, non-volatile 
14 40 % v/v tert-butanol Organic, volatile 
15 40 % v/v 1,3 propanediol Organic, volatile 
16 40 % v/v acetonitrile Organic, volatile 
17 40 % v/v gamma butyrolactone Organic, volatile 
18 40 % v/v propanol Organic, volatile 
19 5 % w/v ethyl acetate Organic, volatile 
20 40 % v/v acetone Organic, volatile 
21 0.3 % v/v dichloromethane Organic, volatile 
22 7 % v/v n-butanol Organic, volatile 
23 40 % v/v 2,2,2 trifluoroethanol Organic, volatile 
24 0.1 M 1,4-Dithio-DL-threitol (DTT) Reducing agent, volatile 
A.2.6 Detergent screens 
These screens are from Hampton Research. 
A.2.6.1 Detergent screen 1 
# Detergent Classification 
1 C12E9 Polyoxyethylene(9)dodecyl ether 
2 C12E8 Octaethyleneglycol Mono-n-dodecyl Ether 
3 n-Dodecyl-ß-D-maltoside n-Dodecyl-β-D-maltopyranoside  
4 
 
Sucrose monolaurate 
 
β-D-Fructopyranosyl-α-D-glucopyranoside 
monododecanoate  
5 CYMAL®-6 6-Cyclohexyl-1-hexyl-β-D-maltoside  
6 TRITON® X-100 Octylphenoxypolyethoxyethanol  
7 CTAB Hexadecyltrimethylammonium bromide  
8 Deoxy BigChap N,N-bis-(3-D-Gluconamidopropyl)deoxycholamide  
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9 n-Decyl-ß-D-maltoside n-Decyl-β-D-maltopyranoside  
10 LDAO Lauryldimethylamine-N-oxide  
11 CYMAL®-5 5-Cyclohexyl-1-pentyl-β-D-maltoside  
12 
 
ZWITTERGENT® 3-12 
 
n-Dodecyl-N,N-dimethyl-3-ammonio-1-
propanesulfonate  
13 Nonyl-ß-D-glucoside n-Nonyl-β-D-glucopyranoside  
14 1-s-Octyl-ß-D-thioglucoside n-Octyl-β-D-thioglucopyranoside  
15 DDAO N,N-Dimethyldecylamine-N-oxide  
16 HECAMEG Methyl-6-O-(N-heptylcarbamoyl)-α-D-glucopyranoside  
17 n-Octanoylsucrose Sucrose monocaproylate  
18 Heptyl-ß-D-thioglucoside Heptyl-β-D-thioglucoside  
19 n-Octyl-ß-D-glucoside n-Octyl-β-D-glucopyranoside  
20 CYMAL®-3 3-Cyclohexyl-1-propyl-β-D-maltoside  
21 C-HEGA-10 Cyclohexylbutanoyl-N-hydroxyethylglucamide  
22 ZWITTERGENT® 3-10 n-Decyl-N,N-dimethyl-3-ammonio-1-propanesulfonate  
23 MEGA-8 Octanoyl-N-methylglucamide  
24 n-Hexyl-ß-D-glucoside n-Hexyl-β-D-glucoside 
A.2.6.2 Detergent screen 2 
# Detergent Classification 
1 Pluronic® F-68 
Polyoxyethylene-polyoxypropylene Block 
Copolymer  
2 Anapoe® 35 Polyethylene glycol (23) monododecyl ether  
3 n-Dodecyl-ß-D-maltotrioside n-Dodecyl-β-D-maltopyranoside  
4 Anapoe® 58 Polyethylene glycol (20) monohexadecyl ether  
5 Anapoe® X-114 
α-[(1,1,3,3-Tetramethylbutyl)phenyl]-w-hydroxy-
poly(oxy-1,2-ethanediyl)  
6 Anapoe® X-305 
α-[4-(1,1,3,3-Tetramethylbutyl)phenyl]-w-hydroxy-
poly(oxy-1,2-ethanediyl)  
7 Anapoe® X-405 
α-[4-(1,1,3,3-Tetramethylbutyl)phenyl]-w-hydroxy-
poly(oxy-1,2-ethanediyl)  
8 Anapoe® 20 Polyoxyethylene(20)sorbitan monolaurate  
9 Anapoe® 80 Polyoxyethylene(80)sorbitan monolaurate  
10 Anapoe® C10E6 Polyoxyethylene(6)decyl ether  
11 Anapoe® C10E9 Polyoxyethylene(9)decyl ether  
12 Anapoe® C12E10 Polyoxyethylene(10)dodecyl ether  
13 Anapoe® C13E8 Polyoxyethylene(8)tridecyl ether  
14 IPTG Isopropyl-β-D-thiogalactopyranoside,  
15 n-Dodecyl-N,N-dimethylglycine None  
16 HEGA-10 Decanoyl-N-hydroxyethylglucamide  
17 C8E5 Pentaethylene glycol monooctyl ether,  
18 
 
CHAPS 
 
3-[(3-Cholamidopropyl)-dimethylammonio]-1-
propane sulfonate  
19 
 
CHAPSO 
 
3-[(3-Cholamidopropyl)dimethylammonio]-2-
hydroxy-1-propanesulfonate  
20 C-HEGA-11 Cyclohexylpentanoyl-N-hydroxyethylglucamide  
21 HEGA-9 Nonanoyl-N-hydroxyethylglucamide  
22 C-HEGA-9 Cyclohexylpropanoyl-N-hydroxyethylglucamide  
23 HEGA-8 Octanoyl-N-hydroxyethylglucamide  
24 CYPFOS-3 Cyclohexylethanoyl-N-hydroxyethylglucamide  
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A.2.6.3 Detergent screen 3 
# Detergent Classification 
1 BAM Benzyldimethyldodecylammonium bromide  
2 n-Hexadecyl-ß-D-maltoside n-Hexadecyl-β-D-maltopyranoside  
3 n-Tetradecyl-ß-D-maltoside n-Tetradecyl-β-D-maltopyranoside  
4 n-Tridecyl-ß-D-maltoside n-Tridecyl-β-D-maltopyranoside  
5 Thesit® Dodecylpoly(ethyleneglycolether)n  
6 Zwittergent® 3-14 
n-Tetradecyl-N,N-dimethyl-3-ammonio-1-
propanesulfonate  
7 n-Undecyl-ß-D-maltoside n-Undecyl-β-D-maltopyranoside  
8 n-Decyl-ß-D-thiomaltoside n-Decyl-β-D-thiomaltopyranoside  
9 FOS-Choline®-12 n-Dodecylphosphocholine  
10 n-Decanoylsucrose α-D-Glucopyranoside  
11 1-s-Nonyl-ß-D-thioglucoside 1-s-Nonyl-β-D-thioglucopyranoside  
12 n-Nonyl-ß-D-maltoside n-Nonyl-β-D-thiomaltopyranoside  
13 DDMAB N-Dodecyl-N,N-(dimethlammonio)butyrate  
14 n-Nonyl-ß-D-maltoside n-Nonyl-β-D-maltopyranoside  
15 Cymal®-4 4-Cyclohexyl-1-butyl-β-D-maltoside  
16 n-Octyl-ß-D-thiomaltoside n-Octyl-β-D-thiomaltopyranoside  
17 FOS-Choline®-10 n-Decylphosphocholine  
18 FOS-Choline®-9 n-Nonylphosphocholine  
19 MEGA-9 Nonanoyl-N-methylglucamide  
20 1-s-Heptyl-ß-D-thioglucoside n-Heptyl-β-D-thioglucopyranoside  
21 FOS-Choline®-8 n-Octylphosphocholine  
22 Cymal®-2 2-Cyclohexyl-1-ethyl-β-D-maltoside  
23 Zwittergent®-3-08 n-Octyl-N,N-dimethyl-3-ammonio-1-propanesulfonate  
24 Cymal®-1 Cyclohexyl-methyl-β-D-maltoside  
A.2.7 Crystal screen 
This screen is from Hampton Research. 
# Buffer Salt Other 
1 0.1 M Na-acetate pH 4.6 0.02  M CaCl2 30% v/v MPD 
2  0.4 M K/Na-tartrate  
3  0.4 M NH4H2PO4   
4 0.1 M Tris pH 8.5 2 M (NH4)2SO4  
5 0.1 M HEPES pH 7.5 0.2 M Na3-citrate 30% v/v MPD 
6 0.1 M Tris pH 8.5 0.2M MgCl2 30% w/v PEG 4000 
7 0.1 M Cacodylate pH 6.5 1.4 M Na-acetate  
8 0.1 M Cacodylate pH 6.5 0.2 M Na3-citrate 30%v/v isopropanol 
9 0.1 M Na3-citrate pH 5.6 0.2 M (NH4)-acetate 30% w/v PEG 4000 
10 0.1 M Na-acetate pH 4.6 0.2 M (NH4)-acetate 30 % w/v PEG 4000 
11 0.1 M Na3-citrate pH 5.6  1 M NH4H2PO4  
12 0.1 M HEPES pH 7.5 0.2 M MgCl2 30%v/v isopropanol 
13 0.1 M Tris pH 8.5 0.2 M  Na3-citrate  30%v/v PEG 400 
14 0.1 M HEPES pH 7.5 0.2 M CaCl2 28%v/v PEG 400 
15 0.1 M Cacodylate pH 6.5 0.2 M (NH4)2SO4  30%w/v PEG 8000 
16 0.1 M HEPES pH 7.5 1.5 M Li2SO4  
17 0.1 M Tris pH 8.5 0.2 M Li2SO4 30%w/v PEG 4000 
18 0.1 M Cacodylate pH 6.5 0.2 M Mg-(acetate)2 20%w/v PEG 8000 
19 0.1 M Tris pH 8.5 0.2M (NH4)-acetate 30%v/v isopropanol 
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20 0.1 M Na-acetate pH 4.6 0.2 M (NH4)2SO4 25%w/v PEG 4000 
21 0.1 M Cacodylate pH 6.5 0.2 M Mg-acetate 30%v/v MPD 
22 0.1 M Tris pH 8.5 0.2 M Na-acetate 30%w/v PEG 4000 
23 0.1 M HEPES pH 7.5 0.2 M MgCl2 30%v/v PEG 400 
24 0.1 M Na-acetate pH 4.6 0.2 M CaCl2 20%v/v isopropanol 
25 0.1 M Imidazole pH 6.5 1 M Na-acetate  
26 0.1 M Na3-citrate pH 5.6 0.2 M (NH4)-acetate 30%v/v MPD 
27 0.1 M HEPES pH 7.5 0.2 M Na3-citrate 20%v/v isopropanol 
28 0.1 M Cacodylate pH 6.5 0.2 M Na-acetate 30%w/v PEG 8000 
29 0.1 M HEPES pH 7.5 0.8 M K/Na-tartrate  
30  0.2 M (NH4)2SO4   30%w/v PEG 8000 
31  0.2 M (NH4)2SO4 30%w/v PEG 4000 
32  2 M (NH4)2SO4  
33  4 M Na-formate  
34 0.1 M Na-acetate pH 4.6 2 M Na-formate  
35 0.1 M HEPES pH 7.5 0.8 M KH2PO4  
36 0.1 M Tris pH 8.5  8%w/v PEG 8000 
37 0.1 M Na-acetate pH 4.6  8%w/v PEG 4000 
38 0.1 M HEPES pH 7.5 1.4 M Na3-citrate  
39 0.1 M HEPES pH 7.5 2 M (NH4)2SO4 2%v/v PEG 400 
40 0.1 M Na3-citrate pH 5.6 
 
 20%v/v isopropanol 
20%w/v PEG 4000 
41 0.1 M HEPES pH 7.5 
 
 10%v/v isopropanol 
20%w/v PEG  4000 
42  0.05 M KH2PO4 20%w/v PEG 8000 
43   30%w/v PEG 1500 
44  0.2 M Mg(formate)2  
45 0.1 M Cacodylate pH 6.5 0.2 M Zn-(acetate)2 18%w/v PEG 8000 
46 0.1 M Cacodylate pH 6.5 0.2 M Ca-(acetate)2 18%w/v PEG 8000 
47 0.1 M Na-acetate pH 4.6 2 M (NH4)2SO4  
48 0.1 M Tris pH 8.5 2 M (NH4)H2PO4  
49  1 M Li2SO4 2%w/v PEG 8000 
50  0.5 M Li2SO4 15%w/v PEG 8000 
A.2.8 Crystallization extension kit for protein 
This screen is from Sigma. 
# Buffer Salt  Other 
1  2 M NaCl 10% PEG 6000  
2  0.5 M NaCl, 0.01 M MgCl2 0.01 M CTAB  
3   25% Ethylene glycol  
4   35% Dioxane  
5  2 M (NH4)2SO4 5% 2-Propanol  
6 1 M Imidazole pH 7.0    
7 
  
 10% PEG 1000  
10% PEG 8000  
8  1.5 M NaCl 10% Ethanol  
9 0.1 M Na-acetate pH 4.6  2 M NaCl  
10 0.1 M Na-acetate pH 4.6  0.2 M NaCl  30% MPD  
11 0.1 M Na-acetate pH 4.6  0.01 M CoCl2 1 M 1,6-Hexanediol 
12 0.1 M Na-acetate pH 4.6  0.1 M CdCl2  30% PEG 400  
13 0.1 M Na-acetate pH 4.6  0.2 M (NH4)2SO4 30% PEG MME 2000  
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14 
 
0.1 M Na-citrate pH 5.6 
 
0.2 M K/Na-tartrate,  
2 M (NH4)2SO4 
 
15 0.1 M  Na-citrate pH 5.6 1 M Li2SO4,  0.5 M (NH4)2SO4  
16 0.1 M Na-citrate pH 5.6  0.5 M NaCl  2% Polyethylenimin  
17 0.1 M Na-citrate pH 5.6  35% tert.-Butanol  
18 0.1 M Na-citrate pH 5.6 0.01 M FeCl3 10% Jeffamine M-600  
19 0.1 M Na-citrate pH 5.6   2.5 M 1,6-Hexanediol  
20 0.1 M MES pH 6.5  1.6 M MgSO4,  
21 0.1 M MES pH 6.5  2 M NaCl, 0.1 M Ka H2PO4   0.1 M NaH2PO4 
22 0.1 M MES pH 6.5   12% PEG 20'000  
23 0.1 M MES pH 6.5 1.6 M (NH4)2SO4 10% Dioxane  
24 0.1 M MES pH 6.5  0.05 M CsCl  30% Jeffamine M-600  
25 0.1 M MES pH 6.5  0.01 M CoCl2, 1.8 M (NH4)2SO4  
26 0.1 M MES pH 6.5  0.2 M (NH4)2SO4 30% PEG MME 5000  
27 0.1 M MES pH 6.5  0.01 M ZnSO4  25% PEG MME 550 
28 1.6 M Na-citrate pH 6.5    
29 0.1 M HEPES pH 7.5  0.5 M (NH4)2SO4 30% MPD 
30 0.1 M HEPES pH 7.5   5% MPD, 10% PEG 6000 
31 0.1 M HEPES pH 7.5  20% Jeffamine M-600  
32 0.1 M HEPES pH 7.5 1.6 M (NH4)2SO4, 0.1 M NaCl  
33 0.1 M HEPES pH 7.5 2.0 M NH4 -formate   
34 0.1 M HEPES pH 7.5  1.0 M Na-acetate, 0.05 M CdSO4  
35 0.1 M HEPES pH 7.5  70% MPD 
36 0.1 M HEPES pH 7.5 4.3 M NaCl  
37 
 
0.1 M HEPES pH 7.5 
 
 8% Ethylene glycol  
10% PEG 8000  
38 0.1 M HEPES pH 7.5  20% PEG 10000  
39 0.1 M Tris-HCl pH 8.5 0.2 M MgCl2   3.4 M 1,6-Hexanediol 
40 0.1 M Tris-HCl pH 8.5  25% tert.-Butanol  
41 0.1 M Tris-HCl pH 8.5  1 M Li2SO4, 0.01 M NiCl2,  
42 0.1 M Tris-HCl pH 8.5 1.5 M (NH4)2SO4 12% Glycerol  
43 0.1 M Tris-HCl pH 8.5  0.2M (NH4)3PO4 50% MPD  
44 0.1 M Tris-HCl pH 8.5  20% Ethanol  
45 0.1 M Tris-HCl pH 8.5 0.01 M NiCl2  20% PEG MME 2000  
46 0.1 M Bicine pH 9.0  0.1M NaCl 20% PEG MME 550  
47 0.1 M Bicine pH 7.5 2 M MgCl2   
48 
 
0.1 M Bicine pH 9.0  
 
 2% Dioxane 
10% PEG 20000  
49 0.1 M Tris-HCl pH 8.5 0.1 M MgCl2  15% PEG 20000  
50   20 % PEG 20000   
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A.2.9 TPH screen 
This screen was designed for chTPH2. 
# Buffer Salt Other 
1 100 mM HEPES pH 7.0 0.2 M (NH4)2SO4 7% PEG 400 
2 100 mM HEPES pH 7.5 1.0 M  (NH4)2SO4  
3 100 mM HEPES pH 7.5 0.6 M Li2SO4  
4 100 mM HEPES pH 7.0 1.0 M (NH4)2SO4  
5 100 mM HEPES pH 7.0 1.2 M (NH4)2SO4  
6 100 mM HEPES pH 7.0 1.4 M (NH4)2SO4   
7 100 mM Bis Tris pH 5.5 0.2 M (NH4)2SO4 3% PEG 4000 
8 100 mM Citrate pH 5.6  3% PEG 10000 
9 100 mM MES pH 6.0 0.2 M K/Na tatrate 3% PEG 6000 
10 100 mM MES pH 6.0 0.2 M Na3-Citrate 6% PEG 1500 
11 100 mM MES pH 6.5 0.2 M Malonate pH 7.2 6% PEG 400 
12 100 mM MES pH 6.5 0.2 M (NH4)2SO4 10% MPD 
13 100 mM Bis Tris pH 6.5 0.2 M Na3-citrate 4% MPEG 550 
14 100 mM PIPES pH 7.0 0.2 M MgCl2 4% PEG 3350 
15 100 mM HEPES pH 7.0 0.2 M Malonate pH 7.2 3% PEG 10000 
16 100 mM HEPES pH 7.0 0.2 M (NH4)2SO4 5% Dioxane 
17 100 mM HEPES pH 7.5 1 M Malonate pH 7.2  
18 100 mM HEPES pH 7.5 0.2 M Na3-Citrate 3% MPEG 5000 
19 100 mM MIB pH 7.5 0.2 M (NH4)2SO4 4%PEG 3350 
20 100 mM Bis Tris Propane pH 8.0 0.2 M Malonate pH 7.2 3% PEG 10000 
21 100 mM Tris pH 8 0.2 M (NH4)2SO4 5% MPEG 550 
22 100 mM Imidazol malate pH 8 0.1 M (NH4)2SO4 3% MPEG 5000,  
10% glycerol 
23 100 mM Tris pH 8.5 0.2 M K/Na tatrate 5% PEG 1500 
24 100 mM Tris pH 8.5 0.2 M NaCl 3% PEG 8000 
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APPENDIX THREE 
A.3 cgTPH1 crystallisation experiments 
 
 
In all the experiments the trays were stored at 4˚C. The drops were 2+2 μL unless 
otherwise stated. Imidazole malate is abbreviated IM and malonate imidazole borate is 
abbreviated MIB. 
Experiment 1. Set up as both sitting and hanging drops.  
Drop cgTPH1 conc. (mg/mL) Buffer  Precipitant 
1+2 3.5, with and without 1 mM BH2 0.2 M IM pH 8.5 18 % PEG 10000 
3+4 3.5, with and without 1 mM BH2 0.2 M IM pH 8.5 19 % PEG 10000 
5+6 3.5, with and without 1 mM BH2 0.2 M IM pH 8.5 20 % PEG 10000 
7+8 3.5, with and without 1 mM BH2 0.2 M IM pH 8.5 21 % PEG 10000 
9+10 3.5, with and without 1 mM BH2 0.2 M IM pH 8.5 22 % PEG 10000 
11+12 3.5, with and without 1 mM BH2 0.2 M IM pH 8.5 23 % PEG 10000 
13+14 3.5, with and without 1 mM BH2 0.2 M IM pH 8.5 24 % PEG 10000 
15+16 3.5, with and without 1 mM BH2 0.2 M IM pH 8.5 25 % PEG 10000 
17+18 3.5, with and without 1 mM BH2 0.2 M IM pH 8.5 26 % PEG 10000 
19+20 3.5, with and without 1 mM BH2 0.2 M IM pH 8.5 27 % PEG 10000 
21+22 3.5, with and without 1 mM BH2 0.2 M IM pH 8.5 28 % PEG 10000 
23+24 3.5, with and without 1 mM BH2 0.2 M IM pH 8.5 29 % PEG 10000 
Experiment 2. Set up as both sitting and hanging drops. 
Drop cgTPH1 conc. (mg/mL) Buffer  Precipitant 
1-4 2.8 0.2 M IM pH 8.5 22.5 % PEG 10000 
5-8 3.5 0.2 M IM pH 8.5 22.5 % PEG 10000 
9-12 4.2 0.2 M IM pH 8.5 22.5 % PEG 10000 
13-16 5.2 0.2 M IM pH 8.5 22.5 % PEG 10000 
17-20 3.5, with 1 mM BH2 0.2 M IM pH 8.5 22.5 % PEG 10000 
21-24 3.5, with 1 mM BH4 0.2 M IM pH 8.5 22.5 % PEG 10000 
Experiment 3. Set up as hanging drops.  
Drop cgTPH1 conc. (mg/mL) Buffer  Precipitant 
1-4 2.8 0.2 M IM pH 8.5 22.5 % PEG 10000 
5-8 3.5 0.2 M IM pH 8.5 22.5 % PEG 10000 
9-12 4.2 0.2 M IM pH 8.5 22.5 % PEG 10000 
13-16 5.2 0.2 M IM pH 8.5 22.5 % PEG 10000 
17-20 6.5 0.2 M IM pH 8.5 22.5 % PEG 10000 
21-24 3.7, with 1 mM BH2 0.2 M IM pH 8.5 22.5 % PEG 10000 
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Experiment 4. Set up as sitting drops. 0.3 μL 0.1 M [Co(NH3)6]Cl3 were added to the 2+2 μL 
drop. 
Drop cgTPH1 conc. (mg/mL) Buffer  Precipitant 
1-4 2.8 0.2 M IM pH 8.5 22.5 % PEG 10000 
5-8 3.5 0.2 M IM pH 8.5 22.5 % PEG 10000 
9-12 4.2 0.2 M IM pH 8.5 22.5 % PEG 10000 
13-16 5.2 0.2 M IM pH 8.5 22.5 % PEG 10000 
17-20 6.1 0.2 M IM pH 8.5 22.5 % PEG 10000 
21-24 3.5, with [Co(NH3)6]3+ 0.2 M IM pH 8.5 22.5 % PEG 10000 
Experiment 5. Set up as sitting drops. Well 1-12 were 2+2 μL and 13-24 were 4+4 μL drops. 
Drop cgTPH1 conc. (mg/mL) Buffer  Precipitant 
1-4 2.8 0.2 M IM pH 8.5 22.5 % PEG 10000 
5-8 3.5 0.2 M IM pH 8.5 22.5 % PEG 10000 
9-12 4.2 0.2 M IM pH 8.5 22.5 % PEG 10000 
13-16 5.2 0.2 M IM pH 8.5 22.5 % PEG 10000 
17-20 6.1 0.2 M IM pH 8.5 22.5 % PEG 10000 
21-24 3.5, with [Co(NH3)6]3+ 0.2 M IM pH 8.5 22.5 % PEG 10000 
Experiment 6. Set up as sitting 4+4 μL drops. The cgTPH1 had been purified the same day as 
the set up.  
Drop cgTPH1 conc. (mg/mL) Buffer  Precipitant 
1-6 2.5 0.2 M IM pH 8.5 22.5 % PEG 10000 
Experiment 7. Set up as sitting drops. The cgTPH1 was from the new purification batch used in 
experiment 6.  
Drop cgTPH1 conc. (mg/mL) Buffer  Precipitant 
1-6 3.5 0.2 M IM pH 8.5 22.5% PEG 10000 
7 3.5 0.2 M IM pH 8.5 5% PEG 10000 
8 3.5 0.2 M IM pH 8.5 6% PEG 10000 
9 3.5 0.2 M IM pH 8.5 7% PEG 10000 
10 3.5 0.2 M IM pH 8.5 8% PEG 10000 
11 3.5 0.2 M IM pH 8.5 9% PEG 10000 
12 3.5 0.2 M IM pH 8.5 10% PEG 10000 
13 3.5 0.2 M IM pH 8.5 11% PEG 10000 
14 3.5 0.2 M IM pH 8.5 12% PEG 10000 
15 3.5 0.2 M IM pH 8.5 13% PEG 10000 
16 3.5 0.2 M IM pH 8.5 14% PEG 10000 
17 3.5 0.2 M IM pH 8.5 15% PEG 10000 
18 3.5 0.2 M IM pH 8.5 16% PEG 10000 
19 3.5 0.2 M IM pH 8.5 17% PEG 10000 
20 3.5 0.2 M IM pH 8.5 18% PEG 10000 
21 3.5 0.2 M IM pH 8.5 19% PEG 10000 
22 3.5 0.2 M IM pH 8.5 20% PEG 10000 
23 3.5 0.2 M IM pH 8.5 21% PEG 10000 
24 3.5 0.2 M IM pH 8.5 22% PEG 10000 
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Experiment 8. Additive screen 1 (1-20). Set up as sitting drops. The cgTPH1 concentration was 
3.5 mg/mL in the protein solution.  
Drop Additive 0.4 μL to a 2+2 μL drop Buffer  Precipitant 
1 barium chloride 0.2 M IM pH 8.5 22.5 % PEG 10000 
2 cadmium chloride dihydrate 0.2 M IM pH 8.5 22.5 % PEG 10000 
3 calcium chloride dihydrate 0.2 M IM pH 8.5 22.5 % PEG 10000 
4 cobaltous chloride dihydrate 0.2 M IM pH 8.5 22.5 % PEG 10000 
5 cupric chloride dihydrate 0.2 M IM pH 8.5 22.5 % PEG 10000 
6 magnesium chloride hexahydrate 0.2 M IM pH 8.5 22.5 % PEG 10000 
7 manganese (II) chloride 0.2 M IM pH 8.5 22.5 % PEG 10000 
8 strontium chloride hexahydrate 0.2 M IM pH 8.5 22.5 % PEG 10000 
9 yttrium chloride hexahydrate 0.2 M IM pH 8.5 22.5 % PEG 10000 
10 zinc chloride 0.2 M IM pH 8.5 22.5 % PEG 10000 
11 ethylene glycol 0.2 M IM pH 8.5 22.5 % PEG 10000 
12 Glycerol anhydrous 0.2 M IM pH 8.5 22.5 % PEG 10000 
13 1,6 hexanediol 0.2 M IM pH 8.5 22.5 % PEG 10000 
14 MPD 0.2 M IM pH 8.5 22.5 % PEG 10000 
15 polyethylene glycol 400 0.2 M IM pH 8.5 22.5 % PEG 10000 
16 trimethylamine HCl 0.2 M IM pH 8.5 22.5 % PEG 10000 
17 guanidine HCl 0.2 M IM pH 8.5 22.5 % PEG 10000 
18 urea 0.2 M IM pH 8.5 22.5 % PEG 10000 
19 1,2,3-heptanetriol 0.2 M IM pH 8.5 22.5 % PEG 10000 
20 benzamidine HCl 0.2 M IM pH 8.5 22.5 % PEG 10000 
Experiment 9. Additive screen 2 (1-23).  The cgTPH1 concentration was 3.5 mg/mL in the 
protein solution. 
Drop Additive 0.4 μL to a 2+2 μL drop Buffer  Precipitant 
1 NaI 0.2 M IM pH 8.5 22.5 % PEG 10000 
2 L-cysteine 0.2 M IM pH 8.5 22.5 % PEG 10000 
3 EDTA sodium salt 0.2 M IM pH 8.5 22.5 % PEG 10000 
4 NAD 0.2 M IM pH 8.5 22.5 % PEG 10000 
5 ATP disodium salt 0.2 M IM pH 8.5 22.5 % PEG 10000 
6 D(+)-glucose monohydrate 0.2 M IM pH 8.5 22.5 % PEG 10000 
7 D(+)-sucrose 0.2 M IM pH 8.5 22.5 % PEG 10000 
8 xylitol 0.2 M IM pH 8.5 22.5 % PEG 10000 
9 spermidine 0.2 M IM pH 8.5 22.5 % PEG 10000 
10 spermine tetra-HCl 0.2 M IM pH 8.5 22.5 % PEG 10000 
11 6-aminocaproic acid 0.2 M IM pH 8.5 22.5 % PEG 10000 
12 1,5-diaminopentane di-HCl 0.2 M IM pH 8.5 22.5 % PEG 10000 
13 1,6-diaminohexane 0.2 M IM pH 8.5 22.5 % PEG 10000 
14 1,8-diaminooctane 0.2 M IM pH 8.5 22.5 % PEG 10000 
15 glycine 0.2 M IM pH 8.5 22.5 % PEG 10000 
16 glycyl-glycyl-glycine 0.2 M IM pH 8.5 22.5 % PEG 10000 
17 hexaminecobalt trichloride 0.2 M IM pH 8.5 22.5 % PEG 10000 
18 taurine 0.2 M IM pH 8.5 22.5 % PEG 10000 
19 betaine monohydrate 0.2 M IM pH 8.5 22.5 % PEG 10000 
20 polyvinylpyrrolidone K15 0.2 M IM pH 8.5 22.5 % PEG 10000 
21 non-detergent sulfo-betaine 195 0.2 M IM pH 8.5 22.5 % PEG 10000 
22 non-detergent sulfo-betaine 201 0.2 M IM pH 8.5 22.5 % PEG 10000 
23 phenol 0.2 M IM pH 8.5 22.5 % PEG 10000 
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Experiment 10. Additive screen 3 (1-13) was tested with sitting drops. The cgTPH1 
concentration was 3.5 mg/mL in the protein solution. 
Drop Additive 0.4 μL to a 2+2 μL drop Buffer  Precipitant 
1 ammonium sulfate 0.2 M IM pH 8.5 22.5 % PEG 10000 
2 cesium chloride 0.2 M IM pH 8.5 22.5 % PEG 10000 
3 potassium chloride 0.2 M IM pH 8.5 22.5 % PEG 10000 
4 lithium chloride 0.2 M IM pH 8.5 22.5 % PEG 10000 
5 sodium chloride 0.2 M IM pH 8.5 22.5 % PEG 10000 
6 sodium fluoride 0.2 M IM pH 8.5 22.5 % PEG 10000 
7 sodium thiocyanate 0.2 M IM pH 8.5 22.5 % PEG 10000 
8 dextran sulfate sodium salt 0.2 M IM pH 8.5 22.5 % PEG 10000 
9 jeffamine M-600 0.2 M IM pH 8.5 22.5 % PEG 10000 
10 2,5 Hexanediol 0.2 M IM pH 8.5 22.5 % PEG 10000 
11 (+/-)-1,3 butanediol 0.2 M IM pH 8.5 22.5 % PEG 10000 
12 polypropylene glycol P400 0.2 M IM pH 8.5 22.5 % PEG 10000 
13 1,4 butanediol 0.2 M IM pH 8.5 22.5 % PEG 10000 
Experiment 11. Detergent screen 1 was tested with sitting drops. The cgTPH1 concentration was 
3.5 mg/mL in the solution used for all drops. 
Drop Additive 0.4 μL to a 2+2 μL drop Buffer  Precipitant 
1 C12E9 0.2 M IM pH 8.5 22.5 % PEG 10000 
2 C12E8 0.2 M IM pH 8.5 22.5 % PEG 10000 
3 n-Dodecyl-ß-D-maltoside 0.2 M IM pH 8.5 22.5 % PEG 10000 
4 Sucrose monolaurate 0.2 M IM pH 8.5 22.5 % PEG 10000 
5 CYMAL®-6 0.2 M IM pH 8.5 22.5 % PEG 10000 
6 TRITON® X-100 0.2 M IM pH 8.5 22.5 % PEG 10000 
7 CTAB 0.2 M IM pH 8.5 22.5 % PEG 10000 
8 Deoxy BigChap 0.2 M IM pH 8.5 22.5 % PEG 10000 
9 n-Decyl-ß-D-maltoside 0.2 M IM pH 8.5 22.5 % PEG 10000 
10 LDAO 0.2 M IM pH 8.5 22.5 % PEG 10000 
11 CYMAL®-5 0.2 M IM pH 8.5 22.5 % PEG 10000 
12 ZWITTERGENT® 3-12 0.2 M IM pH 8.5 22.5 % PEG 10000 
13 Nonyl-ß-D-glucoside 0.2 M IM pH 8.5 22.5 % PEG 10000 
14 1-s-Octyl-ß-D-thioglucoside 0.2 M IM pH 8.5 22.5 % PEG 10000 
15 DDAO 0.2 M IM pH 8.5 22.5 % PEG 10000 
16 HECAMEG 0.2 M IM pH 8.5 22.5 % PEG 10000 
17 n-Octanoylsucrose 0.2 M IM pH 8.5 22.5 % PEG 10000 
18 Heptyl-ß-D-thioglucoside 0.2 M IM pH 8.5 22.5 % PEG 10000 
19 n-Octyl-ß-D-glucoside 0.2 M IM pH 8.5 22.5 % PEG 10000 
20 CYMAL®-3 0.2 M IM pH 8.5 22.5 % PEG 10000 
21 C-HEGA-10 0.2 M IM pH 8.5 22.5 % PEG 10000 
22 ZWITTERGENT® 3-10 0.2 M IM pH 8.5 22.5 % PEG 10000 
23 MEGA-8 0.2 M IM pH 8.5 22.5 % PEG 10000 
24 n-Hexyl-ß-D-glucoside 0.2 M IM pH 8.5 22.5 % PEG 10000 
Experiment 12. Detergent screen 2. Sitting drops. The cgTPH1 concentration was 3.5 mg/mL in 
the solution used for all drops. 
Drop Additive 0.4 μL to a 2+2 μL drop Buffer  Precipitant 
1 Pluronic® F-68 0.2 M IM pH 8.5 22.5 % PEG 10000 
2 Anapoe® 35 0.2 M IM pH 8.5 22.5 % PEG 10000 
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3 n-Dodecyl-ß-D-maltotrioside 0.2 M IM pH 8.5 22.5 % PEG 10000 
4 Anapoe® 58 0.2 M IM pH 8.5 22.5 % PEG 10000 
5 Anapoe® X-114 0.2 M IM pH 8.5 22.5 % PEG 10000 
6 Anapoe® X-305 0.2 M IM pH 8.5 22.5 % PEG 10000 
7 Anapoe® X-405 0.2 M IM pH 8.5 22.5 % PEG 10000 
8 Anapoe® 20 0.2 M IM pH 8.5 22.5 % PEG 10000 
9 Anapoe® 80 0.2 M IM pH 8.5 22.5 % PEG 10000 
10 Anapoe® C10E6 0.2 M IM pH 8.5 22.5 % PEG 10000 
11 Anapoe® C10E9 0.2 M IM pH 8.5 22.5 % PEG 10000 
12 Anapoe® C12E10 0.2 M IM pH 8.5 22.5 % PEG 10000 
13 Anapoe® C13E8 0.2 M IM pH 8.5 22.5 % PEG 10000 
14 IPTG 0.2 M IM pH 8.5 22.5 % PEG 10000 
15 n-Dodecyl-N,N-dimethylglycine 0.2 M IM pH 8.5 22.5 % PEG 10000 
16 HEGA-10 0.2 M IM pH 8.5 22.5 % PEG 10000 
17 C8E5 0.2 M IM pH 8.5 22.5 % PEG 10000 
18 CHAPS 0.2 M IM pH 8.5 22.5 % PEG 10000 
19 CHAPSO 0.2 M IM pH 8.5 22.5 % PEG 10000 
20 C-HEGA-11 0.2 M IM pH 8.5 22.5 % PEG 10000 
21 HEGA-9 0.2 M IM pH 8.5 22.5 % PEG 10000 
22 C-HEGA-9 0.2 M IM pH 8.5 22.5 % PEG 10000 
23 HEGA-8 0.2 M IM pH 8.5 22.5 % PEG 10000 
24 CYPFOS-3 0.2 M IM pH 8.5 22.5 % PEG 10000 
Experiment 13. Detergent screen 3. Sitting drops. The cgTPH1 concentration was 3.5 mg/mL in 
the solution used for all drops. 
Drop Additive 0.4 μL to a 2+2 μL drop Buffer  Precipitant 
1 BAM 0.2 M IM pH 8.5 22.5 % PEG 10000 
2 n-Hexadecyl-ß-D-maltoside 0.2 M IM pH 8.5 22.5 % PEG 10000 
3 n-Tetradecyl-ß-D-maltoside 0.2 M IM pH 8.5 22.5 % PEG 10000 
4 n-Tridecyl-ß-D-maltoside 0.2 M IM pH 8.5 22.5 % PEG 10000 
5 Thesit® 0.2 M IM pH 8.5 22.5 % PEG 10000 
6 Zwittergent® 3-14 0.2 M IM pH 8.5 22.5 % PEG 10000 
7 n-Undecyl-ß-D-maltoside 0.2 M IM pH 8.5 22.5 % PEG 10000 
8 n-Decyl-ß-D-thiomaltoside 0.2 M IM pH 8.5 22.5 % PEG 10000 
9 FOS-Choline®-12 0.2 M IM pH 8.5 22.5 % PEG 10000 
10 n-Decanoylsucrose 0.2 M IM pH 8.5 22.5 % PEG 10000 
11 1-s-Nonyl-ß-D-thioglucoside 0.2 M IM pH 8.5 22.5 % PEG 10000 
12 n-Nonyl-ß-D-maltoside 0.2 M IM pH 8.5 22.5 % PEG 10000 
13 DDMAB 0.2 M IM pH 8.5 22.5 % PEG 10000 
14 n-Nonyl-ß-D-maltoside 0.2 M IM pH 8.5 22.5 % PEG 10000 
15 Cymal®-4 0.2 M IM pH 8.5 22.5 % PEG 10000 
16 n-Octyl-ß-D-thiomaltoside 0.2 M IM pH 8.5 22.5 % PEG 10000 
17 FOS-Choline®-10 0.2 M IM pH 8.5 22.5 % PEG 10000 
18 FOS-Choline®-9 0.2 M IM pH 8.5 22.5 % PEG 10000 
19 MEGA-9 0.2 M IM pH 8.5 22.5 % PEG 10000 
20 1-s-Heptyl-ß-D-thioglucoside 0.2 M IM pH 8.5 22.5 % PEG 10000 
21 FOS-Choline®-8 0.2 M IM pH 8.5 22.5 % PEG 10000 
22 Cymal®-2 0.2 M IM pH 8.5 22.5 % PEG 10000 
23 Zwittergent®-3-08 0.2 M IM pH 8.5 22.5 % PEG 10000 
24 Cymal®-1 0.2 M IM pH 8.5 22.5 % PEG 10000 
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Experiment 14. 0.4 μL 0.1 M cysteine or 0.1 M DTT were added to 2 + 2 μL sitting drops. 
cgTPH1 from a new purification batch was used (new) and older batch when noted (old).   
Drop cgTPH1 conc. (mg/mL) Buffer  Precipitant 
1-2 3.5 (new), cysteine 0.2 M IM pH 8.5 22.5 % PEG 10000 
3 3.5 (new), DTT 0.2 M IM pH 8.5 22.5 % PEG 10000 
4 3.5 (new) 0.2 M IM pH 8.5 22.5 % PEG 10000 
5-6 3.5 (new), cysteine 0.2 M IM pH 8.5 22.5 % PEG 10000 
7 3.5 (new), DTT 0.2 M IM pH 8.5 22.5 % PEG 10000 
8 3.5 (new) 0.2 M IM pH 8.5 22.5 % PEG 10000 
9-10 3.5 (old), cysteine 0.2 M IM pH 8.5 22.5 % PEG 10000 
11 3.5 (old), DTT 0.2 M IM pH 8.5 22.5 % PEG 10000 
12 3.5 (old) 0.2 M IM pH 8.5 22.5 % PEG 10000 
13-14 3.5 (old), cysteine 0.2 M IM pH 8.5 22.5 % PEG 10000 
15 3.5 (old), DTT 0.2 M IM pH 8.5 22.5 % PEG 10000 
16 3.5 (old) 0.2 M IM pH 8.5 22.5 % PEG 10000 
Experiment 15. Sitting drops. cgTPH1 from a new purification batch was used (new) and older 
batch when noted (old).   
Drop cgTPH1 conc. (mg/mL) Buffer  Precipitant 
1 3.5 (old) 0.2 M IM pH 8.5 12 % PEG 10000 
2 0.9 (old) 0.2 M IM pH 8.5 12 % PEG 10000 
3 3.5 (new) 0.2 M IM pH 8.5 12 % PEG 10000 
4 0.9 (new) 0.2 M IM pH 8.5 12 % PEG 10000 
5 3.5 (old) 0.2 M IM pH 8.5 14% PEG 10000 
6 0.9 (old) 0.2 M IM pH 8.5 14% PEG 10000 
7 3.5 (new) 0.2 M IM pH 8.5 14% PEG 10000 
8 0.9 (new) 0.2 M IM pH 8.5 14% PEG 10000 
9 3.5 (old) 0.2 M IM pH 8.5 16% PEG 10000 
10 0.9 (old) 0.2 M IM pH 8.5 16% PEG 10000 
11 3.5 (new) 0.2 M IM pH 8.5 16% PEG 10000 
12 0.9 (new) 0.2 M IM pH 8.5 16% PEG 10000 
13 3.5 (old) 0.2 M IM pH 8.5 18% PEG 10000 
14 0.9 (old) 0.2 M IM pH 8.5 18% PEG 10000 
15 3.5 (new) 0.2 M IM pH 8.5 18% PEG 10000 
16 0.9 (new) 0.2 M IM pH 8.5 18% PEG 10000 
17 3.5 (old) 0.2 M IM pH 8.5 20% PEG 10000 
18 0.9 (old) 0.2 M IM pH 8.5 20% PEG 10000 
19 3.5 (new) 0.2 M IM pH 8.5 20% PEG 10000 
20 0.9 (new) 0.2 M IM pH 8.5 20% PEG 10000 
21 3.5 (old) 0.2 M IM pH 8.5 22% PEG 10000 
22 0.9 (old) 0.2 M IM pH 8.5 22% PEG 10000 
23 3.5 (new) 0.2 M IM pH 8.5 22% PEG 10000 
24 0.9 (new) 0.2 M IM pH 8.5 22% PEG 10000 
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Experiment 16. Sitting drops. cgTPH1 from a new purification batch was used (new) and older 
batch when noted (old).   
Drop cgTPH1 conc. (mg/mL) Buffer  Precipitant 
1 3.5 (old) 0.2 M MIB pH 8.7 22.5 % PEG 10000 
2 0.9 (old) 0.2 M MIB pH 8.7 22.5 % PEG 10000 
3 3.5 (new) 0.2 M MIB pH 8.7 22.5 % PEG 10000 
4 0.9 (new) 0.2 M MIB pH 8.7 22.5 % PEG 10000 
5 3.5 (old) 0.2 M MIB pH 8.5 22.5 % PEG 10000 
6 0.9 (old) 0.2 M MIB pH 8.5 22.5 % PEG 10000 
7 3.5 (new) 0.2 M MIB pH 8.5 22.5 % PEG 10000 
8 0.9 (new) 0.2 M MIB pH 8.5 22.5 % PEG 10000 
9 3.5 (old) 0.2 M MIB pH 8.25 22.5 % PEG 10000 
10 0.9 (old) 0.2 M MIB pH 8.25 22.5 % PEG 10000 
11 3.5 (new) 0.2 M MIB pH 8.25 22.5 % PEG 10000 
12 0.9 (new) 0.2 M MIB pH 8.25 22.5 % PEG 10000 
13 3.5 (old) 0.2 M MIB pH 8.0 22.5 % PEG 10000 
14 0.9 (old) 0.2 M MIB pH 8.0 22.5 % PEG 10000 
15 3.5 (new) 0.2 M MIB pH 8.0 22.5 % PEG 10000 
16 0.9 (new) 0.2 M MIB pH 8.0 22.5 % PEG 10000 
17 3.5 (old) 0.2 M MIB pH 7.5 22.5 % PEG 10000 
18 0.9 (old) 0.2 M MIB pH 7.5 22.5 % PEG 10000 
19 3.5 (new) 0.2 M MIB pH 7.5 22.5 % PEG 10000 
20 0.9 (new) 0.2 M MIB pH 7.5 22.5 % PEG 10000 
21 3.5 (old) 0.2 M MIB pH 7.0 22.5 % PEG 10000 
22 0.9 (old) 0.2 M MIB pH 7.0 22.5 % PEG 10000 
23 3.5 (new) 0.2 M MIB pH 7.0 22.5 % PEG 10000 
24 0.9 (new) 0.2 M MIB pH 7.0 22.5 % PEG 10000 
Experiment  17. Sitting drops. cgTPH1 from a new purification batch was used (new) and older 
batch when noted (old).   
Drop cgTPH1 conc. 
(mg/mL) 
Buffer  additive Precipitant 
1+2 3.5 (old) 0.2 M IM pH 8.5 4 mM DTT 12 % PEG 10000 
3+4 3.5 (new) 0.2 M IM pH 8.5 4 mM DTT 12 % PEG 10000 
5+6 3.5 (old) 0.2 M IM pH 8.5 4 mM DTT 16% PEG 10000 
7+8 3.5 (new) 0.2 M IM pH 8.5 4 mM DTT 16% PEG 10000 
9+10 3.5 (old) 0.2 M IM pH 8.5 4 mM DTT 18% PEG 10000 
11+12 3.5 (new) 0.2 M IM pH 8.5 4 mM DTT 18% PEG 10000 
13+14 3.5 (old) 0.2 M IM pH 8.5 4 mM DTT 20% PEG 10000 
15+16 3.5 (new) 0.2 M IM pH 8.5 4 mM DTT 20% PEG 10000 
17+18 3.5 (old) 0.2 M IM pH 8.5 4 mM DTT 22% PEG 10000 
19+20 3.5 (new) 0.2 M IM pH 8.5 4 mM DTT 22% PEG 10000 
21+22 3.5 (old) 0.2 M IM pH 8.5 4 mM DTT 24% PEG 10000 
23+24 3.5 (new) 0.2 M IM pH 8.5 4 mM DTT 24% PEG 10000 
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Experiment 18. Sitting drops. cgTPH1 from a new purification batch was used (new) and older 
batch when noted (old).   
Drop cgTPH1 conc. (mg/mL) Buffer  β-mercaptoethanol Precipitant 
1+2 3.5 (old) 0.2 M IM pH 8.5 1%(v/v) 12 % PEG 10000 
3+4 3.5 (new) 0.2 M IM pH 8.5 1%(v/v) 12 % PEG 10000 
5+6 3.5 (old) 0.2 M IM pH 8.5 1%(v/v) 16% PEG 10000 
7+8 3.5 (new) 0.2 M IM pH 8.5 1%(v/v) 16% PEG 10000 
9+10 3.5 (old) 0.2 M IM pH 8.5 1%(v/v) 18% PEG 10000 
11+12 3.5 (new) 0.2 M IM pH 8.5 1%(v/v) 18% PEG 10000 
13+14 3.5 (old) 0.2 M IM pH 8.5 1%(v/v) 20% PEG 10000 
15+16 3.5 (new) 0.2 M IM pH 8.5 1%(v/v) 20% PEG 10000 
17+18 3.5 (old) 0.2 M IM pH 8.5 1%(v/v) 22% PEG 10000 
19+20 3.5 (new) 0.2 M IM pH 8.5 1%(v/v) 22% PEG 10000 
21+22 3.5 (old) 0.2 M IM pH 8.5 1%(v/v) 24% PEG 10000 
23+24 3.5 (new) 0.2 M IM pH 8.5 1%(v/v) 24% PEG 10000 
Experiment 19. Testing EDTA. Sitting 2+2 μL drops. cgTPH1 from a new purification batch was 
used (new) and older batch when noted (old). 
Drop cgTPH1 conc. (mg/mL) Buffer  EDTA Precipitant 
1+2 3.5 (old) 0.2 M IM pH 8.5 4 mM 12 % PEG 10000 
3+4 3.5 (new) 0.2 M IM pH 8.5 4 mM 12 % PEG 10000 
5+6 3.5 (old) 0.2 M IM pH 8.5 4 mM 16% PEG 10000 
7+8 3.5 (new) 0.2 M IM pH 8.5 4 mM 16% PEG 10000 
9+10 3.5 (old) 0.2 M IM pH 8.5 4 mM 18% PEG 10000 
11+12 3.5 (new) 0.2 M IM pH 8.5 4 mM 18% PEG 10000 
13+14 3.5 (old) 0.2 M IM pH 8.5 4 mM 20% PEG 10000 
15+16 3.5 (new) 0.2 M IM pH 8.5 4 mM 20% PEG 10000 
17+18 3.5 (old) 0.2 M IM pH 8.5 4 mM 22% PEG 10000 
19+20 3.5 (new) 0.2 M IM pH 8.5 4 mM 22% PEG 10000 
21+22 3.5 (old) 0.2 M IM pH 8.5 4 mM 24% PEG 10000 
23+24 3.5 (new) 0.2 M IM pH 8.5 4 mM 24% PEG 10000 
Experiment 20. Sitting drops. cgTPH1 from a new purification batch was used (new) and older 
batch when noted (old). 
Drop cgTPH1 conc. (mg/mL) Buffer  Precipitant 
1+2 3.5 (old) 0.2 M IM pH 8.5 22.5% PEG 10000 
3+4 3.5 (new) 0.2 M IM pH 8.5 22.5% PEG 10000 
5+6 3.5 (old) 0.2 M IM pH 8.5 22.5% PEG 10000 
7+8 3.5 (new) 0.2 M IM pH 8.5 22.5% PEG 10000 
9+10 3.5 (old) 0.2 M MIB pH 7.0 22.5% PEG 10000 
11+12 3.5 (new) 0.2 M MIB pH 7.0 22.5% PEG 10000 
13+14 3.5 (old) 0.2 M MIB pH 7.5 22.5% PEG 10000 
15+16 3.5 (new) 0.2 M MIB pH 7.5 22.5% PEG 10000 
17+18 3.5 (old) 0.2 M MIB pH 8.0 22.5% PEG 10000 
19+20 3.5 (new) 0.2 M MIB pH 8.0 22.5% PEG 10000 
21+22 3.5 (old) 0.2 M MIB pH 8.5 22.5% PEG 10000 
23+24 3.5 (new) 0.2 M MIB pH 8.5 22.5% PEG 10000 
 
